Example report · Built with AcademicLabs

Every source, triangulated: the insight no single database gives you

This CIDP landscape reads 360° scientific profiles of companies, researchers and labs, clinical trials, publications, patents, funded projects and news together. Triangulating them shows what no single source can: which novel drugs are moving and on what evidence, who the experts behind them are and who they work with, and where the gaps and partnering opportunities are.

It is built on AcademicLabs' comprehensive, continuously updated data. Our AI reads every record against disease-specific questions and stays grounded in the science: no web searches, no facts from model memory, and every figure linked back to its source record.

Explore the report

New to CIDP? Read the plain-language guide to the disease, its treatment and where research is heading.

Landscapes like this, for your field

For your disease, target, technology or any topic.

  1. 1
    Build them yourselfSearch and triangulate all eight types of intelligence with AcademicLabs AI. We show you how.
  2. 2
    Have them built for youIn-depth, comprehensive reports from €1,000 to €10,000 depending on scope, with optional monthly updates.
  3. 3
    Stay ahead every monthA monthly briefing on what is new and relevant for your topic of interest: startups, competitor moves, trials, results, patents, deals, publications, projects, news and experts.
Contact us
The reportThe CIDP Landscape · September 2026
Landscape report · September 2026

The CIDP Landscape 2026

By Arne Smolders, Founder & CEO, AcademicLabs · Published 29 September 2026 · Updated 7 October 2026 · Data as of 30 September 2026

Standard of care is being re-engineered, FcRn is established, complement split in two this year, and the best-validated biology in the disease still has no targeted therapy.

4,264records analysed across eight types of intelligence
216CIDP clinical studies, from 452 registry records
1,166publications, 2024–2026
344patent families, from 391 filings
663companies screened
1,115researchers with a CIDP record, and 156 research groups
30publicly funded projects
26news stories, deduplicated
Where CIDP mechanisms act on a myelinated peripheral nerveA blood vessel carrying IgG above a myelinated axon with two nodes of Ranvier. Numbered pins mark circulating IgG and FcRn, B and plasma cells, complement at the node, paranodal autoantibody targets, a macrophage stripping myelin, a Schwann cell, and axonal damage.Endoneurial vessel node of Ranvier 1 2 3 4 5 6 7
Pins follow the disease path from blood into the nerve. Counts are publications · patent families · clinical studies for that mechanism. Select one to open it in the whitespace map.
Summary

Ten findings

Each finding combines at least two of the eight types of intelligence. The evidence column gives the figures behind it; the link opens the section with the underlying records.

01

Immunoglobulin is being re-engineered, not replaced

Immunoglobulin is still the largest class in the CIDP registry: 76 studies, 19 of them active, and 14 of the 39 readouts expected by 2030. The new work is in how it is given, not whether: subcutaneous and facilitated-subcutaneous products, head-to-head pharmacokinetic studies, de-novo and dose-tapering trials, and an Fc-engineered successor (NVG-2089, Phase 2) that aims for the effect without the plasma.

76immunoglobulin studies
19still active
14of 39 readouts to 2030
02

FcRn is established, and the followers are thinning out

Efgartigimod is approved in CIDP, added an EU subcutaneous approval in June 2025, and runs 3 active studies with the largest literature of any novel agent (75 publications). Behind it the class narrows: nipocalimab is in a Phase 2/3 study with primary completion registered for 2027-05, batoclimab's Phase 2b is described as informing Immunovant's next FcRn molecule, and rozanolixizumab has 3 CIDP studies and none active.

75efgartigimod publications
3active efgartigimod studies
22FcRn / Fc patent families
03

Complement split in two in 2026

All three late-stage complement antibodies act on the classical pathway, and 2026 separated them. Sanofi stopped the Phase 3 MOBILIZE study of riliprubart (anti-C1s) for futility on 10 June; its second Phase 3, VITALIZE, which compares riliprubart with immunoglobulin, is under review by Sanofi. Dianthus received an early go decision for the Phase 3 part of CAPTIVATE with claseprubart (anti-C1s) in March. argenx has empasiprubart (anti-C2) in two Phase 3 studies with primary completions in 2027-09 and 2027-10.

6active complement studies
28complement patent families
80%of complement papers use human data
04

2027 is when the standard of care gets tested

17 of the 39 registered primary completions fall in 2027, 10 of them Phase 2/3 or later: nipocalimab's ARISE (May), riliprubart's VITALIZE (July), empasiprubart's two Phase 3 studies (September and October) and an academic Phase 3 of rituximab (October). Only 2 of the 32 active or planned studies of novel agents compare directly against immunoglobulin, and both, VITALIZE and empasiprubart's NCT06920004, read out that year. Most of the rest are single-arm or placebo-controlled.

17of 39 readouts in 2027
10Phase 2/3 or later
2of 32 novel-agent studies against IVIg
05

Cell therapy reached CIDP through hospitals in China

11 CAR-T studies list CIDP, 8 active and 3 planned, all Phase 1 or 1/2. 7 are sponsored by Chinese hospitals and universities; the industry sponsors are Juventas Cell Therapy, Kite (Gilead) and TG Therapeutics. Most target CD19, BCMA or both; six use off-the-shelf allogeneic cells and one (JY231) is designed to generate CAR-T cells inside the body. Kite's KITE-363 and TG Therapeutics' azer-cel enrol autoimmune nodopathy explicitly. Of the 1,115 researchers with a CIDP record, 2 name a CAR-T product, both of them in China: the wider expert base has not yet engaged with the modality.

11CAR-T studies
7investigator-sponsored
0past Phase 2
06

The best-validated biology has no targeted therapy

Antibodies against the node of Ranvier (neurofascin-155, contactin-1, Caspr1, neurofascin-140/186) define the one CIDP subgroup with a known antigen, and they are the most human-grounded topic in the literature: 48 publications, 83% with patient data, and the largest theme in public funding. Against that: 5 patent families, none CIDP-primary, and no clinical study targeting the antigens. In the preclinical records one programme aims at them: the University of Arizona's patent on DNA aptamers that neutralise anti-neurofascin antibodies, with in vitro data only. The expertise exists: 178 researchers work on these antibodies, most of them in Japan, China and Spain, and only 12% have any industry tie. The subgroup reaches the clinic only as an inclusion criterion in CAR-T studies.

48publications
11of 30 funded projects
0antigen-targeted studies
07

Preclinical work runs ahead of the clinic in T cells, cytokines and repair

Beyond the clinic, 157 preclinical programmes from 146 developers come from CIDP patent families, funded projects and company records. 87 of them work on biology with no active CIDP study: T cells and Treg (22), cytokines (19), nerve repair and remyelination (19), macrophages (17) and tolerance (10). The evidence behind them is thin: only 18 have in vivo, patient-sample or clinical data, and 4 use a drug already tested in people for another disease (RRx-001 from EpicentRx, etifoxine from Biocodex, ruxolitinib at UCLA, P140 from ImmuPharma). Across all 344 CIDP patent families, 133 disclose no supporting data and only 18 treat CIDP as the primary indication.

87preclinical programmes in biology with no active CIDP study
18of them with in vivo or human data
8of all 157 programmes already clinical elsewhere
08

argenx has already recruited the expert base

Of 1,115 researchers with a substantiated CIDP record, 204 have a documented industry tie, and 106 of them are tied to argenx: more than to CSL, Sanofi and Takeda combined (89). 41 of the 50 most-connected researchers have at least one tie. argenx is also the only company with a visible CIDP organisation in the data: 37 staff profiles across clinical development, medical affairs, health economics, market access and launch. Challengers will largely be recruiting investigators who already work with efgartigimod.

106researchers tied to argenx
41/50leading researchers with an industry tie
37argenx staff in the data
09

Challengers have a thin expert bench, and experts sit where trials are not

Efgartigimod is named by 172 researchers and rituximab by 210. The assets that read out in 2027–2028 are named by far fewer: riliprubart 20, empasiprubart 14, nipocalimab 12, claseprubart 0. Daratumumab (12) and ofatumumab (7) are discussed by more experts than several registered programmes, with no CIDP study. Geographically, India, South Korea, Poland, Greece, Turkey, Canada, Brazil hold 189 CIDP researchers between them but only 8 CIDP studies.

41researchers name a late-stage challenger
172name efgartigimod
189researchers in 7 countries with ≤3 studies
10

Published efficacy for new mechanisms rests on one trial

Of the new mechanisms, only efgartigimod has a positive randomised result among the 180 treatment publications read: in ADHERE, 27.9% of responders relapsed on it against 53.6% on placebo, a hazard ratio of 0.39 (0.25 to 0.61). The other published randomised trials of new approaches were negative: rozanolixizumab, a second FcRn blocker, in a 34-patient Phase 2a, and rituximab as a way off immunoglobulin (63.2% against 66.6% worsened). None of the 5 riliprubart Phase 2 records carries a number in its abstract, and its refractory Phase 3 then stopped for futility. The clearest signal outside FcRn is confined to a subgroup: 6 of 8 nodal-antibody patients responded to rituximab, against 1 of 7 on IVIg.

1new mechanism with a positive published randomised trial
2negative randomised trials of new approaches
6/8nodal-antibody patients responding to rituximab
Standard of care

What a new CIDP therapy has to beat

Treatment still rests on immunoglobulin, corticosteroids and plasma exchange, with efgartigimod the first non-immunoglobulin maintenance option since 2024. Below: the treatment pathway, where it falls short, and how each challenger is set up to differ, read from the design of its registered studies.

1

Induction

Newly diagnosed or active disease
IVIg Corticosteroids Plasma exchange

The 2021 EAN/PNS guideline recommends IVIg or corticosteroids as first treatment, and plasma exchange when both fail. Choice turns on severity, comorbidity and access.

394publications mention IVIg
210mention corticosteroids
126mention plasma exchange
2

Maintenance

Responders who relapse when treatment stops
IVIg Subcutaneous Ig (e.g. Hizentra) Facilitated SCIG (HyQvia) Efgartigimod SC (Vyvgart Hytrulo) Corticosteroids

Immunoglobulin, given intravenously every few weeks or subcutaneously at home, carries most patients. Since 2024 it has had its first non-immunoglobulin competitor: efgartigimod SC, approved in the US in June 2024 and in the EU as a subcutaneous injection in June 2025. HyQvia was approved for CIDP maintenance in the US and EU in January 2024.

76immunoglobulin studies in the registry
188publications mention subcutaneous Ig
75efgartigimod publications
3

Inadequate response or dependence

Partial response, IVIg dependence, intolerance
Switch between first-line treatments Rituximab (off-label) Other immunosuppressants Autologous stem-cell transplant (selected patients)

There is no approved option. Treatment is escalated or combined case by case, and most of the evidence is observational. This is where rituximab, complement inhibitors and cell therapies are being tested.

165publications on refractory disease
99on immunoglobulin dependence
20studies enrol active or refractory disease
4

Autoimmune nodopathy

Antibodies to NF155, CNTN1, Caspr1 or NF140/186
Rituximab IVIg, often insufficient

Now classed as a separate disease. Guidelines advise testing for the antibodies when the clinical picture suggests them, and considering rituximab when immunoglobulin fails, which it often does.

36publications name NF155
45rituximab publications
2CAR-T studies enrol nodopathy

Where the standard of care falls short

Dependence

99 publications discuss immunoglobulin dependence, and 9 registered studies test whether treatment can be tapered, spared or stopped.

Burden

12 registered studies switch patients from their current therapy, most of them to a subcutaneous product.

Unmet need

20 studies enrol people with active or refractory disease despite treatment; no therapy is approved specifically for them.

Supply

Immunoglobulin is made from pooled donor plasma. Fc-engineered products (NVG-2089) and FcRn blockers are built partly to reduce that dependence.

How novel agents are being tested

Comparator in the 32 active or planned studies of non-immunoglobulin novel agents.

  • Single-arm · 18
  • Against baseline or history · 4
  • Placebo-controlled · 4
  • Other or not stated · 3
  • Head-to-head against immunoglobulin · 2
  • Randomised withdrawal · 1

Where each asset is trying to win

Each mark means a registered study tests the asset in that setting or design. It says what is being attempted, not what has been shown. Hover or focus a row for the studies behind it.

Asset Approved in CIDP Head-to-head vs IVIg Relapse prevention Switch from IVIg IVIg-sparing or taper Refractory disease Newly diagnosed Subcutaneous or home One-time or episodic Nodopathy enrolled
IVIg (reference) Immunoglobulin
HyQvia (facilitated SCIG) Immunoglobulin
Hizentra (SCIG) Immunoglobulin
Efgartigimod SC FcRn inhibition
Nipocalimab FcRn inhibition
Batoclimab / IMVT-1402 FcRn inhibition
Riliprubart Complement
Empasiprubart Complement
Claseprubart Complement
Rituximab B-cell depletion
Ripertamab B-cell depletion
CAR-T (11 studies) CAR-T
NVG-2089 Fc / FcγR modulation

Asset by asset

Efgartigimod

argenx · FcRn inhibition
75 · 8 · 25 · 6
Approved in CIDP (US June 2024; EU SC June 2025)
Mechanism
Engineered IgG1 Fc fragment that blocks FcRn, lowering all circulating IgG, including pathogenic autoantibodies
Route and schedule
Subcutaneous, weekly, co-formulated with hyaluronidase
Pivotal design
Randomised withdrawal after open-label responders (ADHERE)
Differs from standard of care
The first maintenance option that is not made from plasma. It removes IgG rather than adding it, and is injected under the skin rather than infused.
Open question
How it performs as first treatment instead of after immunoglobulin; the post hoc treatment-naive data are early and uncontrolled.

HyQvia

Takeda · Immunoglobulin
7 · 1 · 7 · 6
Approved for CIDP maintenance (US and EU January 2024; Canada expanded March 2025)
Mechanism
Human immunoglobulin with recombinant hyaluronidase, which lets large volumes be given under the skin
Route and schedule
Subcutaneous, every 2, 3 or 4 weeks
Pivotal design
ADVANCE-1: placebo-controlled relapse prevention, relapse 15.5% vs 31.7%
Differs from standard of care
Keeps immunoglobulin efficacy while moving treatment home, at intervals of up to four weeks rather than the weekly schedule of conventional SCIG.
Open question
How it holds its place as FcRn blockade offers a non-plasma option; Takeda is already testing a 20% successor, TAK-881, against it.

Nipocalimab

Johnson & Johnson · FcRn inhibition
3 · 1 · 4 · 1
Phase 2/3 ARISE, primary completion 2027-05
Mechanism
Full-length anti-FcRn monoclonal antibody
Route and schedule
Intravenous loading dose, then every 2 weeks
Pivotal design
Open-label response, then randomised withdrawal
Differs from standard of care
A second FcRn option with a two-weekly schedule; the same mechanism as the approved agent.
Open question
Whether intravenous two-weekly dosing can compete with a weekly subcutaneous product already on the market.

Batoclimab / IMVT-1402

Immunovant · FcRn inhibition
0 · 3 · 3 · 2
Phase 2b; used to design the IMVT-1402 CIDP study
Mechanism
Anti-FcRn monoclonal antibodies
Route and schedule
Subcutaneous, weekly (340 mg in NCT07188844)
Pivotal design
Placebo-controlled maintenance in patients on immunoglobulin or plasma exchange
Differs from standard of care
Subcutaneous FcRn blockade from a second developer; Immunovant has said the batoclimab data will shape its next-generation molecule's CIDP trial.
Open question
Whether IMVT-1402 enters a CIDP pivotal study, and on what differentiation.

Riliprubart

Sanofi · Complement
11 · 0 · 6 · 3
VITALIZE ongoing, primary completion 2027-07; MOBILIZE stopped for futility June 2026
Mechanism
Anti-C1s antibody, inhibiting the classical complement pathway
Route and schedule
Not stated in the pivotal records; subcutaneous in the extension study
Pivotal design
VITALIZE: against continued IVIg after switching. MOBILIZE: placebo-controlled in refractory disease
Differs from standard of care
Acts downstream of the antibody, on complement-mediated damage at the node, so could add to or replace IgG-directed treatment.
Open question
Whether the refractory-population failure is about the mechanism or the population, and what that means for VITALIZE and for other C1s antibodies.

Empasiprubart

argenx · Complement
2 · 2 · 3 · 3
Two Phase 3 studies, primary completions 2027-09 and 2027-10; adolescent Phase 2/3 planned
Mechanism
Anti-C2 antibody, acting on both the classical and lectin complement pathways
Route and schedule
Intravenous
Pivotal design
One Phase 3 against IVIg, one placebo-controlled
Differs from standard of care
One of only two novel agents tested head-to-head against IVIg in Phase 3 (with riliprubart), the comparison payers and neurologists will ask for. Gives argenx a second mechanism alongside efgartigimod.
Open question
Whether intravenous dosing is acceptable next to subcutaneous alternatives if efficacy matches IVIg.

Claseprubart

Dianthus Therapeutics · Complement
0 · 0 · 4 · 1
Phase 3 CAPTIVATE, early GO March 2026; primary completion 2028-12
Mechanism
Anti-C1s antibody
Route and schedule
Intravenous loading, then subcutaneous every 2 weeks
Pivotal design
Open-label responder phase, then randomised withdrawal
Differs from standard of care
Complement inhibition with a subcutaneous two-weekly schedule; reached its Part A responder threshold before enrolment finished.
Open question
How much of the MOBILIZE result carries over; commentary has raised differences between the two C1s antibodies.

Rituximab

Academic sponsors · B-cell depletion
45 · 0 · 10 · 8
Off-label; Phase 3 academic studies, next completion 2027-10
Mechanism
Anti-CD20 B-cell depletion
Route and schedule
Intravenous infusions, episodic (e.g. 1,000 mg twice, repeat at 6 months)
Pivotal design
Immunoglobulin-sparing add-on, newly diagnosed and Ig-dependent cohorts
Differs from standard of care
Episodic dosing that could shorten or end immunoglobulin courses, and widely used in autoimmune nodopathy.
Open question
Randomised evidence in seronegative CIDP, where most patients are.

CD19 / BCMA CAR-T

Chinese hospitals, Juventas, Kite (Gilead), TG Therapeutics · CAR-T
14 · — · — · 11
11 Phase 1 or 1/2 studies
Mechanism
Depletion of B cells and plasma cells, aiming at an immune reset
Route and schedule
One-time infusion after lymphodepletion (JY231 aims to generate CAR-T cells inside the body)
Pivotal design
Single-arm, relapsed or refractory disease
Differs from standard of care
Potential drug-free remission after one treatment, which no chronic therapy offers.
Open question
Durability, safety of lymphodepletion in a non-fatal disease, and cost against lifelong immunoglobulin.

NVG-2089

Nuvig Therapeutics · Fc / FcγR modulation
2 · 0 · 1 · 1
Phase 2
Mechanism
Engineered Fc protein designed to reproduce the anti-inflammatory action of IVIg
Route and schedule
Intravenous
Pivotal design
Single-arm, treatment-naive and experienced
Differs from standard of care
Aims to give the immunoglobulin effect without depending on pooled donor plasma.
Open question
Whether a recombinant mimic matches IVIg efficacy across the heterogeneous CIDP population.

Evidence counts across sources: publications · patent families · companies · registered studies. Positioning is taken from registered study designs and published news; efficacy has been reported only where stated.

Clinical pipeline

What is in the clinic, and how far it has got

216 CIDP clinical studies after removing registry duplicates and off-target records. 138 test a named intervention, resolved here to 38 assets. Each bar runs to the most advanced phase recorded for that asset; the marker at its end carries any development news from the news corpus.

Bullseye: from launched products to preclinical

Products launched in CIDP sit in the centre; each ring out is an earlier phase, and each slice a mechanism. The outer ring holds preclinical programmes, from clinical in another disease on the inside to no data disclosed on the outside. Crosses mark assets with a negative result or stopped studies; rings mark setbacks. Show the developers, or highlight one, with the controls. Hover a dot for details; select it to find its studies or programme in the tables below.

  • Efgartigimod · Phase 4 / marketed · FcRn · 3 active or planned of 6 studies · next completion 2029-10 · argenx · Approved in CIDP; EU approval of SC formulation (20 Jun 2025)
  • Hizentra (IgPro20) · Phase 4 / marketed · Immunoglobulin · 4 active or planned of 8 studies · next completion 2026-12 · CSL Behring, Grifols, Aarhus University
  • HyQvia (TAK-771) · Phase 4 / marketed · Immunoglobulin · 3 active or planned of 6 studies · next completion 2027-08 · Takeda, Heinrich-Heine University, Duesseldorf · Approved as CIDP maintenance: FDA and EU (Jan 2024)
  • Octapharma Ig (Panzyga / NewGam / Octagam) · Phase 4 / marketed · Immunoglobulin · 3 active or planned of 8 studies · next completion 2027-08 · Octapharma, Copenhagen University Hospital, Endeavor Health
  • Privigen (IgPro10) · Phase 4 / marketed · Immunoglobulin · 2 active or planned of 5 studies · next completion 2029-12 · CSL Behring, Aarhus University
  • Grifols Ig (Gamunex / Xembify) · Phase 4 / marketed · Immunoglobulin · 1 active or planned of 3 studies · next completion 2027-12 · Grifols, Takeda
  • Gammagard / Kiovig · Phase 4 / marketed · Immunoglobulin · 0 active or planned of 3 studies · Takeda, Van Doorne NV · No active or planned study
  • Nipocalimab · Phase 2/3 · FcRn · 1 active or planned of 1 study · next completion 2027-05 · Johnson & Johnson
  • Batoclimab · Phase 2 · FcRn · 1 active or planned of 2 studies · Immunovant · Phase 2b in CIDP intended to inform IMVT-1402 design (2024 updates)
  • Imeroprubart · Phase 2 · FcRn · 1 active or planned of 1 study · next completion 2028-08 · Immunovant
  • Rozanolixizumab · Phase 2 · FcRn · 0 active or planned of 3 studies · UCB · Negative result, no active study · · Negative Phase 2a. It enrolled patients already on immunoglobulin, a different design from ADHERE's responder-enriched withdrawal, so it does not settle whether the mechanism works.
  • NVG-2089 · Phase 2 · Fc / FcγR · 1 active or planned of 1 study · Nuvig Therapeutics
  • PF-06755347 · Phase 1 · Fc / FcγR · 0 active or planned of 1 study · Pfizer · Studies stopped or withdrawn, no results
  • LFB Ig (I10E / Iqymune) · Phase 3 · Immunoglobulin · 0 active or planned of 2 studies · LFB · No active or planned study
  • NPB-01 · Phase 3 · Immunoglobulin · 0 active or planned of 1 study · Nihon Pharmaceutical · No active or planned study
  • … and 179 more.

Preclinical programmes, by level of validation

157 programmes from 146 developers without a CIDP clinical study: one row per developer and mechanism, from CIDP patent families, funded projects and company records. Validation is the strongest evidence in those records: 8 are clinical in another disease, 21 have in vivo or patient-sample data, 39 in vitro or cell data, and 89 disclose no data yet. Select a dot in the outer ring of the bullseye to find its row. Chinese-language patents and pipeline charts on company websites are not yet covered; they come with AcademicLabs asset intelligence.

Developer Mechanism Validation Programme Records
Alpine Immune Sciences Biotech / SME · United States B-cell and plasma-cell Clinical in another disease An engineered BAFF/APRIL-neutralizing TACI-Fc fusion protein is disclosed for reducing pathogenic B-cell activity in CIDP and other immune-mediated diseases. Latest record 2022 Patent
Viela Bio Biotech / SME · United States B-cell and plasma-cell Clinical in another disease An afucosylated humanized anti-CD19 monoclonal antibody that depletes CD19-positive B cells is disclosed for treatment of CIDP as one of many autoimmune diseases. Latest record 2024 Patent
Kyverna Therapeutics Biotech / SME · United States CAR-T Clinical in another disease An anti-CD19 CAR-T cell therapy that depletes pathogenic CD19-positive B cells is disclosed for treatment of CIDP as one of several autoimmune diseases. Latest record 2024 Patent
EpicentRx Biotech / SME · United States Macrophage and innate Clinical in another disease RRx-001 is a small-molecule immunomodulatory asset proposed for CIDP and other immune-mediated neuropathies, intended to suppress inflammatory IL-1β/IL-18-associated… Latest record 2022 Patent
Biocodex Established pharma · France Nerve repair and remyelination Clinical in another disease Etifoxine · Approved anxiolytic (TSPO ligand) with nerve-regeneration and reduced macrophage accumulation in nerve-injury models; CIDP named as a target neuropathy. Company profile Website ↗
Publication
Bexion Pharmaceuticals Biotech / SME · United States Other Clinical in another disease A saposin C–anionic phospholipid nanovesicle formulation is disclosed as a neuroprotective/neuroregenerative therapy intended to reduce neuropathy symptoms, including… Latest record 2022 Patent
University of California Los Angeles Academic / hospital · United States T-cell and Treg Clinical in another disease Ruxolitinib · Aging and T cell Senescence in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Latest record 2026 Funded project NIH RePORTER ↗
ImmuPharma Biotech / SME · United Kingdom Tolerance Clinical in another disease P140 (Lupuzor) · Peptide immune-tolerance restorer tested in Phase 3 in lupus; the company lists CIDP as a lead indication. Company profile
Nagoya University Academic / hospital · Japan Complement In vivo or patient-sample data Elucidation of Glycan and Complement-Related Pathophysiology and Development of Therapeutic Strategies in Immune-Mediated Neuropathy. Latest record 2025 Funded project KAKEN ↗
Kyung Hee University Academic / hospital · South Korea Cytokine and chemokine In vivo or patient-sample data PLGA-siSTAT3 is a nanoparticle-delivered STAT3 siRNA RNA-therapy candidate intended to treat CIDP and other autoimmune neurological disorders by suppressing pathogenic… Latest record 2023 Patent
Loyola University Chicago Academic / hospital · United States Cytokine and chemokine In vivo or patient-sample data BAG3 gene/protein/peptide replacement or expression enhancement is disclosed as an anti-inflammatory, TNF-signaling-reducing approach intended to treat CIDP and other… Latest record 2022 Patent
Paragon Therapeutics Biotech / SME · United States FcRn In vivo or patient-sample data An engineered FcRn-binding Fc–albumin fusion protein intended to deplete circulating IgG, including pathogenic autoantibodies, for treatment of CIDP and other autoimmune… Latest record 2024 Patent
Ascentage Pharma Group Biotech / SME · China Macrophage and innate In vivo or patient-sample data A broad family of small-molecule epigenetic/immune modulators, including Cpd. Latest record 2022 Patent
ImmuNext Biotech / SME · United States Macrophage and innate In vivo or patient-sample data An anti-VISTA antibody–glucocorticoid ADC platform (including INX/INXSM steroid-linker payloads) is disclosed to deliver steroids into VISTA-expressing immune cells for… Latest record 2022 Patent
Saga University Academic / hospital · Japan Macrophage and innate In vivo or patient-sample data Elucidation of the pathogenesis of cidp and development of new treatment methods focusing on macrophages. Latest record 2023 Funded project KAKEN ↗
The University of Texas Health Science Center at Houston Academic / hospital · United States Macrophage and innate In vivo or patient-sample data Modulation of CSF1R Signaling to Treat Inflammatory Neuropathies. Latest record 2023 Funded project NIH RePORTER ↗
Funded project NIH RePORTER ↗
Johannes Gutenberg University Mainz Academic / hospital · Germany Nerve repair and remyelination In vivo or patient-sample data A transdermal aminophylline/theophylline patch for CIDP and other demyelinating neuropathies, intended to provide sustained systemic exposure to support treatment or… Latest record 2023 Patent
Mayo Foundation for Medical Education and Research Academic / hospital · United States Nerve repair and remyelination In vivo or patient-sample data Short DNA aptamers, including multimeric forms, intended to stimulate myelin repair/remyelination in CIDP and other demyelinating diseases. Latest record 2019 Patent
Progentos Therapeutics Biotech / SME · United States Nerve repair and remyelination In vivo or patient-sample data Brain-penetrant PDGFRα-inhibiting small molecules (and potentially antibodies) intended to promote oligodendrocyte differentiation and nerve remyelination for CIDP and… Latest record 2022 Patent
Shenzhen ExoNeuglia Biomedical Technology Biotech / SME · China Nerve repair and remyelination In vivo or patient-sample data WIN55212-2-enabled production of transplantable oligodendrocyte progenitor cells is disclosed as a regenerative cell-therapy approach intended to restore myelin in CIDP… Latest record 2022 Patent
The University of Chicago Academic / hospital · United Kingdom Nerve repair and remyelination In vivo or patient-sample data A guanabenz/guanabenz-derivative small-molecule repurposing asset for CIDP and other demyelinating disorders, intended to treat disease by supporting myelin protection… Latest record 2021 Patent
MD Healthcare Academic / hospital · North Korea Other In vivo or patient-sample data Extracellular vesicles derived from Sphingomonas bacteria are proposed as a therapeutic technology for treating or alleviating CIDP and other neurological diseases,… Latest record 2021 Patent
MedRegen Biotech / SME · United States Other In vivo or patient-sample data AMD3100 (plerixafor) plus sub-immunosuppressive tacrolimus is proposed as a stem/immune-cell-mobilizing, pathway-modulating combination for CIDP as one of multiple named… Latest record 2024 Patent
The General Hospital Corporation Academic / hospital · United States Other In vivo or patient-sample data A trisulfide-based small-molecule therapeutic approach (GSSSG, pantethine trisulfide, or lipoic-acid trisulfide) is disclosed for treatment of CIDP among other… Latest record 2023 Patent
The University of Hong Kong Academic / hospital · Hong Kong Other In vivo or patient-sample data DDO-7263, a 1,2,4-oxadiazole state-dependent voltage-gated sodium-channel inhibitor with proposed NRF2/antioxidant activity, is intended to relieve neuropathic pain,… Latest record 2025 Patent
Therabest Biotech / SME · United Kingdom Other In vivo or patient-sample data An iPSC-derived, mass-expanded NK-cell therapy is disclosed for potential treatment of CIDP as one of many peripheral autoimmune/neurological diseases, although no… Latest record 2023 Patent
Jiangsu Asieris Pharmaceuticals Biotech / SME · China T-cell and Treg In vivo or patient-sample data A CIDP-relevant disclosed technology is repurposing small-molecule DBH inhibitors, particularly nepicastat and related agents, to immunomodulate autoimmune neuropathies… Latest record 2022 Patent
Mount Sinai Health System Academic / hospital · United States T-cell and Treg In vivo or patient-sample data A whole-body/high-exposure blue LED phototherapy method (400–490 nm) intended to activate T cells and treat CIDP as one of several named autoimmune diseases. Latest record 2025 Patent
EpiVax Biotech / SME · United States Tolerance In vivo or patient-sample data Tregitopes · IgG-derived Treg epitope peptides proposed as an active component of IVIg, with ex vivo human-cell and mouse autoimmune-model data; CIDP named. Company profile Website ↗
Publication
Apellis Pharmaceuticals Biotech / SME · United States Complement In vitro or cell data Small-molecule C3-convertase inhibitors that suppress complement alternative-pathway activity, intended as potential treatment for CIDP and other complement-mediated… Latest record 2024 Patent
Patent
Alvit LCS Pharma Biotech / SME · Israel Cytokine and chemokine In vitro or cell data A fixed-dose CBD plus Cordyceps or Reishi combination intended to suppress pro-inflammatory cytokine/nitric-oxide signaling for treatment of CIDP and other… Latest record 2025 Patent
Patent
Catholic University of Louvain Academic / hospital · Belgium Cytokine and chemokine In vitro or cell data Latent-TGFβ1-activating monoclonal antibodies/fragments intended to suppress pathological immune responses and treat autoimmune neuropathies including CIDP. Latest record 2023 Patent
National Centre for Scientific Research Academic / hospital · France Cytokine and chemokine In vitro or cell data CXCR4-minor-pocket-targeting cyclic isothiourea small molecules that suppress inflammatory cytokines, intended to treat or prevent CIDP among a broad range of… Latest record 2021 Patent
Patent
Tanabe Pharma Corporation Biotech / SME · Germany Cytokine and chemokine In vitro or cell data A Tanabe Pharma small-molecule pan-SIK1/2/3 inhibitor series is disclosed for potential treatment of CIDP and other immune-mediated inflammatory diseases by suppressing… Latest record 2024 Patent
Viela Bio Biotech / SME · United States Cytokine and chemokine In vitro or cell data A CD40L-binding engineered Tn3 protein scaffold is disclosed as a potential immunomodulatory therapy for CIDP within a broad autoimmune-disease treatment use. Latest record 2025 Patent
Gliknik Biotech / SME · United States Fc / FcγR In vitro or cell data Stradomers (GL-2045) · Recombinant multimerized IgG1 Fc–IgG2 hinge “stradomer” fusion proteins that polyvalently engage Fcγ receptors, intended as an immunomodulatory treatment for CIDP and… Latest record 2024 Patent
Patent
Draupnir Bio Biotech / SME · Denmark FcRn In vitro or cell data In CIDP, the relevant disclosed technology is a sortilin-recruiting bifunctional lysosomal-degradation platform intended to remove pathogenic extracellular… Latest record 2023 Patent
Inhibrx LP Biotech / SME · United States FcRn In vitro or cell data A multivalent FcRn-blocking VHH biologic, optionally albumin-binding for half-life extension, intended to reduce pathogenic IgG/autoantibodies for treatment of CIDP and… Latest record 2023 Patent
Coherus BioSciences Biotech / SME · United States Macrophage and innate In vitro or cell data An anti-ILT4 monoclonal-antibody technology that blocks ILT4-HLA-G/HLA-A immune-inhibitory signaling, proposed for treatment of CIDP as one of many autoimmune disorders. Latest record 2023 Patent
Consorcio Regenero S.A Biotech / SME · Chile Macrophage and innate In vitro or cell data A defined extracellular-vesicle preparation from umbilical-cord mesenchymal cells is disclosed as an immunomodulatory regenerative therapy intended for treatment of CIDP… Latest record 2022 Patent
… and 117 more rows in the interactive table.
P1 P1/2 P2 P2/3 P3 P4
FcRn
EfgartigimodFcRn · argenx BV
3 active of 6 · next 2029-10
NipocalimabFcRn · Johnson & Johnson
1 active of 1 · next 2027-05
BatoclimabFcRn · Immunovant Sciences GmbH
1 active of 2
ImeroprubartFcRn · Immunovant Sciences GmbH
1 active of 1 · next 2028-08
RozanolixizumabFcRn · UCB, UCB Biopharma S.P.R.L.
0 active of 3
Complement
EmpasiprubartComplement (C2) · argenx BV
3 active of 3 · next 2027-09
RiliprubartComplement (C1s) · Sanofi
2 active of 4 · next 2027-07
ClaseprubartComplement (C1s) · Dianthus Therapeutics Inc
1 active of 1 · next 2028-12
B-cell and plasma-cell
AlemtuzumabCD52 lymphocyte · Johns Hopkins University
0 active of 1
RituximabCD20 B-cell · Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC), The University of Kansas +2
3 active of 8 · next 2027-10
RipertamabCD20 B-cell · Zhongming Qiu
1 active of 1 · next 2027-06
aHSCTImmune reset · St Vincent's Hospital Sydney, Northwestern University +1
3 active of 4
ObinutuzumabCD20 B-cell · Zhongming Qiu
1 active of 1 · next 2030-01
TelitaciceptBAFF / APRIL · University of Electronic Science and Technology of China
0 active of 1
CAR-T
BAFF-R CAR-TBAFF-R CAR-T · Tianjin Medical University
1 active of 1 · next 2027-12
Universal CD19/BCMA CAR-TCD19/BCMA CAR-T · Tongji Hospital, Tianjin Huanhu Hospital +1
5 active of 5 · next 2026-12
Azer-celCD19 CAR-T · TG Therapeutics Inc
1 active of 1 · next 2026-12
BCMA CAR-T (other)BCMA CAR-T · Tongji Hospital
1 active of 1 · next 2026-12
CNCT19CD19 CAR-T · Juventas Cell Therapy Ltd
1 active of 1 · next 2027-06
HY001NCAR-T · Juventas Cell Therapy Ltd
1 active of 1 · next 2026-12
JY231CAR-T · Tongji Hospital
1 active of 1 · next 2026-12
KITE-363CAR-T · Kite IT GmbH
1 active of 1 · next 2029-06
QH103CAR-T · Tongji Hospital
1 active of 1 · next 2027-12
RD06-05CAR-T · Tongji Hospital
1 active of 1 · next 2026-12
Fc / FcγR
NVG-2089Fc / FcγR · Nuvig Therapeutics
1 active of 1
PF-06755347Fc / FcγR · Pfizer
0 active of 1
Other
Acthar gelCorticotropin · Mamatha Pasnoor, MD
0 active of 1
Interferon beta-1aInterferon · Biogen
0 active of 1
MD1003 (biotin)Metabolic / myelin · MedDay Pharmaceuticals
0 active of 1
KINE-101Peptide (not stated) · Kine Sciences
0 active of 1

Generic intravenous and subcutaneous immunoglobulin, corticosteroids, plasma exchange and broad immunosuppressants are studied as comparators or background in many trials and are left out of the chart; they appear in the table and the explorer. Phase 4 marks a study of a product that is already approved, in CIDP or another disease; in CIDP only efgartigimod and a set of immunoglobulin products are approved.

Assets and their studies

Asset Mechanism Most advanced Studies Active Next primary completion Sponsors
Hizentra (IgPro20) Immunoglobulin Immunoglobulin Phase 4 8 4 2026-12 Grifols, CSL Behring, CSL Behring BmbH, CSL
Octapharma Ig (Panzyga / NewGam / Octagam) Immunoglobulin Immunoglobulin Phase 4 8 3 2027-08 Octapharma AG
Efgartigimod Approved in CIDP; EU approval of SC formulation (20 Jun 2025) FcRn inhibition FcRn Phase 4 6 3 2029-10 argenx BV
HyQvia (TAK-771) Approved as CIDP maintenance: FDA and EU (Jan 2024) Immunoglobulin Immunoglobulin Phase 4 6 3 2027-08 Takeda
Privigen (IgPro10) Immunoglobulin Immunoglobulin Phase 4 5 2 2029-12 CSL Behring, CSL Behring BmbH
Grifols Ig (Gamunex / Xembify) Immunoglobulin Immunoglobulin Phase 4 3 1 2027-12 Grifols, Takeda
Gammagard / Kiovig Immunoglobulin Immunoglobulin Phase 4 3 0 — Takeda
Alemtuzumab Lymphocyte depletion CD52 lymphocyte Phase 4 1 0 — Johns Hopkins University
Rituximab B-cell depletion CD20 B-cell Phase 3 8 3 2027-10 Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC), The University of Kansas, Istituto Clinico Humanitas, Nagoya University
Empasiprubart Complement Complement (C2) Phase 3 3 3 2027-09 argenx BV
Riliprubart Phase 3 MOBILIZE discontinued for futility (10 Jun 2026) Complement Complement (C1s) Phase 3 4 2 2027-07 Sanofi
Claseprubart Phase 3 CAPTIVATE: early GO after interim responder analysis (9 Mar 2026) Complement Complement (C1s) Phase 3 1 1 2028-12 Dianthus Therapeutics Inc
Ripertamab B-cell depletion CD20 B-cell Phase 3 1 1 2027-06 Zhongming Qiu
LFB Ig (I10E / Iqymune) Immunoglobulin Immunoglobulin Phase 3 2 0 — LFB Sa
NPB-01 Immunoglobulin Immunoglobulin Phase 3 1 0 — Nihon Pharmaceutical Co Ltd
Nipocalimab FcRn inhibition FcRn Phase 2/3 1 1 2027-05 Johnson & Johnson
aHSCT Immune reset (HSCT) Immune reset Phase 2 4 3 — St Vincent's Hospital Sydney, Northwestern University, Alfred Health
Batoclimab Phase 2b in CIDP intended to inform IMVT-1402 design (2024 updates) FcRn inhibition FcRn Phase 2 2 1 — Immunovant Sciences GmbH
NVG-2089 Fc / FcγR modulation Fc / FcγR Phase 2 1 1 — Nuvig Therapeutics
Imeroprubart FcRn inhibition FcRn Phase 2 1 1 2028-08 Immunovant Sciences GmbH
Rozanolixizumab FcRn inhibition FcRn Phase 2 3 0 — UCB, UCB Biopharma S.P.R.L.
MD1003 (biotin) Neuroprotection / myelin Metabolic / myelin Phase 2 1 0 — MedDay Pharmaceuticals
Acthar gel Other Corticotropin Phase 2 1 0 — Mamatha Pasnoor, MD
Interferon beta-1a Other Interferon Phase 2 1 0 — Biogen
Obinutuzumab B-cell depletion CD20 B-cell Phase 1/2 1 1 2030-01 Zhongming Qiu
BAFF-R CAR-T CAR-T BAFF-R CAR-T Phase 1/2 1 1 2027-12 Tianjin Medical University
Universal CD19/BCMA CAR-T CAR-T CD19/BCMA CAR-T Phase 1 5 5 2026-12 Tongji Hospital, Tianjin Huanhu Hospital, Capital Medical University
QH103 CAR-T CAR-T Phase 1 1 1 2027-12 Tongji Hospital
RD06-05 CAR-T CAR-T Phase 1 1 1 2026-12 Tongji Hospital
BCMA CAR-T (other) CAR-T BCMA CAR-T Phase 1 1 1 2026-12 Tongji Hospital
KITE-363 CAR-T CAR-T Phase 1 1 1 2029-06 Kite IT GmbH
CNCT19 CAR-T CD19 CAR-T Phase 1 1 1 2027-06 Juventas Cell Therapy Ltd
HY001N CAR-T CAR-T Phase 1 1 1 2026-12 Juventas Cell Therapy Ltd
JY231 CAR-T CAR-T Phase 1 1 1 2026-12 Tongji Hospital
Azer-cel CAR-T CD19 CAR-T Phase 1 1 1 2026-12 TG Therapeutics Inc
KINE-101 Phase 1b/2a: first CIDP patient dosed (13 Sep 2024) Other / not stated Peptide (not stated) Phase 1 1 0 — Kine Sciences
PF-06755347 Fc / FcγR modulation Fc / FcγR Phase 1 1 0 — Pfizer
Telitacicept B-cell / plasma-cell BAFF / APRIL Phase not stated 1 0 — University of Electronic Science and Technology of China
IVIG (unbranded / generic) background / comparator Immunoglobulin Immunoglobulin Phase 4 41 6 2027-09 Kedrion SpA, Grifols, Biopharma Plasma LLC, CSL
SCIG (unbranded) background / comparator Immunoglobulin Immunoglobulin Phase 4 5 2 — Aarhus University, Amsterdam UMC Location AMC, Odense University Hospital, Aarhus University Hospital
… and 4 more rows in the interactive table.

Study starts per year, by mechanism

CIDP studies with a named intervention, 2012 onward.

  • 2012 · B-cell and plasma-cell · 1 studies started
  • 2012 · Immunoglobulin · 1 studies started
  • 2013 · Immunoglobulin · 6 studies started
  • 2014 · Immunoglobulin · 8 studies started
  • 2015 · Immunoglobulin · 8 studies started
  • 2015 · Other · 1 studies started
  • 2016 · Immunoglobulin · 3 studies started
  • 2016 · Other · 1 studies started
  • 2017 · Fc / FcγR · 1 studies started
  • 2017 · Immunoglobulin · 4 studies started
  • 2018 · B-cell and plasma-cell · 1 studies started
  • 2018 · Other · 1 studies started
  • 2019 · FcRn · 1 studies started
  • 2019 · B-cell and plasma-cell · 2 studies started
  • 2019 · Immunoglobulin · 5 studies started
  • … and 26 more.
FcRn Complement B-cell and plasma-cell CAR-T Fc / FcγR Immunoglobulin Other

Where active studies run

Countries named on active or planned CIDP studies.

  • Germany · 28
  • China · 27
  • United States · 20
  • Netherlands · 11
  • Japan · 10
  • Australia · 10
  • Italy · 7
  • France · 6
  • Denmark · 6
  • Colombia · 5
  • United Kingdom · 4
  • Iran · 4
  • Spain · 3
  • Switzerland · 3

36 active or planned studies do not name a country in the registry record.

Trial results

What the published trials show, drug by drug

180 publications on CIDP treatments from 2024 to 2026 were read, together with company news and registry records; 120 of them report figures. The results are set out below by drug: how each is given, what the trials measured, what they found, what went wrong, and what reads out next. Every number was checked against the record it came from.

1 new mechanism with a positive published randomised trial

Efgartigimod: relapse in 27.9% against 53.6% on placebo.

2 randomised trials of new approaches were negative

Rozanolixizumab (FcRn) and rituximab as an IVIg-sparing add-on.

5 riliprubart Phase 2 records, none with a number in its abstract

Its refractory Phase 3, MOBILIZE, then stopped for futility.

6 of 8 nodal-antibody patients responded to rituximab

Against 1 of 7 on IVIg, in a retrospective cohort.

Read across trials with care

Trials enrolled different patients (untreated, dependent on immunoglobulin, refractory), used different scales and time points, and some only randomised patients who had already responded. A higher bar in one trial than another is not evidence that one drug is better. The charts group results by population for that reason, and only head-to-head trials can rank drugs.

Evidence map

Publications per drug and evidence type. Bar length is the number of publications; the filled part is those whose abstract reports figures. Click a drug to open its card.

Drug Randomised or pooled Other trials Observational Case reports Rows Verdict Next completion
Immunoglobulin
IVIg Plasma-derived; many manufacturers 6 2 18 14 6 Supported 2027-08 NCT04153422 · Phase 2
Subcutaneous immunoglobulin (SCIg) CSL Behring (Hizentra) and others 6 — 11 1 4 Supported 2026-12 NCT05584631 · Phase 1
HyQvia (facilitated SCIg) Takeda 1 2 — — 2 Supported 2027-08 NCT06538064 · Phase 4 (inferred)
FcRn
Efgartigimod argenx 12 19 7 9 8 Supported 2029-10 NCT07264426 · Phase 4 (inferred)
Rozanolixizumab UCB 1 — — — 1 Setback —
Nipocalimab Johnson & Johnson 1 — — — 1 Awaiting data 2027-05 NCT05327114 · Phase 2/3
Batoclimab and imeroprubart Immunovant (HanAll) — — — — 1 Awaiting data 2028-08 NCT07032662 · Phase 2
Complement
Riliprubart Sanofi 1 7 — — 3 Setback 2027-07 NCT06290141 · Phase 3
Claseprubart Dianthus Therapeutics — — — — 1 Awaiting data 2028-12 NCT06858579 · Phase 3
Empasiprubart argenx 1 1 — — 1 Awaiting data 2027-09 NCT06920004 · Phase 3
B-cell and plasma-cell
Rituximab Academic sponsors (off-label) 4 2 8 26 5 Mixed 2027-10 NCT06714838 · Phase 3
CAR-T
CAR-T and stem-cell transplant Chinese hospitals, Juventas, Kite (Gilead), TG Therapeutics — 2 — 1 3 Awaiting data 2026-12 NCT07337785 · Phase 1
Fc / FcγR
NVG-2089 Nuvig Therapeutics — 1 — — 1 Awaiting data —
Other treatments
Corticosteroids and steroid-sparing add-ons Academic 1 — 2 7 3 Mixed —
Plasma exchange and immunoadsorption Hospital apheresis units 3 — 9 4 3 Awaiting data 2027-09 NCT04881682 · Phase 2
Palmitoylethanolamide (for nerve pain) Academic — — — — 1 Awaiting data —

Randomised comparisons

Share of patients with the event on the drug (filled) and in the control arm (hollow). The arrow shows which direction is better.

  • Efgartigimod, ADHERE · Relapse in stage B · Drug 27.9% (31/111) · placebo 53.6% (59/110) · HR 0.39 (0.25 to 0.61)
  • HyQvia, ADVANCE-CIDP 1 · Relapse · Drug 15.5% · placebo 31.7% · -16.2 points (-29.92 to -1.27)
  • Rituximab, Italian RCT · Worsening after stopping immunoglobulin · Drug 63.2% (12/19) · placebo 66.6% (12/18) · OR 0.86 (0.22 to 3.32)
  • IV methylprednisolone + IVIg · Remission at 52 weeks · Drug 38% (14/37) · IVIg + placebo 28% (11/40) · difference 10% (-11 to 31)
  • Efgartigimod, I-RODS (post hoc) · Daily-activity gain of 4 points or more · Drug 38.1% (37/97) · placebo 26.1% (24/92) · post hoc
  • Tacrolimus + prednisone · Relapse over 12 months · Drug 12.5% (n=16) · prednisone alone 33.3% (n=18) · not randomised · Not randomised
Drug arm Control arm ↓ lower is better · ↑ higher is better

Adverse events against control

Share with any adverse event. Most are mild; serious events are named where reported.

  • Efgartigimod, ADHERE stage B · Any adverse event · Drug 64% · placebo 56% · serious: 5% vs 5%
  • Rozanolixizumab, CIDP01 · Any adverse event · Drug 82% · placebo 76% · no deaths
  • Nipocalimab, healthy volunteers · Any adverse event · Drug 40% (12/30) · placebo 10% (1/10) · none severe
  • SCIg after switching from IVIg · Any side effect · Drug 29.2% · IVIg, same patients 66.7% · not randomised · Not randomised
Drug arm Control arm ↓ lower is better · ↑ higher is better

Thromboembolic events: 1.8 per 100 patient-years on IVIg against 0.14 on subcutaneous immunoglobulin (34 studies, mixed indications). Publication 2026 DOI ↗

How many patients improve, by population

Share improving, with 95% confidence interval. Dashed intervals were computed here (Wilson) because the source reported none. Compare only within a group.

  • Efgartigimod, ADHERE stage A · 214 of 322 (66.5%), within 12 weeks · 95% CI 61 to 71.6% · Confirmed improvement on aINCAT, I-RODS or grip
  • Efgartigimod, Chinese participants · 45 of 58 (77.6%), within 12 weeks · 95% CI 64.7 to 87.5% · Confirmed improvement
  • Efgartigimod, real-world · 11 of 12 (91.7%), week 5 · 95% CI 64.6 to 98.5% (computed) · Clinical improvement
  • IVIg 10% re-treatment · 19 of 20 (95%), on re-treatment · 95% CI 76.4 to 99.1% · 1-point aINCAT improvement
  • Rituximab, open-label · 13 of 17 (76.5%), 6 months · 95% CI 50.1 to 93.2% · Clinical improvement
  • Plasma exchange · 14 of 23 (60.9%), after course · 95% CI 40.8 to 77.8% (computed) · Clinical improvement (retrospective)
  • Immunoadsorption · 11 of 21 (52.4%), after course · 95% CI 32.4 to 71.7% (computed) · Clinical improvement (retrospective)
  • Rituximab · 6 of 8 (75%), follow-up · 95% CI 40.9 to 92.9% (computed) · Treatment response (retrospective)
  • IVIg · 1 of 7 (14.3%), follow-up · 95% CI 2.6 to 51.3% (computed) · Treatment response (retrospective)

Treatment burden: 24 weeks of dosing

Each mark is one administration in the first 24 weeks, as described in the trial or publication. Squares are intravenous infusions, usually in a clinic; circles are injections under the skin, usually at home.

  • IVIg maintenance · every 3 weeks in trials; every 4 in practice
  • SCIg · weekly at home
  • HyQvia · every 4 weeks for most patients
  • Efgartigimod · 1000 mg weekly
  • Nipocalimab · loading dose, then every 2 weeks
  • Claseprubart · IV load, then SC every 2 weeks
  • Riliprubart · SC; frequency not stated in the records
  • Empasiprubart · IV; frequency not stated in the records
  • Rituximab · day 1 and day 15, repeated at 6 months
  • CAR-T · one infusion after conditioning
Intravenous infusion Subcutaneous injection Hover a row for the schedule and its source

Drug by drug

IVIgPlasma-derived; many manufacturers · Standard of care for induction and maintenanceSupported

The benchmark every new drug is measured against: high-certainty benefit over placebo and near-universal re-treatment response in patients who depend on it. Its costs are lifelong infusions, a thrombotic risk, and a poor response in nodal-antibody disease.

How it is given
Intravenous infusion, usually in hospital. Induction 2 g/kg, then maintenance every 3 weeks in trials; in practice around 0.6 g/kg every 4 weeks.
What is missing
Few head-to-head data against newer options; response in nodal-antibody disease is poor.
Study Patients Endpoint Result
RandomisedCochrane review, IVIg vs placebo Meta-analysis of RCTs Definite or probable CIDP n: 5 trials, 269 participants Significant improvement in disability within 6 weeks IVIg more than doubled the chance of improvement (RR 2.40, 1.72 to 3.36); about 4 patients treated for one extra responder (NNTB 4). No clear difference in serious adverse events (RR 0.82, 0.36 to 1.87).
Trial or cohortADVANCE-CIDP IVIG, re-treatment after relapse Open-label trial IVIg-dependent patients who relapsed after withdrawal n: 20 1-point or greater aINCAT improvement 19 of 20 (95.0%) responded to IVIg 10% re-treatment, with a median of 25 days to improvement; mean change -1.9 aINCAT and +12.9 R-ODS centile points.
RetrospectiveStopping maintenance IVIg Retrospective cohort IVIg-responsive patients n: 31 Relapse after stopping IVIg Sixteen of 31 (52%) relapsed after IVIg was stopped, at a mean of 6 months; nerve-conduction changes did not predict who would relapse.
RetrospectiveMaintenance in practice, Australia Retrospective cohort IVIg-dependent patients n: 22 Dose, duration and weaning Mean maintenance of 0.6 g/kg every 4 weeks for a mean 64 months; of six patients who attempted a wean, five (83%) stopped IVIg completely.
Trial or cohort18-month post-marketing surveillance Prospective cohort Patients on maintenance IVIg n: 86 Relapse over 18 months 21 of 86 (24%) relapsed on maintenance; one serious adverse reaction (cardiac failure).
RetrospectiveNodal-antibody patients Retrospective cohort Nodal/paranodal antibody-positive n: 7 treated Treatment response Only 1 of 7 (14.3%) responded to IVIg.
Safety
  • Thromboembolic events: 1.8 per 100 patient-years on IVIg against 0.14 on subcutaneous immunoglobulin (34 studies, mixed indications). Publication 2026 DOI ↗
  • 76,138 FDA adverse-event reports: infusion reactions, infections, headache and chills most common; haemolytic anaemia and aseptic meningitis rare but important. Publication 2026 DOI ↗
Next registered completions

All 40 publications assigned to this drug, 27 with figures

Subcutaneous immunoglobulin (SCIg)CSL Behring (Hizentra) and others · Approved for maintenanceSupported

Moderate-certainty randomised evidence for maintenance, and it moves treatment home. Patients trade systemic side effects for local ones.

How it is given
Subcutaneous at home, usually weekly; around 0.32 g/kg per week in practice.
What is missing
Little evidence for SCIg as first (induction) treatment.
Study Patients Endpoint Result
RandomisedCochrane review, SCIg vs placebo (maintenance) Meta-analysis of RCTs Patients stable on immunoglobulin n: 3 RCTs, 333 participants Clinically significant deterioration at 12 to 24 weeks SCIg cut the risk of deterioration by 60% (RR 0.40, 0.28 to 0.56) and improved grip strength by 6.46 kPa.
Trial or cohortSwitch from IVIg, 12-month follow-up Prospective cohort IVIg-responsive patients n: CIDP and MMN cohort Staying on SCIg, stability 84% remained on SCIg at 12 months and were stable, but 31% needed treatment intensified, mostly a higher dose.
Trial or cohortWho relapses when SCIg is tapered Prospective cohort Patients on SCIg n: Not stated Relapse predictors A dose above 25 g/week (OR 6.3) and high baseline serum neurofilament light (OR 8.2) predicted relapse during tapering.
RetrospectiveSwitching in practice Retrospective cohort IVIg-dependent patients n: 19 evaluable Stability after switch 12 of 19 (63%) stayed stable after switching; every patient who relapsed restabilised on a higher dose; 55% found SCIg easier to tolerate than IVIg.
Safety
  • Local reactions more common than with placebo (RR 3.39); systemic reactions not (RR 0.94). Publication 2026 DOI ↗
  • Hizentra post-marketing: 82.7% of doses given at home (62.0% self-administered); injection-site reactions in 37.0%, mostly redness and swelling. Publication 2024 DOI ↗
  • After switching from IVIg, side effects were reported by 29.2% on SCIg against 66.7% on IVIg (mixed neuromuscular cohort). Publication 2025 DOI ↗
Next registered completions

All 18 publications assigned to this drug, 12 with figures

HyQvia (facilitated SCIg)Takeda · Approved for maintenance (US, EU, Canada)Supported

Placebo-controlled relapse prevention at intervals of up to four weeks, with long-term follow-up showing a low relapse rate.

How it is given
Subcutaneous with hyaluronidase, at home, every 4 weeks (88.2% of patients) or every 3 weeks (11.8%); a mean infusion of 135.5 minutes.
What is missing
The pivotal trial's numbers reach the records only through company news.
Study Patients Endpoint Result
RandomisedADVANCE-CIDP 1 Phase 3 RCT (company-reported) Patients stabilised on IVIg n: Not stated Relapse Relapse in 15.5% on HyQvia against 31.7% on placebo; difference -16.2 percentage points (-29.92 to -1.27).
Trial or cohortADVANCE-CIDP 3 extension Open-label extension ADVANCE-CIDP 1 completers n: 85 Long-term safety; relapse (exploratory) 220 patient-years of follow-up (median 33 months); relapse in 10 of 77 (13.0%), an annual rate of 4.5%.
Safety
  • 1,406 adverse events, of which 48 severe and 30 serious; 3 infusions (0.1%) slowed or stopped for intolerance. Publication 2024 DOI ↗
  • Anti-hyaluronidase antibodies in 14 of 84 (16.7%), without a clearly higher relapse rate (16.7% vs 12.3%). Publication 2024 DOI ↗
Next registered completions

Efgartigimodargenx · Approved in CIDP (US 2024, EU 2025)Supported

The only new mechanism with positive randomised efficacy in the records: relapse risk 61% lower than placebo in responders. It has not been tested head-to-head against IVIg, and a third of patients did not respond in the open-label run-in.

How it is given
Subcutaneous 1000 mg once weekly, co-formulated with hyaluronidase; can be given by the patient or a carer.
What is missing
No comparison against IVIg; how it performs as first treatment rests on post hoc and company-reported data.
Study Patients Endpoint Result
RandomisedADHERE stage B RCT, randomised withdrawal Responders to open-label efgartigimod n: 221 randomised Time to relapse (aINCAT worsening of 1 point or more) Relapse in 27.9% (31/111) on efgartigimod against 53.6% (59/110) on placebo; HR 0.39 (0.25 to 0.61), p<0.0001.
Trial or cohortADHERE stage A Open-label run-in Active CIDP, most previously treated n: 322 Confirmed clinical improvement within 12 weeks 214 of 322 (66%, 61.0 to 71.6) improved on weekly treatment; median about 22 days to first improvement.
RandomisedADHERE, Chinese participants RCT subgroup (descriptive) Participants from mainland China n: 58 Stage A response; stage B time to deterioration 45 of 58 (77.6%) improved in stage A; in stage B, median time to deterioration was not reached on efgartigimod against 113 days on placebo (HR 0.313, 0.109 to 0.905).
RandomisedADHERE daily activities (post hoc) RCT post hoc Stage B participants n: 97 vs 92 I-RODS gain of 4 points or more 38.1% (37/97) on efgartigimod against 26.1% (24/92) on placebo reached a meaningful I-RODS gain.
Trial or cohortWalking (post hoc) Open-label post hoc Stage A participants needing walking support n: 144 Walking outdoors 33 of 144 (22.9%) who needed walking support could walk outdoors unaided after stage A; 9 of 25 (36.0%) wheelchair users could walk outdoors with support.
Trial or cohortADHERE+ extension Open-label extension ADHERE participants n: 228 Change from run-in baseline at week 36 Stage A responders improved by 1.2 aINCAT points, 8.8 I-RODS centile points and 17.5 kPa grip strength.
Trial or cohortTreatment-naive and IVIg-switch analyses Post hoc and physician survey (company-reported) Treatment-naive; patients switching from IVIg n: 91 switchers Early improvement; stability after switch 87.5% of treatment-naive patients improved (median 39.5 days); 85.7% of 91 patients switching from IVIg improved or stayed stable.
Trial or cohortReal-world, China Prospective cohort Mixed CIDP n: 12 Improvement at week 5 11 of 12 (91.7%) improved by week 5; INCAT fell from 4.42 to 1.42.
Safety
  • Stage B: adverse events in 64% on efgartigimod and 56% on placebo; serious events in 5% of each group. Publication 2024 DOI ↗
  • ADHERE+: adverse events in 75.0% and grade 3 or worse in 18.0% of 228, with no rise over time (longest exposure 187.3 weeks). Publication 2026 DOI ↗
  • Pooled across 715 participants in three diseases: albumin did not fall and LDL cholesterol did not rise. Publication 2025 DOI ↗
Next registered completions

All 47 publications assigned to this drug, 28 with figures

First 40 shown.

RozanolixizumabUCB · No active CIDP studySetback

Negative Phase 2a. It enrolled patients already on immunoglobulin, a different design from ADHERE's responder-enriched withdrawal, so it does not settle whether the mechanism works.

How it is given
Subcutaneous 10 mg/kg once weekly for 12 weeks in the trial.
What is missing
Development in CIDP has not continued.
Study Patients Endpoint Result
RandomisedCIDP01 Phase 2a RCT Patients on immunoglobulin maintenance n: 34 Change in iRODS at day 85 No benefit: iRODS change 2.0 on rozanolixizumab against 3.4 on placebo, difference -1.5 (90% CI -7.5 to 4.5).
Safety

NipocalimabJohnson & Johnson · Phase 2/3 ARISEAwaiting data

No CIDP efficacy data in the records. ARISE uses the same responder-then-withdrawal design as ADHERE, so its result will be read directly against efgartigimod's.

How it is given
Intravenous loading dose, then every 2 weeks.
What is missing
First CIDP efficacy data expected from ARISE.
Study Patients Endpoint Result
Healthy volunteersInfusion-rate study Phase 1, healthy volunteers Healthy adults n: 40 Safety, pharmacokinetics Doses up to 60 mg/kg infused as fast as 4 mg/kg/min were tolerated; adverse events in 40% against 10% on placebo, none severe.
Next registered completions

Batoclimab and imeroprubartImmunovant (HanAll) · Batoclimab Phase 2b used to design imeroprubart's Phase 2bAwaiting data

No CIDP results in the records. The batoclimab Phase 2b was extended to inform the design of the next molecule's CIDP study; imeroprubart is now in a placebo-controlled Phase 2b.

How it is given
Batoclimab 340 mg subcutaneously once weekly in the extension study.
What is missing
Imeroprubart's Phase 2b (relapse-free at week 24) is the next data point.
Study Patients Endpoint Result
Design or news onlyBatoclimab Phase 2b Company news Patients on immunoglobulin or plasma exchange n: Not stated Maintenance of response (aINCAT) Study duration extended to optimise the design of the IMVT-1402 (imeroprubart) CIDP trial; no results in the records.
Next registered completions

RiliprubartSanofi · MOBILIZE stopped for futility; VITALIZE (vs IVIg) ongoingSetback

A setback. The Phase 3 in refractory patients failed an interim futility test, and none of the Phase 2 records carries a number in its abstract. The head-to-head VITALIZE study against IVIg remains, with primary completion in July 2027.

How it is given
Intravenous and subcutaneous in Phase 2; subcutaneous in the long-term extension. Half-life of 9.52 to 11.0 weeks.
What is missing
Phase 2 efficacy numbers are not visible in the records.
Study Patients Endpoint Result
RandomisedMOBILIZE Phase 3 RCT (company-reported) Refractory CIDP n: Not stated aINCAT response at week 24 Stopped for futility on 10 June 2026 after an independent interim review; the findings were not disclosed.
Trial or cohortPhase 2, five conference records Phase 2 (abstracts) Treated, refractory and treatment-naive groups n: Not stated Relapse, response, fatigue, quality of life Five records from 2024 to 2026, including 76-week results, and none reports a number in its abstract.
Healthy volunteersEast-Asian pharmacokinetics Phase 1, healthy volunteers Healthy adults n: 37 Pharmacokinetics, complement activity 50 mg/kg IV or 600 mg SC gave overlapping complement suppression; SC bioavailability 74.6%; well tolerated.
Next registered completions

All 8 publications assigned to this drug, 1 with figures

ClaseprubartDianthus Therapeutics · Phase 3 CAPTIVATE, early go to Part BAwaiting data

An early interim signal only: no response rate, effect size or safety data yet. Part B measures time to relapse.

How it is given
Intravenous loading dose, then subcutaneous every 2 weeks.
What is missing
No quantitative efficacy or safety data in the records.
Study Patients Endpoint Result
Trial or cohortCAPTIVATE Part A Open-label Phase 3 part (company-reported) Active CIDP n: Fewer than 40 Confirmed responders Reached 20 confirmed responders before 40 planned participants completed Part A, triggering an early move to the randomised Part B.
Next registered completions

Empasiprubartargenx · Two Phase 3 studiesAwaiting data

No CIDP results in the records yet. EMVIGORATE is one of only two novel-agent studies designed head-to-head against IVIg.

How it is given
Intravenous; dosing frequency not stated in the records.
What is missing
First results from primary completions in September and October 2027.
Study Patients Endpoint Result
Design or news onlyEMVIGORATE and EMNERGIZE Phase 3 designs Adults with CIDP n: Not stated aINCAT improvement of 1 point or more at week 24 Design abstracts only: one study against IVIg, one against placebo.
Next registered completions

RituximabAcademic sponsors (off-label) · Off-label; academic Phase 3 studiesMixed

Failed as an IVIg-sparing drug in unselected patients, but responses are consistent in nodal-antibody disease, the subgroup where IVIg works least.

How it is given
Intravenous 1 g on day 1 and day 15, repeated at day 180 in the randomised trial.
What is missing
No randomised result in seronegative CIDP, where most patients are.
Study Patients Endpoint Result
RandomisedItalian RCT (7 hospitals) RCT, add-on then IVIg withdrawal Patients on immunoglobulin, which was then stopped n: 37 Worsening within 6 months of stopping immunoglobulin No benefit: 63.2% (12/19) worsened on rituximab against 66.6% (12/18) on placebo; OR 0.86 (0.22 to 3.32).
Trial or cohortOpen-label, refractory patients Open-label trial No response to at least two first-line therapies n: 17 Improvement at 6 months 13 of 17 (76.5%, 50.1 to 93.2) improved at 6 months and 13 of 14 (92.9%) at 12 months; none stopped for side effects.
RetrospectiveNodal-antibody patients Retrospective cohort Nodal/paranodal antibody-positive n: 8 treated Treatment response 6 of 8 (75.0%) responded to rituximab, against 1 of 7 (14.3%) to IVIg.
RetrospectiveAnti-NF155 patients, Korea Retrospective cohort Anti-neurofascin-155 positive n: 6 Treatment response All 3 treated with rituximab responded well; corticosteroids gave partial or no response in 5 of 5.
RandomisedIgG4-antibody RCT RCT Refractory CIDP with IgG4 autoantibodies n: Not stated Not stated in the record Rituximab was tested against placebo in this subgroup, but the record carries no numbers.
Safety
Next registered completions

All 40 publications assigned to this drug, 31 with figures

CAR-T and stem-cell transplantChinese hospitals, Juventas, Kite (Gilead), TG Therapeutics · 11 Phase 1 or 1/2 studiesAwaiting data

Striking single-patient results, three CIDP patients in the records, and no controlled data. The question is durability against the risks of conditioning in a non-fatal disease.

How it is given
A single intravenous infusion of CAR-T cells after fludarabine and cyclophosphamide conditioning.
What is missing
No controlled or multi-patient CIDP data.
Study Patients Endpoint Result
Case reportAnti-BCMA CAR-T Case series Relapsed or refractory CIDP n: 2 Remission Both patients reached drug-free remission within 6 months; one relapsed at 12 months after severe COVID-19, the other remained in remission beyond 24 months.
Case reportBCMA-CD19 CAR-T Single patient (news) Relapsed CIDP n: One patient Walking speed, relapse 10-metre walk time fell from 21 to 13 seconds by day 180; relapse-free off immunosuppressants for over a year.
Trial or cohortAutologous stem-cell transplant Phase 2, mixed diseases Refractory neuroimmune disease (3 CIDP) n: 12 Transplant-related mortality No transplant-related deaths by day 100; CIDP outcomes were not reported separately.
Safety
  • Single CAR-T patient: fever, a transient IL-6 rise and grade 2 hypotension. News 2024-06-20
Next registered completions

NVG-2089Nuvig Therapeutics · Phase 2Awaiting data

A recombinant stand-in for IVIg. Only a healthy-volunteer study so far, with no numbers in its record.

How it is given
Intravenous.
What is missing
Phase 2 single-arm studies started in 2025.
Study Patients Endpoint Result
Healthy volunteersDose escalation Phase 1, healthy volunteers Healthy adults n: Not stated Safety, pharmacokinetics No numbers in the record.

Corticosteroids and steroid-sparing add-onsAcademic · First-line (corticosteroids); add-ons off-labelMixed

Adding pulsed steroids to IVIg did not raise remission and caused clots. Tacrolimus and mycophenolate show retrospective steroid- and IVIg-sparing signals, without randomised data.

How it is given
IV methylprednisolone 1000 mg every 3 weeks for 18 weeks on top of IVIg in the add-on trial; oral tacrolimus or mycophenolate as add-ons.
What is missing
No randomised data for the oral steroid-sparing drugs.
Study Patients Endpoint Result
RandomisedAdd-on RCT RCT, double-blind Treatment-naive or relapsing CIDP n: 77 Remission at 52 weeks Remission in 38% (14/37) with methylprednisolone against 28% (11/40) with placebo; difference 10% (-11 to 31), p=0.47.
RetrospectiveTacrolimus plus prednisone Retrospective cohort Mixed CIDP, one Chinese centre n: 34 Relapse and steroid use over 12 months Relapse in 12.5% with tacrolimus against 33.3% on prednisone alone; prednisone stopped in 43.8% against 11.1%.
RetrospectiveMycophenolate in refractory CIDP Retrospective case-control Refractory CIDP n: 11 Strength, disability, day-care use MRC sum score rose from 58 to 68.5 and I-RODS from 47 to 78 after a year; day-care use fell from 2.89 to 1.65 days a month.
Safety

All 10 publications assigned to this drug, 10 with figures

Plasma exchange and immunoadsorptionHospital apheresis units · Standard option, mainly short-term or refractoryAwaiting data

Works about as well as IVIg in small trials and helps in refractory disease, but venous access and clotting limit long-term use.

How it is given
Apheresis in hospital through venous access, a median of 5 sessions per course.
Study Patients Endpoint Result
RandomisedPlasma exchange vs IVIg Meta-analysis of RCTs CIDP n: 2 RCTs, 32 participants Deficit at 6 weeks No significant difference between plasma exchange and IVIg.
RetrospectivePlasma exchange vs immunoadsorption Retrospective cohort Mixed CIDP n: 44 Clinical improvement Improvement in 14 of 23 (60.9%) with plasma exchange and 11 of 21 (52.4%) with immunoadsorption; shorter hospital stay with immunoadsorption.
Trial or cohortRefractory patients Prospective cohort Refractory CIDP n: Not stated Rate of progression Against prior therapy, progression slowed from 3.8 to 0.2 points a month on immunoadsorption and from 4.2 to -1.1 on plasma exchange.
Safety
  • Jugular vein thrombosis in 15 of 240 immunoadsorption cycles and 6 of 79 plasma-exchange cycles. Publication 2026 DOI ↗
Next registered completions

All 16 publications assigned to this drug, 10 with figures

Palmitoylethanolamide (for nerve pain)Academic · Symptomatic add-onAwaiting data

A small open-label signal for neuropathic pain, which disease-modifying trials rarely measure.

How it is given
Oral 600 mg twice daily for 60 days, on top of immunoglobulin.
Study Patients Endpoint Result
Trial or cohortProof of concept Open-label, crossover timing Patients on immunoglobulin with neuropathic pain n: 14 Pain intensity, quality of life Pain symptoms (p=0.0007) and quality of life (p=0.0036) improved over time.

Terms used

aINCAT
Adjusted INCAT disability score, 0 (no disability) to 10, arms and legs. A change of 1 point is the usual threshold for improvement or relapse.
I-RODS
Patient-reported daily-activity scale, centile 0 to 100. A gain of 4 or more is taken as meaningful.
Grip strength
Measured in kilopascals (kPa). A change of 8 kPa or more is taken as meaningful.
Randomised withdrawal
Everyone gets the drug first; only responders are then randomised to stay on it or switch to placebo. It shows that the drug keeps working, not how many people it helps from the start.
HR / RR / OR
Hazard, risk or odds ratio against the control arm. Below 1 means fewer events on the drug. The brackets give the 95% confidence interval.

How this was built

Publications were assigned to a drug through the asset dictionary and sorted by evidence type automatically. The result rows were then written by an analyst from each record's AI-written key results and abstract, from the findings of company news items and from registry entries, and every number in them is checked by the pipeline against the cited record. Only 2024 to 2026 publications are in the export, so older pivotal trials (for example ICE or PATH) appear only as far as recent reviews cite them. Abstract-level data can differ from the full paper; each row links to its source.

Readout calendar

When the evidence arrives

39 active or planned studies of named interventions carry a registered primary completion date between now and 2030. Each line runs from study start to that date. Registry dates are sponsor estimates and move; treat them as a sequence, not a schedule.

  • RD06-05 · Phase 1 · NCT07337785 · Tongji Hospital · Recruiting · start 2025-12 · primary completion 2026-12 · CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
  • HY001N · Phase 1 · NCT07265206 · Juventas Cell Therapy Ltd · Not yet recruiting · start 2025-12 · primary completion 2026-12 · A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
  • JY231 · Phase 1 (inferred) · NCT06797024 · Tongji Hospital · Recruiting · start 2025-02 · primary completion 2026-12 · JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
  • Azer-cel · Phase 1 · NCT06680037 · TG Therapeutics Inc · Recruiting · start 2025-05 · primary completion 2026-12 · A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
  • Universal CD19/BCMA CAR-T · Phase 1 · NCT06485232 · Capital Medical University · Not yet recruiting · start 2025-02 · primary completion 2026-12 · Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
  • Hizentra (IgPro20) · Phase 1 · NCT05584631 · Rutgers The State University of New Jersey · Recruiting · start 2022-09 · primary completion 2026-12 · IVIG vs SCIG in CIDP
  • Nipocalimab · Phase 2/3 · NCT05327114 · Johnson & Johnson · Recruiting · start 2022-09 · primary completion 2027-05 · Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Universal CD19/BCMA CAR-T · Phase 1 · NCT07392528 · Tianjin Huanhu Hospital · Not yet recruiting · start 2026-03 · primary completion 2027-06 · Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
  • CNCT19 · Phase 1 · NCT07275736 · Juventas Cell Therapy Ltd · Recruiting · start 2025-03 · primary completion 2027-06 · A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
  • Ripertamab · Phase 3 · NCT06858722 · Zhongming Qiu · Not yet recruiting · start 2025-03 · primary completion 2027-06 · Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
  • Riliprubart · Phase 3 · NCT06290141 · Sanofi · Recruiting · start 2024-08 · primary completion 2027-07 · A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating
  • HyQvia (TAK-771) · Phase 4 (inferred) · NCT06538064 · Takeda · Recruiting · start 2025-04 · primary completion 2027-08 · A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
  • Octapharma Ig (Panzyga / NewGam / Octagam) · Phase 2 · NCT04153422 · Endeavor Health · Recruiting · start 2023-12 · primary completion 2027-08 · IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies
  • Empasiprubart · Phase 3 · NCT06920004 · argenx BV · Recruiting · start 2025-08 · primary completion 2027-09 · A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
  • Plasma exchange / immunoadsorption · Phase 2 · NCT04881682 · Ulm University · Recruiting · start 2023-05 · primary completion 2027-09 · Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • … and 24 more.
Riliprubart is not on this calendar the way the registry suggests

Sanofi discontinued the Phase 3 MOBILIZE study for futility on 10 June 2026 and ClinicalTrials.gov has closed it. Its Japanese and EU mirror records still read as not yet recruiting and recruiting, and would place it on this chart. Only VITALIZE (NCT06290141, primary completion 2027-07-09) and the long-term extension are shown.

By quarter

Expected Intervention Phase Sponsor Study Registry
2026 Q4 RD06-05 Phase 1 Tongji Hospital NCT07337785 ClinicalTrials.gov ↗ CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases ClinicalTrials.gov
2026 Q4 HY001N Phase 1 Juventas Cell Therapy Ltd NCT07265206 ClinicalTrials.gov ↗ A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases ClinicalTrials.gov
2026 Q4 JY231 Phase 1 (inferred) Tongji Hospital NCT06797024 ClinicalTrials.gov ↗ JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders ClinicalTrials.gov
2026 Q4 Azer-cel Phase 1 TG Therapeutics Inc NCT06680037 ClinicalTrials.gov ↗ A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders WHO ICTRP
2026 Q4 Universal CD19/BCMA CAR-T Phase 1 Capital Medical University NCT06485232 ClinicalTrials.gov ↗ Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. WHO ICTRP
2026 Q4 Hizentra (IgPro20) Phase 1 Rutgers The State University of New Jersey NCT05584631 ClinicalTrials.gov ↗ IVIG vs SCIG in CIDP WHO ICTRP
2027 Q2 Nipocalimab Phase 2/3 Johnson & Johnson NCT05327114 ClinicalTrials.gov ↗ Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ClinicalTrials.gov
2027 Q2 Universal CD19/BCMA CAR-T Phase 1 Tianjin Huanhu Hospital NCT07392528 ClinicalTrials.gov ↗ Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases ClinicalTrials.gov
2027 Q2 CNCT19 Phase 1 Juventas Cell Therapy Ltd NCT07275736 ClinicalTrials.gov ↗ A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases ClinicalTrials.gov
2027 Q2 Ripertamab Phase 3 Zhongming Qiu NCT06858722 ClinicalTrials.gov ↗ Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy ClinicalTrials.gov
2027 Q3 Riliprubart Phase 3 Sanofi NCT06290141 ClinicalTrials.gov ↗ A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating ClinicalTrials.gov
2027 Q3 HyQvia (TAK-771) Phase 4 (inferred) Takeda NCT06538064 ClinicalTrials.gov ↗ A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care WHO ICTRP
2027 Q3 Octapharma Ig (Panzyga / NewGam / Octagam) Phase 2 Endeavor Health NCT04153422 ClinicalTrials.gov ↗ IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies ClinicalTrials.gov
2027 Q3 Empasiprubart Phase 3 argenx BV NCT06920004 ClinicalTrials.gov ↗ A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP WHO ICTRP
2027 Q3 Plasma exchange / immunoadsorption Phase 2 Ulm University NCT04881682 ClinicalTrials.gov ↗ Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) WHO ICTRP
2027 Q3 Plasma exchange / immunoadsorption Not stated / observational Ulm University NCT04871035 ClinicalTrials.gov ↗ Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS) WHO ICTRP
2027 Q4 Empasiprubart Phase 3 argenx BV NCT07091630 ClinicalTrials.gov ↗ A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP ClinicalTrials.gov
2027 Q4 Rituximab Phase 3 Amsterdam University Medical Center (UMC), Location Academic Medical C NCT06714838 ClinicalTrials.gov ↗ Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy WHO ICTRP
2027 Q4 Hizentra (IgPro20) Phase 3 Grifols NCT07540221 ClinicalTrials.gov ↗ A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy ClinicalTrials.gov
2027 Q4 QH103 Phase 1 Tongji Hospital NCT07526493 ClinicalTrials.gov ↗ Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. ClinicalTrials.gov
2027 Q4 BAFF-R CAR-T Phase 1/2 Tianjin Medical University NCT07022197 ClinicalTrials.gov ↗ Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases ClinicalTrials.gov
2027 Q4 IVIG (unbranded / generic) Phase 3 Kedrion SpA NCT06752356 ClinicalTrials.gov ↗ A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ClinicalTrials.gov
2027 Q4 Hizentra (IgPro20) Phase 4 (inferred) CSL Behring NCT04672733 ClinicalTrials.gov ↗ Hizentra® in Inflammatory Neuropathies - pHeNIx Study ClinicalTrials.gov
2028 Q1 HyQvia (TAK-771) Not stated / observational Heinrich-Heine University, Duesseldorf NCT07273903 ClinicalTrials.gov ↗ Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices ClinicalTrials.gov
2028 Q2 Empasiprubart Phase 2/3 argenx BV NCT07638566 ClinicalTrials.gov ↗ A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating ClinicalTrials.gov
2028 Q2 HyQvia (TAK-771) Phase 3 Takeda NCT06747351 ClinicalTrials.gov ↗ A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) ClinicalTrials.gov
2028 Q3 Imeroprubart Phase 2 Immunovant Sciences GmbH NCT07032662 ClinicalTrials.gov ↗ Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) WHO ICTRP
2028 Q4 IVIG (unbranded / generic) Not stated / observational University Hospital Centre Nice NCT07719153 ClinicalTrials.gov ↗ Ultrasound-driven Stratification in CIDP ClinicalTrials.gov
2028 Q4 Claseprubart Phase 3 Dianthus Therapeutics Inc NCT06858579 ClinicalTrials.gov ↗ A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) ClinicalTrials.gov
2028 Q4 Octapharma Ig (Panzyga / NewGam / Octagam) Phase 3 Octapharma AG NCT04929236 ClinicalTrials.gov ↗ Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients WHO ICTRP
2029 Q1 Plasma exchange / immunoadsorption Phase 2 (inferred) Ulm University NCT07154524 ClinicalTrials.gov ↗ Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ClinicalTrials.gov
2029 Q2 KITE-363 Phase 1 Kite IT GmbH NCT07304154 ClinicalTrials.gov ↗ A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases ClinicalTrials.gov
2029 Q4 Efgartigimod Phase 4 (inferred) argenx BV NCT07264426 ClinicalTrials.gov ↗ Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study ClinicalTrials.gov
2029 Q4 Riliprubart Phase 3 Sanofi NCT06859099 ClinicalTrials.gov ↗ Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP ClinicalTrials.gov
2029 Q4 Octapharma Ig (Panzyga / NewGam / Octagam) Phase 3 Octapharma AG NCT07220915 ClinicalTrials.gov ↗ Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections ClinicalTrials.gov
2029 Q4 Privigen (IgPro10) Phase 4 CSL Behring NCT03684018 ClinicalTrials.gov ↗ Two Dose Levels of Privigen in Pediatric CIDP WHO ICTRP
2030 Q1 Obinutuzumab Phase 1/2 Zhongming Qiu NCT07696377 ClinicalTrials.gov ↗ An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy ClinicalTrials.gov
2030 Q4 Hizentra (IgPro20) Phase 4 Aarhus University NCT04589299 ClinicalTrials.gov ↗ Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) WHO ICTRP
2030 Q4 Plasma exchange / immunoadsorption Not stated / observational Charles M Knudson NCT05004493 ClinicalTrials.gov ↗ Biorepository and Registry for Plasma Exchange Patients WHO ICTRP
Developers

Who is doing what, on the evidence

51 organisations appear in at least two of the seven organisation-level sources. Status is set by the strongest evidence available: a post-approval study or approval news, then sponsorship of an active interventional study, then completed studies, then patents. Each company's own written assessment is shown alongside, and where the registry is newer it takes precedence.

Developer Status Seen in Patent families Studies sponsored Active Latest signal
argenx Website ↗ United States · Post IPO Equity · 1001 - 5000 staff · founded 2008

Company assessment

argenx BV — CIDP drug-development assessment argenx has built a two-mechanism CIDP franchise: an established FcRn-blocking therapy intended to lower pathogenic IgG, and a late-stage complement C2 inhibitor intended to interrupt complement-mediated nerve injury. The company is also investing in long-term, real-world, switching, biomarker and burden-of-illness evidence—consistent with its stated focus on antibody-based medicines for severe autoimmune disease. 1. Empasiprubart (ARGX-117) — novel late-stage asset - Modality / target / mechanism: Intravenous humanized “sweeping” monoclonal antibody against complement component C2 . Its proposed mechanism is upstream inhibition of the classical/lectin complement cascade, distinct from FcRn-mediated IgG reduction. Patent filings specifically describe blockade of the C2b domain and position C2 inhibition for CIDP, MMN and Guillain–Barré syndrome

 Marketed in CIDP 10 9 6 Efgartigimod approved; empasiprubart (anti-C2) in two Phase 3 trials
CSL Website ↗ Australia · Post IPO Equity · 10001+ staff

Company assessment

CSL in CIDP: portfolio assessment CSL’s recent CIDP activity is focused on lifecycle development, real-world evidence and optimized delivery of plasma-derived immunoglobulin , rather than a new molecular entity. The central asset is subcutaneous IgPro20 (Hizentra); intravenous IgPro10 (Privigen) serves principally as an established stabilization/maintenance comparator and antecedent therapy. This strategy is commercially and clinically material: CSL identifies CIDP among the core drivers of immunoglobulin demand, while Hizentra sales grew 18% in the first half of FY2024. Assets — from newer/lifecycle innovation to most established IgPro20 / Hizentra® — subcutaneous human normal immunoglobulin (SCIG), 20% liquid Indication and stage: Approved/marketed maintenance therapy for CIDP; current work is post-marketing, health-economic and implementation-focused rather than registrational develop

 Marketed in CIDP 4 7 2 Active or planned: Hizentra (IgPro20), Privigen (IgPro10) (2 studies)
Takeda Website ↗ Japan · 10001+ staff

Company assessment

Takeda’s CIDP portfolio combines a novel modified immunoglobulin candidate with lifecycle development of immunoglobulin-based maintenance and rescue therapies. The recent evidence base is concentrated on optimizing immune-globulin delivery, durability, safety, and patient convenience rather than on a disclosed new antigen-specific mechanism. 1. TAK-411 — early clinical, modified immunoglobulin asset - Modality / mechanism: Chemically modified human-source immunoglobulin G (hsIgG), derived from human plasma. The stated rationale is immunomodulation to decrease inflammation and improve CIDP symptoms; a specific molecular target or detailed mechanism has not been disclosed in the supplied metadata. - Indication / stage: CIDP; Phase 2 , open-label proof-of-concept CASCA study. It began in May 2025, is recruiting, and has a planned primary completion in December 2027. - Study design and valid

 Marketed in CIDP 2 6 2 HyQvia approved for CIDP maintenance (FDA and EU, January 2024)
Octapharma Website ↗ Switzerland · 10001+ staff · founded 1983

Company assessment

Octapharma AG — CIDP drug-development assessment Octapharma’s CIDP portfolio is centred on PANZYGA® (10% liquid intravenous immunoglobulin; IVIG) , a human-protein replacement/immunomodulatory product rather than a novel molecularly targeted agent. The company’s current CIDP development emphasis is expansion into paediatric CIDP and dose optimisation, supported by completed pivotal adult dose-ranging evidence. Its broader immunoglobulin research includes adjacent immune-mediated neuropathies, but no new CIDP-specific non-IVIG asset is evident in the supplied recent metadata. 1. PANZYGA® / IVIG 10% — paediatric CIDP dose-regimen programme - Asset / modality: PANZYGA is a ready-to-infuse 10% human normal IVIG preparation. It is a pooled, polyvalent immunoglobulin product, not an antigen-specific antibody or small molecule. - Indication: Paediatric chronic inflammatory demyelinating polyrad

 Marketed in CIDP — 5 2 Active or planned: Octapharma Ig (Panzyga / NewGam / Octagam) (2 studies)
Grifols Website ↗ Spain · Post IPO Debt · 10001+ staff

Company assessment

Grifols’ CIDP drug-development focus is concentrated on immunoglobulin replacement/immunomodulation rather than novel molecular entities. Its most current CIDP program evaluates a subcutaneous formulation as a potentially more convenient maintenance option, alongside research intended to individualize IVIG dosing. 1. XEMBIFY® (subcutaneous immune globulin; SCIG) — Phase 3, recruiting - Asset/modality: XEMBIFY is a weekly, subcutaneous human immunoglobulin G (IgG) product. In CIDP, it represents a route-of-administration and pharmacokinetic-development strategy, rather than a new target-specific drug. - Indication and stage: Grifols is sponsoring a recruiting Phase 3 open-label, multicenter CIDP study, initiated April 2026, with expected completion in December 2027. - Study design / validation objective: Participants receive Gamunex-C intravenously every three weeks for 19 weeks, then tra

 Marketed in CIDP — 4 2 Active or planned: Grifols Ig (Gamunex / Xembify), Hizentra (IgPro20) (2 studies)
Sanofi Website ↗ France

Company assessment

Sanofi—CIDP R&amp;D assessment Sanofi’s recent CIDP research is concentrated in a single, mechanism-led asset, riliprubart (SAR445088; previously BIVV020) . The program targets classical-complement biology in immune-mediated peripheral nerve injury and has been supported by translational, Phase 1 and Phase 2 work. However, its late-stage outlook changed materially in June 2026 when the Phase 3 MOBILIZE study in refractory CIDP was stopped for futility. The available metadata does not establish discontinuation of the separate IVIg-comparator program or long-term extension. 1. Riliprubart (SAR445088; previously BIVV020) — most advanced / only identified CIDP drug asset Modality and target: Humanized IgG4 monoclonal antibody that selectively inhibits activated C1s , a serine protease in the classical complement pathway. The therapeutic premise is to reduce complement-mediated inflammation i

 Active clinical 8 4 2 Phase 3 MOBILIZE (riliprubart) discontinued for futility, June 2026
Immunovant Website ↗ United States · Post IPO Equity · 251 - 500 staff · founded 2018

Company assessment

Immunovant: CIDP-focused drug-development assessment Immunovant is a clinical-stage immunology company concentrating on FcRn blockade for IgG-mediated autoimmune diseases. For CIDP, the available recent metadata identifies one investigational asset—batoclimab (IMVT-1401; formerly RVT-1401) . No CIDP-specific clinical-trial record, efficacy readout, regulatory designation, or collaboration is included in the supplied metadata; conclusions on development stage and clinical differentiation should therefore be treated cautiously. Batoclimab / IMVT-1401 (formerly RVT-1401) - Asset and modality: Batoclimab is Immunovant’s fully human monoclonal antibody against the neonatal Fc receptor (FcRn), designed for subcutaneous administration. IMVT-1401 is the company’s prior development name for the same candidate—not a separate pipeline asset. Immunovant’s stated strategy is to use anti-FcRn therapy

Active clinical 4 3 2 Batoclimab Phase 2b; imeroprubart Phase 2 active
Dianthus Therapeutics Website ↗ United States · Post IPO Equity · 51 - 100 staff · founded 2019

Company assessment

CIDP-focused pipeline assessment — Dianthus Therapeutics Claseprubart (DNTH103) — lead and only disclosed CIDP asset | Phase 3 - Asset / modality: Claseprubart (formerly DNTH103) is an investigational, fully human, long-acting monoclonal antibody designed for low-volume, subcutaneous self-administration, potentially every two or four weeks. It is Dianthus’ core neuromuscular-franchise asset, also being developed in generalized myasthenia gravis and multifocal motor neuropathy. - Indication / stage: In adults with chronic inflammatory demyelinating polyneuropathy (CIDP), claseprubart is in the global Phase 3 CAPTIVATE trial, a randomized-withdrawal study. The registered pivotal trial began in February 2025, remains recruiting, and has primary completion projected for December 2028. - Mechanism and target: The molecule selectively binds the active form of C1s , aiming to inhibit the classi

 Active clinical 4 1 1 Early GO in Phase 3 CAPTIVATE (claseprubart), March 2026
Johnson & Johnson Website ↗ United States · IPO · 10001+ staff · founded 1886

Company assessment

CIDP-focused new-drug assessment Johnson & Johnson’s recent CIDP work is concentrated on nipocalimab (IMAAVY®) , rather than a broad collection of distinct CIDP assets. The programme applies an established autoantibody-targeting platform to CIDP, where substantial diagnostic delay, residual disability and dissatisfaction with current guideline-directed treatments remain documented in multinational real-world research. 1. Nipocalimab / IMAAVY® (formerly M281) — lead and only identified CIDP development asset - Modality / target: Fully human, aglycosylated, effectorless IgG1 monoclonal antibody that binds the neonatal Fc receptor ( FcRn ). FcRn blockade interrupts IgG recycling, lowering circulating total IgG and pathogenic IgG autoantibodies—an immunoselective strategy relevant to antibody-mediated CIDP. In Phase 1, the asset showed dose-dependent IgG reduction and was tolerable across in

 Active clinical 4 1 1 Nipocalimab Phase 2/3 (ARISE)
Nuvig Therapeutics Website ↗ United States · Series B · 11 - 50 staff · founded 2020

Company assessment

Nuvig Therapeutics’ CIDP-focused pipeline is centered on NVG-2089 , an IV recombinant IgG1 Fc-domain immunomodulator designed as a dose-efficient, mechanistically targeted alternative to IVIg. The company’s approach aligns with its stated strategy of restoring immune homeostasis rather than broadly suppressing immunity. - NVG-2089 — most advanced and only CIDP asset identified - Modality / administration: Recombinant human IgG1 Fc-domain protein (IgG1 Fc-F241A), administered intravenously. - Indication: Chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated demyelinating peripheral neuropathy. Nuvig’s current clinical program explicitly evaluates safety, tolerability and treatment response in CIDP. - Stage: Phase 2, open-label . Trial records show the study started in 2025, has a planned primary completion in July 2026, and is listed as recruiting in one current reg

 Active clinical — 1 1 Active or planned: NVG-2089 (1 study)
Juventas Cell Therapy Website ↗ China · Series C · 51 - 100 staff

Company assessment

Juventas Cell Therapy: CIDP / autoimmune-neurology pipeline assessment Juventas is developing immune-cell therapies, with its recent clinical activity in autoimmune neurology centered on two CAR-T cell products. Although the available trial records use the broad label “relapsed or refractory neurological autoimmune diseases” rather than naming chronic inflammatory demyelinating polyneuropathy (CIDP) specifically, these programmes may be relevant to CIDP through a B-cell-directed cellular-therapy approach. Importantly, no CIDP-specific cohort, eligibility criteria, efficacy data, or target/MOA details are provided in the available metadata . HY001N — early clinical autoimmune-neurology CAR-T programme - Asset / modality: HY001N cell injection; described by trial keywords as a CAR-T therapy. - Indication: Relapsed/refractory neurological autoimmune diseases. CIDP is not explicitly identifi

 Active clinical — 2 2 Active or planned: CNCT19, HY001N (2 studies)
Kedrion Website ↗ Italy · 1001 - 5000 staff · founded 2001

Company assessment

Kedrion’s CIDP drug-development and access portfolio Kedrion’s CIDP activity is centered on plasma-derived intravenous immunoglobulin (IVIG) rather than novel molecular targets or gene/cell therapies. Its most substantive current development program is a Phase 3 dose-optimization study of KIg10/QIVIGY, complemented by commercialization of GAMMAKED in the United States. This focus is consistent with the company’s plasma fractionation and immunoglobulin expertise. 1. KIg10 / QIVIGY — Phase 3, maintenance-dose development in CIDP - Asset and modality: KIg10 (QIVIGY), an intravenous human normal immune globulin 10% (IVIG) plasma-derived product. - Indication: Maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) . - Stage and timeline: A recruiting Phase 3 , randomized, double-blind, multicenter study began in August 2026. Primary completion is anticipated in Dece

 Active clinical — 3 1 Active or planned: immunoglobulin (1 study)
Kite (Gilead) Website ↗ Germany · 51 - 200 staff · founded 2019

Company assessment

CIDP-focused drug-development assessment The available recent research metadata identifies one investigational asset, KITE-363 , being developed in a recruiting, early-phase basket trial that includes chronic inflammatory demyelinating polyneuropathy (CIDP). No publications or organizational web-page research records were provided, so scientific validation is presently limited to the registered clinical-trial description. KITE-363 — autologous anti-CD19/CD20 CAR T-cell therapy - Modality / asset: Autologous chimeric antigen receptor (CAR) T-cell therapy directed against CD19 and CD20 . This is a cell-based B-cell–depleting strategy, rather than a conventional chronic maintenance immunotherapy. - CIDP indication: Enrolled within a basket of relapsed/refractory autoimmune neurologic diseases , alongside myasthenia gravis and multiple sclerosis. Thus, CIDP is a named target population, but

Active clinical — 1 1 Active or planned: KITE-363 (1 study)
TG Therapeutics Website ↗ United States · Post IPO Debt · 251 - 500 staff · founded 2011

Company assessment

CIDP-focused development - Azercabtagene zapreleucel (azer-cel) — Phase 1, recruiting - Asset / modality: Investigational cell therapy; the supplied record identifies azer-cel by its full name but does not specify its cellular engineering, antigen target, or manufacturing approach. - CIDP indication: CIDP is explicitly included among the study keywords within a broader program for B-cell–mediated autoimmune disorders . This supports an early exploratory development effort in CIDP rather than a CIDP-specific registrational program. - Stage and design: Open-label Phase 1 study, initiated May 2025 and recruiting. The primary objective is to establish the recommended Phase 2 dose (RP2D) , with primary completion anticipated in December 2027. Thus, clinical efficacy, durability, and benefit–risk in CIDP remain unproven. - Mechanistic rationale: The trial’s enrollment in B-cell–mediated autoim

 Active clinical — 1 1 Active or planned: Azer-cel (1 study)
Halozyme Website ↗ United States · Post IPO Debt · 251 - 500 staff · founded 1998

Company assessment

CIDP focus — Halozyme Inc. Halozyme’s CIDP relevance is primarily as a drug-delivery technology partner , rather than as the originator of the active immunotherapies. Its proprietary ENHANZE® platform uses recombinant human hyaluronidase PH20 ( rHuPH20 ) to improve dispersion and absorption of co-formulated biologics in subcutaneous tissue, enabling high-volume and, in some settings, patient-administered delivery. The current CIDP portfolio includes two commercially approved partnered therapies with distinct therapeutic mechanisms: FcRn blockade (argenx) and immunoglobulin replacement/immunomodulation (Takeda). VYVGART® Hytrulo / VYVDURA® / VYVDURA pre-filled syringe (efgartigimod alfa + hyaluronidase-qvfc) - Asset / modality: A targeted IgG1 Fc fragment that blocks the neonatal Fc receptor ( FcRn ), co-formulated with Halozyme’s rHuPH20 for subcutaneous delivery. This is a partner produ

 Technology partner — — — Subcutaneous delivery technology (ENHANZE) in the efgartigimod SC approvals
Pfizer Website ↗ United States

Company assessment

Pfizer: CIDP-focused drug-development assessment The available recent metadata does not identify a Pfizer-sponsored clinical-stage or marketed drug specifically for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) . Pfizer’s most relevant current exposure is indirect: Pfizer Ventures is an investor in Montis Biosciences, whose lead C1q-antibody program is being positioned for CIDP and Guillain–Barré syndrome. Pfizer’s recent listed patents concern CGRP inhibitors and MAGL inhibitors rather than CIDP, so they do not substantiate an internal CIDP pipeline. MB0109 (Montis Biosciences; Pfizer Ventures portfolio company) — preclinical / IND-enabling - Asset and modality: MB0109 is a first-in-class anti-C1q monoclonal antibody . It is being developed by Montis Biosciences, not Pfizer; Pfizer’s connection in the provided evidence is through Pfizer Ventures’ investment in Montis.

 Clinical, none active 2 1 — Completed or stopped: PF-06755347
Kine Sciences Website ↗ South Korea · Venture Round · 11 - 50 staff · founded 2012

Company assessment

Kine Sciences: CIDP drug-development assessment Kine Sciences is a clinical-stage peptide therapeutics company focused on ultra-small, immune-modulating peptides derived from the anti-inflammatory cytokine ERDR1. For CIDP, the available recent evidence supports a single clinical asset— KINE-101 —with a differentiated regulatory-T-cell (Treg) activation hypothesis. The company also has recent CIDP-focused patent activity covering both a treatment peptide and its administration regimen. No peer-reviewed publications or clinical efficacy results were provided; consequently, clinical validation remains preliminary. 1. KINE-101 — lead clinical CIDP asset - Modality / asset: Ultra-small “nanopeptide” (<1 kDa; stated to comprise nine amino acids in the company overview), administered intravenously in the documented CIDP trial. The company describes it as a disease-modifying immune peptide rathe

 Clinical, none active 2 1 — KINE-101 Phase 1b/2a, first patient dosed September 2024
Biogen Website ↗ United States

Company assessment

Biogen’s CIDP-focused drug-development evidence is limited and largely historical. The available recent metadata identifies a 2024 patent that explicitly includes CIDP among potential autoimmune indications, but does not disclose a named CIDP development candidate or CIDP-specific clinical data. The only identified CIDP trials involve older assets, with no active/recruiting Biogen-sponsored CIDP study in the supplied dataset. 1. BTK inhibitor + fumaric acid ester combination — early patent-stage concept - Asset/modality: An unspecified combination of a Bruton’s tyrosine kinase (BTK) inhibitor and a fumaric acid ester (FAE) ; individual compounds, formulation, dosing, and route are not provided in the available record. - CIDP relevance/indication: CIDP is included among example autoimmune diseases that could be treated by the combination. This is an IP claim and should not be interpreted

Clinical, none active 1 1 — Completed or stopped: Interferon beta-1a
UCB Website ↗ Belgium

Company assessment

UCB: CIDP-focused drug-development assessment The recent CIDP-specific evidence identifies rozanolixizumab as UCB’s principal clinically tested asset. Its Phase 2a study did not demonstrate efficacy, despite acceptable medium/longer-term tolerability. A more exploratory patent-based opportunity is fenfluramine for demyelinating disease , but the available metadata do not establish CIDP-specific clinical development. UCB also retains a substantial FcRn-antibody intellectual-property estate that supports its antibody platform. 1. Fenfluramine — exploratory / patent-stage demyelination program - Asset / modality: Fenfluramine, a small-molecule drug repurposing concept for demyelinating diseases. - CIDP relevance / indication: The patent covers modifying progression of neurodegenerative diseases or conditions associated with demyelination, inadequate myelination, or myelin-sheath underdevelo

 Clinical, none active — 3 — Completed or stopped: Rozanolixizumab
LFB Website ↗ France · Debt Financing · 1001 - 5000 staff

Company assessment

LFB’s CIDP-focused drug portfolio is centered on intravenous human immunoglobulin (IVIG), with clinical evidence for its 10% IVIG product IqYmune and earlier real-world/retrospective evidence for Tegeline. The company also has earlier exploratory work around recombinant Fc-based immunomodulation, but the supplied metadata do not establish a current CIDP clinical-development program for that approach. 1. Recombinant modified Fc fragments — exploratory / preclinical concept - Asset/modality: Recombinant antibody Fc fragments engineered to alter Fc-receptor binding; this is a potentially differentiated, non–plasma-derived immunomodulatory approach. - Potential indication and stage: Autoimmune/inflammatory diseases broadly; CIDP relevance is preclinical/exploratory in the available record. A 2017 LFB-affiliated report describes therapeutic activity of human immunoglobulins or a recombinant F

 Clinical, none active — 3 — Completed or stopped: LFB Ig (I10E / Iqymune)
MedDay Pharmaceuticals Website ↗ France · Series B · 1 - 10 staff

Company assessment

MD1003 (high-dose pharmaceutical-grade biotin) — lead/only identified CIDP-relevant asset - Modality / asset: Orally administered, high-dose pharmaceutical-grade biotin (vitamin B7) ; evaluated at 100 mg three times daily for up to 52 weeks in the published study. - CIDP indication and rationale: MedDay positioned MD1003 for demyelinating peripheral neuropathies, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) , alongside anti-MAG neuropathy and Charcot–Marie–Tooth disease. This fits the company’s stated broader strategy of pursuing neuro-repair/disease-modifying therapies through neurometabolic pathways, although the available CIDP-specific evidence remains limited. - Stage / development status: A MedDay-sponsored, single-centre, open-label Phase II/IIb pilot (SERENDEM; NCT02967679) enrolled 15 patients with demyelinating neuropathies and completed in March 20

 Clinical, none active — 1 — Completed or stopped: MD1003 (biotin)
Nihon Pharmaceutical Japan · 251 - 500 staff

Company assessment

Nihon Pharmaceutical: CIDP drug-development assessment Nihon Pharmaceutical’s identifiable CIDP-focused clinical development is limited to NPB-01 , an intravenous immunoglobulin (IVIG) maintenance regimen. Although the available study is not recent—it completed in 2015—it represents a completed Phase III programme in CIDP. No more recent CIDP patents, publications, organisational web pages, or additional clinical assets were provided. The company’s general description primarily positions it as a manufacturer of OTC drugs and medicines, rather than as a broad innovative neurology R&amp;D organisation. 1. NPB-01 — most advanced identified CIDP asset Modality: Intravenous immunoglobulin (IVIG); a plasma-derived polyclonal immunoglobulin replacement/immunomodulatory therapy. Indication: Chronic inflammatory demyelinating polyneuropathy (CIDP). Development stage: Completed Phase III maintenan

 Clinical, none active — 1 — Completed or stopped: NPB-01
Novartis Website ↗ Switzerland · Post IPO Debt · 10001+ staff · founded 1996

Company assessment

Novartis: CIDP new-drug assessment Based on the available topic-specific research record, Novartis has no active or recent CIDP drug-development programme disclosed . Its identifiable CIDP asset was fingolimod (FTY720), which reached Phase III but did not demonstrate clinical benefit versus placebo. Recent Novartis neurological innovation referenced in the supplied data is in genetic Charcot–Marie–Tooth disease rather than CIDP, and should not be interpreted as a CIDP pipeline programme. Fingolimod (FTY720) — most advanced CIDP asset; discontinued/negative programme Modality: Oral small-molecule sphingosine-1-phosphate (S1P) receptor modulator / immunosuppressive agent. Indication: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Stage: Phase III (FORCIDP), completed in September 2016; no evidence in the supplied recent records of further CIDP development. The trial was

Collaborator / non-drug study 5 — — Named as collaborator, not sponsor, on CIDP studies
AstraZeneca / Alexion Website ↗ United Kingdom

Company assessment

AstraZeneca: CIDP-focused new-drug assessment The recent document set does not identify an AstraZeneca drug in clinical development specifically for chronic inflammatory demyelinating polyneuropathy (CIDP) . The company’s most relevant activity is an early complement-inhibition discovery/IP portfolio, alongside an ongoing observational study that uses CIDP as a comparator in differentiating neuropathy from transthyretin amyloidosis. Thus, AstraZeneca currently appears better positioned in neuropathy mechanism research and diagnostic differentiation than in a disclosed, CIDP-directed clinical drug program. 1. Undisclosed complement C1s inhibitor compounds — preclinical/discovery (novel assets) - Asset/modality: Undisclosed pharmaceutical compounds, including a peptide-based series; no development code, pharmacokinetic profile, or clinical program is provided. - Stage: Discovery/preclinica

 Collaborator / non-drug study 2 — — Named as collaborator, not sponsor, on CIDP studies
Teijin Japan · IPO · 10001+ staff · founded 1918

Company assessment

CIDP-focused drug-development assessment - Unnamed vitamin D derivative program — preclinical / patent-stage; potential remyelination approach - Asset/modality: Small-molecule vitamin D derivatives, including solid-form (crystal/solvate) inventions and derivatives containing a cyclic amine side chain. - Relevance to CIDP: The patent portfolio describes pharmacological promotion of oligodendrocyte progenitor-cell differentiation into oligodendrocytes and remyelination. This represents a potentially disease-modifying repair strategy conceptually relevant to inflammatory demyelinating disorders, including CIDP. However, the supplied materials do not identify CIDP as an explicit development indication, nor do they report CIDP efficacy, dose, safety, or clinical studies. - Mechanism/target: Vitamin D derivative-based biology; the disclosed functional endpoint is oligodendrocyte progenitor-cel

 Collaborator / non-drug study 2 — — Named as collaborator, not sponsor, on CIDP studies
HanAll Biopharma South Korea · 201 - 500 staff · founded 1973

Company assessment

HanAll Biopharma’s CIDP-relevant innovation is concentrated in an FcRn-inhibition franchise designed to lower pathogenic IgG antibodies. The company’s principal CIDP program is licensed to Immunovant in the US and Europe; the available metadata contains development updates through March 2025, but no CIDP clinical-trial record or post-2025 efficacy readout. Accordingly, the reported CIDP timelines should be treated as historical guidance rather than confirmation of current status. - HL161ANS / IMVT-1402 — next-generation anti-FcRn asset; CIDP program design-stage - Modality / mechanism: Fully human, subcutaneously administered anti-FcRn monoclonal antibody. It is engineered to inhibit FcRn-mediated IgG recycling, with the intended result of substantial pathogenic-IgG reduction while minimizing effects on albumin recycling. - CIDP status: No dedicated CIDP efficacy study or patient data ar

 Patents / preclinical 2 — — Top-ranked family: Anti-FCRN Antibody or Antigen Binding Fragment Thereof With Improved Stability (FcRn / Fc receptor)
Incyte Website ↗ United States · IPO · 1001 - 5000 staff

Company assessment

Incyte and CIDP: recent research assessment The available recent metadata does not identify an Incyte-sponsored drug candidate in clinical development for chronic inflammatory demyelinating polyneuropathy (CIDP) . Incyte’s CIDP-related contribution is currently limited to a patient-experience publication involving Incyte-affiliated authors, rather than interventional drug-development evidence. Its newest inflammation-related assets in the supplied records are preclinical/patent-stage MRGPRX2 antagonists , with no stated CIDP indication. 1. Bicyclic heterocycles targeting MRGPRX2 — early discovery / patent stage - Asset / modality: Undisclosed bicyclic heterocyclic compounds; likely orally available small-molecule GPCR antagonists, consistent with Incyte’s stated small-molecule discovery focus. - Target and proposed mechanism: Antagonism/inhibition of MRGPRX2 (mas-related G-protein-couple

 Patents / preclinical 2 — — 2 patent families naming CIDP
Sitryx Therapeutics Website ↗ United Kingdom · Series A · 11 - 50 staff · founded 2018

Company assessment

CIDP-focused assessment: Sitryx’s available recent research metadata does not identify chronic inflammatory demyelinating polyneuropathy (CIDP) as a named indication, and there are no disclosed CIDP clinical trials, development projects, publications, or company news items in the supplied record. The evidence instead supports an early discovery/preclinical immuno-inflammation portfolio of small-molecule chemical series broadly claimed for inflammatory diseases and undesirable immune responses. Consequently, none of the assets below can currently be considered a clinically validated CIDP programme. Newer / less-defined discovery assets - Substituted pyridine series - Modality: Small-molecule substituted pyridines. - Indication positioning: Broad inflammatory disease and undesirable immune-response settings; CIDP is not specifically disclosed . - Stage: Discovery/patent stage; no clinical-

 Patents / preclinical 10 — — 10 patent families naming CIDP
Bristol-Myers Squibb Website ↗ United States · Post IPO Debt · 10001+ staff

Company assessment

CIDP-focused assessment: The supplied recent metadata does not identify a Bristol Myers Squibb (BMS) drug, clinical trial, or patent explicitly being developed for chronic inflammatory demyelinating polyneuropathy (CIDP) . A March 2026 news item references CIDP among therapeutic areas covered in the week’s biotech news, but does not name a BMS CIDP product or establish that the reported BMS FDA action concerned CIDP. The following are BMS autoimmune/neurology-adjacent assets and research concepts present in the metadata, ordered from earlier-stage/newer concepts to the most clinically advanced disclosed program. They should not be interpreted as evidence of a CIDP pipeline unless further primary-source disclosures emerge. Unnamed anti-TREM-1 antibodies — preclinical/patent-stage; not CIDP-specific - Modality / target: Antagonistic monoclonal antibodies or antigen-binding fragments direct

 Patents / preclinical 4 — — 4 patent families naming CIDP
Gliknik Website ↗ United States · Series C · 2 - 10 staff · founded 2007

Company assessment

CIDP relevance and new-drug assessment Gliknik’s recent documented activity is centered on its Stradomer/multivalent Fc platform —recombinant, multimerized IgG Fc constructs intended to reproduce or improve selected immunomodulatory effects of pooled intravenous immunoglobulin (IVIG). This is mechanistically relevant to CIDP, where IVIG is an established immunomodulatory treatment. However, the supplied recent metadata contains no CIDP-specific clinical trials, efficacy publications, development-stage disclosures, or named CIDP program . Accordingly, CIDP positioning remains a scientifically plausible platform opportunity rather than a clinically substantiated Gliknik indication. 1. Stradomer / multivalent Fc compounds — preclinical/platform-stage; CIDP-relevant but not clinically disclosed - Asset/modality: Fully recombinant multimerized human IgG1 Fc fusion proteins (“Stradomers”), for

 Patents / preclinical 3 — — Top-ranked family: FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS (FcRn / Fc receptor)
Autobahn Therapeutics Website ↗ United States · Series C · 11 - 50 staff · founded 2017

Company assessment

Assessment of Autobahn Therapeutics’ CIDP-relevant drug research Bottom line: The supplied recent research metadata does not identify a program specifically in chronic inflammatory demyelinating polyneuropathy (CIDP) , nor does it provide CIDP clinical-trial, publication, news, or partnering evidence. Autobahn’s disclosed work is instead centered on CNS-directed, small-molecule thyromimetic chemistry, including prodrug approaches designed around fatty acid amide hydrolase (FAAH). This may have conceptual relevance to repair-oriented neuroimmunology and demyelinating disease biology, but a CIDP indication, efficacy dataset, and clinical development plan cannot be substantiated from the available documents. 1. FAAH-cleavable thyromimetic prodrugs + peripherally restricted FAAH inhibitor combinations — discovery / preclinical-enabling IP - Asset name: No individual development candidate is

Patents / preclinical 3 — — 3 patent families naming CIDP
Augustine Therapeutics Website ↗ Belgium · Series A · 11 - 50 staff · founded 2019

Company assessment

Assessment for CIDP Augustine Therapeutics has a differentiated HDAC6-inhibition platform directed at neuromuscular and neurodegenerative disorders. However, the supplied recent research metadata does not identify chronic inflammatory demyelinating polyneuropathy (CIDP) as a named development indication, nor does it provide CIDP-specific preclinical, clinical, biomarker, or partnership evidence. Its relevance to CIDP is therefore currently mechanistic and exploratory , rather than a documented CIDP development program. Drug/asset findings Unnamed substituted-quinazoline HDAC6 inhibitor series — discovery/preclinical platform Modality: Small-molecule, selective HDAC6 inhibitors based on substituted quinazoline chemistry. The company describes its broader platform as a non-hydroxamate/non-hydrazide approach designed for chronic dosing. Indications: The recent patent family broadly claims p

 Patents / preclinical 3 — — 3 patent families naming CIDP
Ono Pharmaceutical Website ↗ United States · IPO · 1001 - 5000 staff

Company assessment

Assessment: CIDP-focused drug development ONO Pharmaceutical has a credible, though currently preclinical/IP-led , position in chronic inflammatory demyelinating polyneuropathy (CIDP). The most directly relevant program is a patented small-molecule benzene-derivative series claimed to protect and/or repair peripheral nerves, with CIDP explicitly listed among potential uses. The provided recent records do not identify a registered ONO-sponsored clinical trial in CIDP, disclose a molecular target for this series, or report CIDP patient efficacy data. ONO’s more advanced clinical peripheral-neuropathy activity is ONO-2910 in chemotherapy-induced peripheral neuropathy (CIPN), not CIDP. Pipeline and research findings PD-1×CD3 bispecific antibody — exploratory autoimmune platform Modality / stage: Bispecific antibody; patent-stage, with no CIDP-specific clinical study or named development cand

 Patents / preclinical 3 — — 3 patent families naming CIDP
Developer Status Seen in Patent families Studies sponsored Active Latest signal
Viela Bio / Horizon Website ↗ United States · Post IPO Equity · 101 - 250 staff · founded 2018

Company assessment

Assessment: CIDP relevance Viela Bio’s available recent research metadata does not identify a clinical-stage or preclinical program specifically in chronic inflammatory demyelinating polyneuropathy (CIDP) . There are no CIDP-focused trials, publications, or news items in the supplied record. The company was acquired by Horizon Therapeutics in March 2021; consequently, the patent portfolio should be interpreted as evidence of historical Viela-originated platform and discovery work, rather than confirmation of an active standalone Viela pipeline. The most relevant assets are patent-stage immune-modulating biologic concepts for autoimmune/inflammatory disease. None is explicitly validated for CIDP in the provided materials. Patent-stage / emerging assets - CD40L-targeting Tn3 scaffold - Modality: Engineered Tenascin-3 fibronectin type III (Tn3 FnIII) domain scaffold proteins, including CD40

 Patents / preclinical 2 — — Top-ranked family: Humanized Anti-Cd19 Antibodies and Their Use in Treatment of Oncology, Transplantation and Autoimmune Disease (B cells / plasma cells)
Muna Therapeutics Website ↗ Denmark · Series A · 11 - 50 staff · founded 2020

Company assessment

Relevance to CIDP Based on the available recent research metadata, Muna Therapeutics has no disclosed drug candidate, clinical study, patent claim, or development program specifically for chronic inflammatory demyelinating polyneuropathy (CIDP) . Its stated therapeutic focus is neurodegeneration (including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and multiple sclerosis), rather than peripheral immune-mediated demyelinating neuropathies such as CIDP. The company’s most recent disclosed drug-related work consists of small-molecule TREM2 modulators . While TREM2 is relevant to myeloid-cell biology and neuroinflammation broadly, the supplied documents position these compounds for loss-of-function TREM2 conditions and neurodegenerative diseases , not CIDP. Accordingly, CIDP applicability remains speculative and is not supported by the provided evidence. Drug/asset fi

 Patents / preclinical 2 — — Top-ranked family: Trem2 Modulators (Macrophage / innate)
Topas Therapeutics Website ↗ Germany · Series B · 51 - 100 staff · founded 2016

Company assessment

Relevance to CIDP No CIDP-specific drug candidate, clinical trial, publication, project, or news item is represented in the supplied recent research metadata. Topas’ documented technology is nevertheless conceptually relevant to autoimmune diseases: it uses antigen-bearing nanoparticles designed to suppress specific immune responses, an approach that could in principle be adapted if validated CIDP-relevant autoantigens and a development program were selected. This should not be interpreted as evidence of a current CIDP program or clinical activity. Drug/asset findings - Topas Particle Conjugates / antigen-coupled nanoparticle platform - Modality: Antigen-specific nanoparticle immunotherapy. The recent patent estate describes micellar nanoparticles based on amphiphilic polymers (number-average molecular weight ≤20,000 g/mol) carrying peptides containing T-cell epitopes. - Proposed mechani

 Patents / preclinical 2 — — 2 patent families naming CIDP
Sana Biotechnology Website ↗ United States · Post IPO Equity · 251 - 500 staff · founded 2018

Company assessment

Assessment of Sana Biotechnology’s recent drug research relevant to CIDP No CIDP-specific drug candidates, clinical trials, publications, or company news were included in the supplied recent metadata. Accordingly, there is no evidence in this document set that Sana Biotechnology is developing a therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) . The recent record instead supports an early, platform-oriented effort in hypoimmune allogeneic engineered-cell technologies , aimed at reducing inflammatory and immune-mediated barriers to cell therapy. Hypoimmune allogeneic engineered-cell platform — complement-protection configuration - Asset/platform: Genetically modified allogeneic cells with increased CD46 and CD59 expression; no clinical asset name is reported. - Modality: Gene-engineered, hypoimmune allogeneic cell therapy. - Potential relevance to CIDP: Indirect only. C

 Patents / preclinical 2 — — 2 patent families naming CIDP
Nykode Website ↗ Norway · IPO · 101 - 250 staff · founded 2007

Company assessment

Nykode: relevance to CIDP and new-drug research Assessment: Nykode’s available recent research metadata does not identify a named drug candidate, clinical trial, or preclinical program specifically for chronic inflammatory demyelinating polyneuropathy (CIDP) . The company’s stated primary focus is clinical-stage DNA vaccine/immunotherapy development for HPV-induced malignancies. However, recent patent activity describes a potentially relevant antigen-specific immune-tolerance platform that could, in principle, be adaptable to autoimmune diseases such as CIDP. No CIDP-specific target antigen, efficacy data, development stage, or partner is disclosed in the supplied materials. Early platform / un-named tolerance-inducing constructs — preclinical / patent-stage - Asset / modality: Unnamed nucleic-acid/vector-based tolerance-inducing constructs and compositions. The patents describe DNA plas

 Patents / preclinical 2 — — 2 patent families naming CIDP
Seismic Therapeutic Website ↗ United States · Series B · 51 - 200 staff · founded 2020

Company assessment

Relevance to CIDP: Seismic Therapeutic’s most directly relevant disclosed program is S-1117 , a pan-IgG protease intended for antibody-mediated diseases. This mechanism is conceptually relevant to CIDP—particularly antibody-driven disease biology—because it aims to reduce pathogenic circulating IgG. However, the provided materials do not identify CIDP as a named clinical indication , do not report CIDP patient data, and do not disclose a CIDP-specific development stage or trial design. Novel / discovery-stage immune-regulating biologics - Unnamed dual-targeted immune-regulating compositions - Modality: Engineered polypeptide/biologic compositions designed to engage at least two cell types . - Indication focus: Broad autoimmune disease and cancer claims; no CIDP-specific indication is disclosed. - Stage: Discovery/preclinical inferred from patent disclosure; no named clinical candidate, I

 Patents / preclinical 2 — — 2 patent families naming CIDP
Canopy Growth Website ↗ Canada · Post IPO Debt · 1001 - 5000 staff

Company assessment

CIDP-focused assessment: No clinical trials, publications, news items, or organisation webpages in the supplied record identify a Canopy Growth drug candidate being developed for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The company’s recent evidence base is instead an early, patent-led portfolio of synthetic cannabinoid derivatives. While CB2/cannabinoid-pathway modulation could be of broad interest in inflammatory or neuropathic biology, the available documents do not provide CIDP-specific efficacy, immune-mechanistic validation, dosing, safety, or clinical-development evidence. Novel / early discovery assets - Multi-target cannabinoid-derivative series - Modality: Small-molecule synthetic cannabinoid derivatives; compositions and therapeutic-use claims. - Proposed targets/MOA: Cannabinoid-receptor ligands spanning CB1/CB2 and, across series, serotonergic recept

 Patents / preclinical 2 — — 2 patent families naming CIDP
… and 11 more rows in the interactive table.

"Seen in" marks, in order: patents, clinical studies, publications, company profile, news, funded projects.

Whitespace

Evidence, IP and clinical activity, mechanism by mechanism

Publications, patents, trials and grants were each mapped onto one shared set of mechanisms. Read across a row: a mechanism with strong human evidence and little IP or clinical activity is open; one with dense IP and thin evidence is crowded on a hypothesis.

Mechanism Publications Human evidence Patent families CIDP-primary Clinical studies Active studies Funded projects
FcRn / Fc receptor 9665 human 68% 22 5 14 6 4
Complement 1512 human 80% 28 4 8 6 4
B cells / plasma cells 3828 human 74% 20 0 21 14 4
T cells / Treg 1915 human 79% 45 0 0 0 0
Nodal/paranodal autoantibodies 4840 human 83% 5 0 0 0 11
Cytokine / chemokine 1811 human 61% 28 0 0 0 0
Macrophage / innate 62 human 33% 22 0 0 0 1
Schwann cell / remyelination 64 human 67% 30 1 1 0 4
Axonal protection 5529 human 53% 2 1 0 0 0
Antigen-specific tolerance 00 human 0 12 0 0 0 0
Genetic susceptibility 2515 human 60% 0 0 0 0 0
Blood-nerve barrier 20 human 0 0 0 0 0 0

Human evidence is the share of that mechanism's publications reporting data from people with CIDP. Clinical studies count CIDP studies whose named intervention acts on the mechanism; cell therapies and stem-cell transplantation are counted under B cells and plasma cells.

Four positions

Open: evidence without owners

Human evidence is strong and neither IP nor clinical activity has followed.

Nodal/paranodal autoantibodies — 48 publications (83% human), 5 patent families, 0 clinical studies.
Axonal protection — 55 publications (53% human), 2 patent families, 0 clinical studies.
Genetic susceptibility — 25 publications (60% human), 0 patent families, 0 clinical studies.

Contested: where the money is

Dense in all three sources. Entry needs a differentiated molecule or a defined subgroup.

FcRn / Fc receptor — 96 publications (68% human), 22 patent families, 14 clinical studies (6 active).
Complement — 15 publications (80% human), 28 patent families, 8 clinical studies (6 active).
B cells / plasma cells — 38 publications (74% human), 20 patent families, 21 clinical studies (14 active).

Crowded on thin evidence

More patent families than CIDP publications, and no active clinical study.

T cells / Treg — 19 publications (79% human), 45 patent families, 0 clinical studies.
Cytokine / chemokine — 18 publications (61% human), 28 patent families, 0 clinical studies.
Schwann cell / remyelination — 6 publications (67% human), 30 patent families, 1 clinical studies (0 active).
Macrophage / innate — 6 publications (33% human), 22 patent families, 0 clinical studies.

Hypothesis only

Claimed in patents or discussed in reviews, with no CIDP patient data.

Antigen-specific tolerance — 0 publications, 12 patent families, 0 clinical studies.
Blood-nerve barrier — 2 publications (0% human), 0 patent families, 0 clinical studies.

Evidence against IP

Publications against patent families. Bubble area is the number of clinical studies.

  • 4. B cells / plasma cells · 38 publications · 20 patent families · 21 clinical studies (14 active)
  • 1. FcRn / Fc receptor · 96 publications · 22 patent families · 14 clinical studies (6 active)
  • 8. Complement · 15 publications · 28 patent families · 8 clinical studies (6 active)
  • 10. Schwann cell / remyelination · 6 publications · 30 patent families · 1 clinical studies (0 active)
  • 6. T cells / Treg · 19 publications · 45 patent families · 0 clinical studies (0 active)
  • 3. Nodal/paranodal autoantibodies · 48 publications · 5 patent families · 0 clinical studies (0 active)
  • 7. Cytokine / chemokine · 18 publications · 28 patent families · 0 clinical studies (0 active)
  • 9. Macrophage / innate · 6 publications · 22 patent families · 0 clinical studies (0 active)
  • 2. Axonal protection · 55 publications · 2 patent families · 0 clinical studies (0 active)
  • 12. Antigen-specific tolerance · 0 publications · 12 patent families · 0 clinical studies (0 active)
  • 5. Genetic susceptibility · 25 publications · 0 patent families · 0 clinical studies (0 active)
  • 11. Blood-nerve barrier · 2 publications · 0 patent families · 0 clinical studies (0 active)
  1. FcRn / Fc receptor 96 · 22 · 14
  2. Axonal protection 55 · 2 · 0
  3. Nodal/paranodal autoantibodies 48 · 5 · 0
  4. B cells / plasma cells 38 · 20 · 21
  5. Genetic susceptibility 25 · 0 · 0
  6. T cells / Treg 19 · 45 · 0
  7. Cytokine / chemokine 18 · 28 · 0
  8. Complement 15 · 28 · 8
  9. Macrophage / innate 6 · 22 · 0
  10. Schwann cell / remyelination 6 · 30 · 1
  11. Blood-nerve barrier 2 · 0 · 0
  12. Antigen-specific tolerance 0 · 12 · 0

Key: publications · patent families · clinical studies. Colour gives the position from the four panels above.

Biology

What the literature says CIDP is

1,166 publications from 2024 to 2026. 698 report data from people with CIDP and 550 name an actionable target, pathway or modality. The organising fact in this literature is the split between antibody-defined nodopathies and the seronegative majority.

The organising split

Autoimmune nodopathy: a known antigen, and no drug aimed at it

A minority of people diagnosed with CIDP, usually put at 5–10%, carry mostly IgG4 antibodies against the proteins that hold the node and paranode together. They tend to respond poorly to immunoglobulin and often well to B-cell depletion, and current guidelines class them as a separate disease, autoimmune nodopathy. The literature discusses these antibodies about as often as it discusses FcRn.

36 Neurofascin-155
30 Contactin-1
16 Caspr1
11 Neurofascin-140/186
5 Pan-neurofascin

Publications naming each antigen in their target, finding or hypothesis fields, 2024–2026; 108 mention nodal or paranodal antibodies in any form, against 103 for FcRn. The 48 on the right are publications whose main mechanism is nodal autoimmunity.

Across the eight types of intelligence
Publications on the mechanism48
Share with patient data83%
Funded projects (largest theme)11 of 30
Patent families5
CIDP-primary patent families0
Researchers working on these antibodies178
of whom with any industry tie12%
Clinical studies targeting the antigens0
CAR-T studies enrolling nodopathy explicitly2

The CAR-T studies are KITE-363 (Kite (Gilead)) ClinicalTrials.gov ↗ and Azer-cel (TG Therapeutics) ClinicalTrials.gov ↗. Both deplete B cells broadly rather than the antigen-specific clone.

Mechanism addressed

  • Neuroinflammation · 154
  • Multiple mechanisms · 135
  • Fc receptor/IgG recycling biology · 96
  • Axonal degeneration · 55
  • Autoantibodies against nodal/paranodal proteins · 48
  • B-cell biology · 38
  • Genetic susceptibility · 25
  • T-cell biology · 19
  • Cytokine/chemokine signaling · 18
  • Complement activation · 15
  • Schwann-cell biology/remyelination · 6
  • Macrophage/innate immunity · 6

543 further publications are clinical or diagnostic and address no mechanism.

Human evidence by mechanism

  • Nodal/paranodal autoantibodies · 83% · 40 of 48 publications
  • Complement · 80% · 12 of 15 publications
  • T cells / Treg · 79% · 15 of 19 publications
  • B cells / plasma cells · 74% · 28 of 38 publications
  • FcRn / Fc receptor · 68% · 65 of 96 publications
  • Schwann cell / remyelination · 67% · 4 of 6 publications
  • Cytokine / chemokine · 61% · 11 of 18 publications
  • Genetic susceptibility · 60% · 15 of 25 publications
  • Axonal protection · 53% · 29 of 55 publications
  • Macrophage / innate · 33% · 2 of 6 publications

Mechanisms with at least five publications.

Molecular entities named

Publications naming each entity in their target, finding or hypothesis fields.

  • FcRn · 103
  • CD20 · 69
  • Neurofascin-155 (NF155) · 36
  • Contactin-1 (CNTN1) · 30
  • Neurofilament light (NfL) · 30
  • Schwann cell / remyelination · 24
  • Caspr1 (CNTNAP1) · 16
  • Neurofascin-140/186 · 11
  • TNF-α · 11
  • Macrophage / monocyte · 10
  • Complement C1s · 9
  • Treg / TGF-β · 9
  • CD19 · 8
  • BTK · 7
  • Blood-nerve barrier · 7
  • … and 6 more.

Evidence stage

  • Case report/case series · 356
  • Other · 247
  • Retrospective clinical cohort · 172
  • Prospective observational study · 88
  • Interventional clinical trial · 73
  • Exploratory clinical observation · 60
  • Diagnostic-validation study · 47
  • Systematic review/meta-analysis · 45
  • Ex vivo human-sample study · 30
  • Clinical guideline/consensus · 17
  • Preclinical model · 12
  • Basic/mechanistic research · 10
Case reports outnumber trials

356 case reports or series against 73 interventional trials and 88 prospective studies. Most of what is known about new agents in CIDP, including B-cell depletion and CAR-T, still rests on individual patients.

Populations studied

  • Mixed CIDP population · 411
  • Other · 377
  • Autoantibody-positive nodopathy · 51
  • Refractory CIDP · 41
  • Acute-onset CIDP · 31
  • Pediatric CIDP · 28
  • Healthy controls/comparator disease only · 26
  • IVIG-dependent CIDP · 16
  • Treatment-naive CIDP · 15
  • IVIG-responsive CIDP · 14
  • Typical CIDP · 12

What biomarkers are for

  • No intended biomarker use · 290
  • Differential diagnosis · 243
  • Diagnostic support · 175
  • Endpoint assessment · 158
  • CIDP subtype stratification · 87
  • Disease activity monitoring · 56
  • Pharmacodynamic monitoring · 33
  • Treatment-response prediction · 29
  • Other · 25
  • Multiple · 25
  • Safety monitoring · 16
  • Prognosis · 15
  • Patient selection/enrichment · 12
Partnering signals

Who could be partnered with, and on what evidence

332 organisations outside the established CIDP companies own or run something partnerable in CIDP: a patent family that names the disease, a company programme, a study of a novel asset with no major company as sponsor, or a publicly funded project. Each card brings together what every source says about that party, including its researchers who have no documented industry tie and any news that names it.

332 partnerable organisations

250 biotech or SME, 78 academic or hospital, 4 investigators or other

172 have no CIDP patent family

and would not appear in a patent-only view

18 academic or investigator sponsors

already run clinical studies of a novel asset without a major company; 8 biotechs are clinical in CIDP

56 are seen in two or more sources

16 have researchers with no documented industry tie

A screening rank, not an assessment of any organisation

The score adds up what the records show: CIDP stage, active studies, CIDP-primary patents, the number of independent sources, work on mechanisms nobody owns, and recency. It does not see financing, existing licences, freedom to operate or programme decisions. Use it to choose what to read, not what to conclude.

#1 · 72

Dianthus Therapeutics Opco, Inc.

Biotech / SME · United States · Phase 3 in CIDP
Patents 4 Company assessment Studies 1

Evidence from each source

Company assessment

Active CIDP clinical programme · Phase 3 Website ↗ · Post IPO Equity · 51 - 100 employees · founded 2019

CIDP-focused pipeline assessment — Dianthus Therapeutics Claseprubart (DNTH103) — lead and only disclosed CIDP asset | Phase 3 - Asset / modality: Claseprubart (formerly DNTH103) is an investigational, fully human, long-acting monoclonal antibody designed for low-volume, subcutaneous self-administration, potentially every two or four weeks. It is Dianthus’ core neuromuscular-franchise asset, also being developed in generalized myasthenia gravis and multifocal motor neuropathy. - Indication / stage: In adults with c…

Studies of novel assets (1) CIDP patent families (4) Why it ranks here

Phase 3 · active study · latest 2025 · 3 sources · score 72

#2 · 72

Immunovant

Biotech / SME · United States · Phase 2 in CIDP

A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP WHO ICTRP ↗ 2024-518364-12 · Phase 2 · Active

Batoclimab, Imeroprubart · FcRn / Fc receptor

Patents 2 Company assessment Studies 3

Evidence from each source

Company assessment

Platform relevant, no CIDP programme Website ↗ · Post IPO Equity · 251 - 500 employees · founded 2018

Immunovant: CIDP-focused drug-development assessment Immunovant is a clinical-stage immunology company concentrating on FcRn blockade for IgG-mediated autoimmune diseases. For CIDP, the available recent metadata identifies one investigational asset—batoclimab (IMVT-1401; formerly RVT-1401) . No CIDP-specific clinical-trial record, efficacy readout, regulatory designation, or collaboration is included in the supplied metadata; conclusions on development stage and clinical differentiation should therefore be treated …

Studies of novel assets (3) CIDP patent families (2) Why it ranks here

Phase 2 · active study · CIDP-primary patent · latest 2025 · 3 sources · score 72

#3 · 63

Kine Sciences

Biotech / SME · South Korea · Phase 1 in CIDP

A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP ClinicalTrials.gov ↗ NCT07343310 · Phase 1 · Completed · primary completion 2025-04

KINE-101 · Schwann cell / remyelination

Patents 2 Company assessment Studies 1 News 1

Evidence from each source

Company assessment

Active CIDP clinical programme · Phase 1 Website ↗ · Venture Round · 11 - 50 employees · founded 2012

Kine Sciences: CIDP drug-development assessment Kine Sciences is a clinical-stage peptide therapeutics company focused on ultra-small, immune-modulating peptides derived from the anti-inflammatory cytokine ERDR1. For CIDP, the available recent evidence supports a single clinical asset— KINE-101 —with a differentiated regulatory-T-cell (Treg) activation hypothesis. The company also has recent CIDP-focused patent activity covering both a treatment peptide and its administration regimen. No peer-reviewed publications …

Studies of novel assets (1) CIDP patent families (2) News Why it ranks here

Phase 1 · CIDP-primary patent · latest 2025 · 4 sources · score 63

#4 · 60

Hanall Biopharma Co Ltd

Biotech / SME · South Korea · Phase 3 in CIDP

Anti-FCRN Antibody or Antigen Binding Fragment Thereof With Improved Stability Filed 2023-05-26 · T2 Named neuropathy · Clinical-stage asset

Batoclimab · FcRn / Fc receptor

Patents 2 Company assessment News 2

Evidence from each source

Company assessment

Active CIDP clinical programme · Phase 3 · 201 - 500 employees · founded 1973

HanAll Biopharma’s CIDP-relevant innovation is concentrated in an FcRn-inhibition franchise designed to lower pathogenic IgG antibodies. The company’s principal CIDP program is licensed to Immunovant in the US and Europe; the available metadata contains development updates through March 2025, but no CIDP clinical-trial record or post-2025 efficacy readout. Accordingly, the reported CIDP timelines should be treated as historical guidance rather than confirmation of current status. - HL161ANS / IMVT-1402 — next-gener…

CIDP patent families (2) News Why it ranks here

Phase 3 · latest 2023 · 3 sources · score 60

#5 · 53

Stichting Amsterdam UMC

Academic / hospital · Phase 3 in CIDP

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy ClinicalTrials.gov ↗ NCT06714838 · Phase 3 · Active · primary completion 2027-10

Rituximab · B cells / plasma cells

Patents 1 Studies 1

Evidence from each source

Studies of novel assets (1) CIDP patent families (1) Why it ranks here

Phase 3 · active study · latest 2024 · score 53

#6 · 50

The University of Kansas

Academic / hospital · United States · Phase 2 in CIDP

Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy ClinicalTrials.gov ↗ NCT04480450 · Phase 2 · Stopped · primary completion 2025-09

Rituximab · B cells / plasma cells, Schwann cell / remyelination

Patents 1 Studies 1 Untied researchers 1

Evidence from each source

Studies of novel assets (1) CIDP patent families (1) Researchers with no documented industry tie

Mazen Dimachkie M.D.

Why it ranks here

Phase 2 · latest 2025 · 3 sources · score 50

#7 · 46

Johns Hopkins University

Academic / hospital · United States · Phase 3 in CIDP

Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) ClinicalTrials.gov ↗ NCT01757574 · Phase 4 · Stopped · primary completion 2016-08

Alemtuzumab · B cells / plasma cells, Cytokine / chemokine

Patents 1 Studies 1

Evidence from each source

Studies of novel assets (1) CIDP patent families (1) Why it ranks here

Phase 3 · latest 2026 · score 46

#8 · 42

Nagoya University

Academic / hospital · Japan · Phase 2 in CIDP

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies ClinicalTrials.gov ↗ NCT03864185 · Phase 2 · Completed · primary completion 2021-05

Rituximab · B cells / plasma cells, Complement, Nodal/paranodal autoantibodies, Schwann cell / remyelination

Studies 1 Funded projects 3 Untied researchers 2

Evidence from each source

Studies of novel assets (1) Funded projects Researchers with no documented industry tie

Masahiro Iijima, Yuki Fukami

Why it ranks here

Phase 2 · open mechanism · latest 2025 · 3 sources · score 42

#9 · 42

Zhongming Qiu

Investigator / other · Phase 3 in CIDP

Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy ClinicalTrials.gov ↗ NCT06858722 · Phase 3 · Planned · primary completion 2027-06

Obinutuzumab, Ripertamab · B cells / plasma cells

Studies 2

Evidence from each source

Studies of novel assets (2) Why it ranks here

Phase 3 · active study · latest 2026 · score 42

#10 · 41

Alpine Immune Sciences, Inc.

Biotech / SME · Preclinical clinical in another indication

Methods of Dosing and Treatment With a Taci-Fc Fusion Immunomodulatory Protein Filed 2022-05-06 · T2 Named neuropathy · Clinical-stage asset

B cells / plasma cells, T cells / Treg

Patents 4

Evidence from each source

CIDP patent families (4) Why it ranks here

Preclinical · clinical in another indication · latest 2025 · score 41

#11 · 40

Gliknik

Biotech / SME · United States · Preclinical

FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS Filed 2024-08-05 · T2 Named neuropathy · Preclinical efficacy evidence

Stradomers (GL-2045) · Complement, FcRn / Fc receptor

Patents 3 Company assessment

Evidence from each source

Company assessment

Platform relevant, no CIDP programme Website ↗ · Series C · 2 - 10 employees · founded 2007

CIDP relevance and new-drug assessment Gliknik’s recent documented activity is centered on its Stradomer/multivalent Fc platform —recombinant, multimerized IgG Fc constructs intended to reproduce or improve selected immunomodulatory effects of pooled intravenous immunoglobulin (IVIG). This is mechanistically relevant to CIDP, where IVIG is an established immunomodulatory treatment. However, the supplied recent metadata contains no CIDP-specific clinical trials, efficacy publications, development-stage disclosures, …

CIDP patent families (3) Why it ranks here

Preclinical · latest 2024 · score 40

#12 · 40

Nuvig Therapeutics

Biotech / SME · United States · Phase 2 in CIDP
Company assessment Studies 1

Evidence from each source

Company assessment

Active CIDP clinical programme · Phase 2 Website ↗ · Series B · 11 - 50 employees · founded 2020

Nuvig Therapeutics’ CIDP-focused pipeline is centered on NVG-2089 , an IV recombinant IgG1 Fc-domain immunomodulator designed as a dose-efficient, mechanistically targeted alternative to IVIg. The company’s approach aligns with its stated strategy of restoring immune homeostasis rather than broadly suppressing immunity. - NVG-2089 — most advanced and only CIDP asset identified - Modality / administration: Recombinant human IgG1 Fc-domain protein (IgG1 Fc-F241A), administered intravenously. - Indication: Chronic inf…

Studies of novel assets (1) Why it ranks here

Phase 2 · active study · latest 2025 · score 40

#13 · 40

TG Therapeutics Inc

Biotech / SME · United States · Phase 2 in CIDP
Company assessment Studies 1

Evidence from each source

Company assessment

Active CIDP clinical programme · Phase 2 Website ↗ · Post IPO Debt · 251 - 500 employees · founded 2011

CIDP-focused development - Azercabtagene zapreleucel (azer-cel) — Phase 1, recruiting - Asset / modality: Investigational cell therapy; the supplied record identifies azer-cel by its full name but does not specify its cellular engineering, antigen target, or manufacturing approach. - CIDP indication: CIDP is explicitly included among the study keywords within a broader program for B-cell–mediated autoimmune disorders . This supports an early exploratory development effort in CIDP rather than a CIDP-specific registr…

Studies of novel assets (1) Why it ranks here

Phase 2 · active study · latest 2025 · score 40

#14 · 39

Apellis Pharmaceuticals Inc

Biotech / SME · United States · Preclinical

Complement Inhibition Filed 2024-01-05 · T2 Named neuropathy · Preclinical candidate

Complement

Patents 2 Company assessment News 1

Evidence from each source

Company assessment

Platform relevant, no CIDP programme Website ↗ · Post IPO Debt · 501 - 1000 employees · founded 2008

CIDP-focused assessment The supplied recent evidence does not identify an Apellis-sponsored clinical or preclinical drug program specifically for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) . There are no CIDP clinical trials, publications, or company projects in the provided metadata. Apellis’ relevance to CIDP is therefore presently platform/IP-based rather than asset- or clinical-stage-based : the company describes a broad strategy of controlling complement centrally at C3, while recent pate…

CIDP patent families (2)
  • Complement Inhibition Filed 2024-01-05 · T2 Named neuropathy · Preclinical candidate · Complement pathway
  • Complement Inhibition Filed 2022-06-30 · T2 Named neuropathy · Preclinical candidate · Complement pathway
News Why it ranks here

Preclinical · latest 2024 · 3 sources · score 39

#16 · 36

Viela Bio

Biotech / SME · Preclinical clinical in another indication

Humanized Anti-Cd19 Antibodies and Their Use in Treatment of Oncology, Transplantation and Autoimmune Disease Filed 2024-01-17 · T2 Named neuropathy · Clinical-stage asset

B cells / plasma cells, Cytokine / chemokine

Patents 2

Evidence from each source

CIDP patent families (2) Why it ranks here

Preclinical · clinical in another indication · latest 2025 · score 36

#17 · 36

Western Sydney Local Health District

Academic / hospital · Phase 2 in CIDP
Studies 1

Evidence from each source

Studies of novel assets (1) Why it ranks here

Phase 2 · active study · latest 2024 · score 36

#18 · 36

Yale University

Academic / hospital · United States · Discovery, platform or IP

Targeted Bifunctional Degraders Filed 2020-10-09 · T2 Named neuropathy · Discovery-stage platform

Efgartigimod, Rozanolixizumab · FcRn / Fc receptor, Nodal/paranodal autoantibodies, T cells / Treg

Patents 3 Funded projects 2

Evidence from each source

CIDP patent families (3) Funded projects Why it ranks here

Discovery / IP · open mechanism · latest 2026 · score 36

#19 · 35

Muna Therapeutics

Biotech / SME · Denmark · Preclinical

Trem2 Modulators Filed 2023-07-04 · T2 Named neuropathy · Preclinical candidate

Macrophage / innate

Patents 2 Company assessment

Evidence from each source

Company assessment

CIDP preclinical / discovery asset Website ↗ · Series A · 11 - 50 employees · founded 2020

Relevance to CIDP Based on the available recent research metadata, Muna Therapeutics has no disclosed drug candidate, clinical study, patent claim, or development program specifically for chronic inflammatory demyelinating polyneuropathy (CIDP) . Its stated therapeutic focus is neurodegeneration (including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and multiple sclerosis), rather than peripheral immune-mediated demyelinating neuropathies such as CIDP. The company’s most recent disclosed drug…

CIDP patent families (2)
  • Trem2 Modulators Filed 2023-07-04 · T2 Named neuropathy · Preclinical candidate · Macrophages/monocytes
  • Trem2 Modulators Filed 2025-01-03 · T2 Named neuropathy · Discovery-stage platform · Macrophages/monocytes
Why it ranks here

Preclinical · latest 2025 · score 35

#20 · 35

The General Hospital Corporation

Academic / hospital · Preclinical

Administration of Glutathione Trisulfide to Ameliorate Peripheral Neuropathy Filed 2023-09-26 · T2 Named neuropathy · Preclinical efficacy evidence

Cytokine / chemokine, T cells / Treg

Patents 3

Evidence from each source

CIDP patent families (3) Why it ranks here

Preclinical · latest 2025 · score 35

… and 40 more in the interactive report.

Showing the top 60 of 332. Narrow the filters or search to see the rest.

Patent view: the 48 highest-ranked patent families (the previous version of this tab)

Every family where CIDP is the primary indication

18 of 344 families. 294 more name CIDP in a list of neuropathies and 32 reach it only through a broad claim.

Filed Applicant Technology Mechanism Maturity
2025-07-01 Kine Sciences Biotech / SME Peptide Administration Regimen for Chronic Inflammatory Demyelinating Polyneuropathy A SEQ ID NO: 1 peptide therapeutic regimen for treating chronic inflammatory demyelinating polyneuropathy (CIDP). Unspecified / multifactorial Early scientific concept
2025-05-12 CSL Established pharma Treatment of Cidp An immunoglobulin G therapy is disclosed for biomarker-selected CIDP patients with preserved or mildly impaired axonal function, intended to treat disease and reduce relapse. Unspecified / multifactorial Clinical-stage asset
2024-10-30 Kine Sciences Biotech / SME Peptide for Treating Demyelinating Diseases and Use Thereof A trimeric peptide therapeutic from Kine Sciences is disclosed for CIDP, intended to reduce demyelination, promote myelination/nerve repair, and improve neuropathic symptoms. Myelin repair/regeneration Preclinical efficacy evidence
2024-07-16 argenx BV Established pharma Methods for Treating Chronic Inflammatory Demyelinating Polyneuropathy An argenx FcRn-antagonist therapy, particularly efgartigimod, for treatment of CIDP by reducing pathogenic IgG autoantibody exposure. Fc receptor/FcRn Commercialized/marketed product extension
2024-07-16 アルジェニクス ビーブイ Other 慢性炎症性脱髄性多発神経炎を治療するための方法 Efgartigimod, an FcRn-blocking engineered Fc biologic, is disclosed for treatment of CIDP by lowering circulating pathogenic IgG. Fc receptor/FcRn Commercialized/marketed product extension
2024-07-16 argenx BV Established pharma Methods of Treating Chronic Inflammatory Demyelinating Polyneuropathy An FcRn-antagonist therapy, including efgartigimod, is disclosed for treating CIDP by reducing pathogenic circulating IgG autoantibodies that drive immune-mediated peripheral-nerve demyelination. Fc receptor/FcRn Commercialized/marketed product extension
2023-09-05 Immunovant Sciences GmbH Biotech / SME Methods of Treating Chronic Inflammatory Demyelinating Polyneuropathy Using Anti-FCRN Antibodies A sequence-defined anti-FcRn antibody technology is disclosed for subcutaneous treatment of CIDP by lowering pathogenic IgG exposure, including maintenance and relapse management. Fc receptor/FcRn Clinical-stage asset
2023-09-05 イミュノバント・サイエンシズ・ゲーエムベーハー Other 抗ＦｃＲＮ抗体を用いた慢性炎症性脱髄性多発神経障害の治療方法 An anti-FcRn antibody therapeutic for CIDP, intended to reduce disease-driving IgG autoantibodies by blocking FcRn-mediated IgG recycling. Fc receptor/FcRn Clinical-stage asset
2023-07-07 Bioverativ USA Inc. Established pharma Anti-C1S antibodies and methods of use thereof A sequence-defined engineered IgG4 anti-activated-C1s antibody is disclosed for complement inhibition to treat CIDP. Complement pathway Commercialized/marketed product extension
2023-06-23 Bioverativ USA Inc. Established pharma Methods for Treating Complement-Mediated Diseases A humanized anti-C1s monoclonal antibody (sutimlimab-class technology) is disclosed for CIDP treatment by inhibiting classical complement activation, using a 50 mg/kg loading dose followed by fixed maintenance dosing. Complement pathway Clinical-stage asset
2023-06-23 バイオベラティブ・ユーエスエイ・インコーポレイテッド Other 補体が媒介する疾患を処置するための方法 A humanized anti-C1s monoclonal antibody, consistent with sutimlimab, is disclosed for CIDP to inhibit classical complement activity using a weight-based loading dose followed by fixed maintenance dosing. Complement pathway Clinical-stage asset
2023-06-22 Ageronix Biotech / SME Alpha1-Antitrypsin for Use in the Treatment of Diseases or Disorders of the Nervous System Such as Chronic Inflammatory Demyelinating Polyne AAT-based ADAM17-inhibitory therapy, including use with IVIG/IgG, is disclosed for treatment of CIDP and related immune-mediated neurological inflammation. Neuroinflammation Early scientific concept
2023-05-01 Applicant not stated Unknown 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 A plasma-derived immunoglobulin product, consistent with subcutaneous immunoglobulin maintenance therapy, is disclosed for treatment of CIDP. Unspecified / multifactorial Commercialized/marketed product extension
2021-06-29 Applicant not stated Unknown Prognosis of Chronic Inflammatory Demyelinating Poly-Neuropathy A serum neurofilament light chain biomarker assay for CIDP, intended to monitor axonal injury and guide prediction of disease progression, treatment response, and potential therapy switching. Axonal protection Diagnostic validation concept
2019-10-11 Momenta Pharmaceuticals, Inc. Biotech / SME Treatment With Highly Silylated Igg Compositions A highly sialylated IgG immunoglobulin product is disclosed as a low-dose IVIG alternative for treating CIDP, intended to retain IVIG-like efficacy with lower immunoglobulin exposure. Unspecified / multifactorial Unclear
2019-05-23 CSL Established pharma Treatment of CIDP An immunoglobulin G product is disclosed for biomarker-guided treatment and relapse reduction in CIDP patients with non-axonal or mild axonal damage identified by compound muscle action potential testing. Unspecified / multifactorial Commercialized/marketed product extension
2019-05-23 Applicant not stated Unknown Ｃｉｄｐの治療 A plasma-derived immunoglobulin therapy for CIDP patients with absent or mild axonal damage, intended to treat the immune-mediated neuropathy in this selected patient subgroup. Unspecified / multifactorial Clinical-stage asset
2017-10-12 Bioverativ USA Inc. Established pharma Anti-C1s Antibodies and Methods of Use Thereof A sequence-defined anti-activated-C1s IgG4 antibody therapeutic is disclosed for treating CIDP by inhibiting classical complement-pathway activation. Complement pathway Unclear
Experts

Who the CIDP experts are, and who has engaged them

Two views of the same expertise. Researchers: 1,377 profiles matched CIDP in a recent publication, patent, trial or project, or in a function title or about-text, and AcademicLabs AI wrote a drug-research assessment for each. After merging 14 duplicates, 1,115 have a substantiated CIDP record; the other 248 reach the search through a neighbouring condition, a single diagnostic case or an unrelated role. Their assessments link by record ID to 507 of the 1,166 publications in this report, and 47, 44 and 29 researchers link to clinical studies, patents and funded projects. Research groups: 120 of 156 groups have a substantiated CIDP role; the other 36 appear only through a co-author on a CIDP paper.

Researchers: what they work on

  • Treatment evidence & optimisation · 500
  • Diagnosis & biomarkers · 286
  • Incidental / limited CIDP link · 248
  • Mechanism & target discovery · 184
  • Novel-therapy clinical development · 145
Most experts optimise the treatments that exist

500 researchers work mainly on how immunoglobulin, steroids, plasma exchange and rituximab are used, and 286 on diagnosis and biomarkers. 145 have a documented role in testing a new therapy, and 184 work on mechanism or targets.

Researchers: who they are tied to

Researchers whose assessment names a company in a sentence about funding, sponsorship, co-authorship or employment, or who work there.

  • argenx · 106 · 68 in novel-therapy development · 35 of the top 50 · 30 staff · Filip Eftimov, Luís Querol, Eduardo Nobile-Orazio, Jeffrey A. Allen
  • CSL · 31 · 8 in novel-therapy development · 3 of the top 50 · 8 staff · Jeffrey A. Allen, Ingemar S. J. Merkies, Motoi Kuwahara, Murray Lowe
  • Sanofi · 30 · 18 in novel-therapy development · 9 of the top 50 · 8 staff · Luís Querol, Jeffrey A. Allen, Jeffrey T. Guptill, Pieter A. van Doorn
  • Takeda · 28 · 12 in novel-therapy development · 7 of the top 50 · 11 staff · Satoshi Kuwabara, Vera Bril, Mamatha Pasnoor, Ivana Basta
  • Johnson & Johnson · 8 · 4 in novel-therapy development · 3 of the top 50 · 1 staff · Eduardo Nobile-Orazio, Ingemar S. J. Merkies, Yusuf A. Rajabally, Masayoshi Nakano
  • Nuvig Therapeutics · 8 · 3 in novel-therapy development · 0 of the top 50 · 4 staff · Kazim Sheikh, Pamela B. Conley, Tong Gao, Jessica Bright
  • Novartis · 6 · 4 in novel-therapy development · 0 of the top 50 · 1 staff · Marinos C. Dalakas, Erik Wallstroem, Annie Dionne, Rami Massie
  • Octapharma · 6 · 3 in novel-therapy development · 2 of the top 50 · 1 staff · Ingemar S. J. Merkies, Hans Katzberg, Emilien Delmont, Francoise Bouhour
  • LFB · 5 · 5 in novel-therapy development · 3 of the top 50 · Eduardo Nobile-Orazio, Yusuf A. Rajabally, Jean-Philippe Camdessanché, Angelo Schenone
  • Roche · 4 · 0 in novel-therapy development · 0 of the top 50 · 1 staff · Björn Tackenberg, Norbert Sommer, David Mengel, Hendrik Van Der Wurp
  • Biogen · 4 · 0 in novel-therapy development · 0 of the top 50 · 4 staff · Michael Mingueneau, Catherine Barbey, Alex Pellerin, Matthew Scaramozza
  • UCB · 3 · 3 in novel-therapy development · 3 of the top 50 · Filip Eftimov, Luís Querol, Todd Levine
One company has engaged the field

204 of 1,115 researchers (18%) have a documented tie; 106 of them to argenx, against 31 to CSL, 30 to Sanofi and 28 to Takeda. 41 of the 50 highest-ranked researchers are tied to at least one company. Dianthus, whose claseprubart has an early go in Phase 3, is tied to 1.

Expert bench against clinical activity

Researchers whose assessment names each asset, against its CIDP studies. Immunoglobulin brands are left out; assets named by fewer than two researchers are shown only when they are in late-stage development.

Asset Mechanism Most advanced in CIDP Researchers naming it In novel-therapy development CIDP studies Active Publications
Rituximab B-cell depletion Phase 3 210 58 8 3 45
Efgartigimod FcRn inhibition Phase 4 / marketed 172 92 6 3 75
Riliprubart Complement Phase 3 20 19 4 2 11
Empasiprubart Complement Phase 3 14 12 3 3 2
Claseprubart Complement Phase 3 0 0 1 1 —
aHSCT Immune reset (HSCT) Phase 2 17 1 4 3 3
Nipocalimab FcRn inhibition Phase 2/3 12 11 1 1 3
Daratumumab B-cell / plasma-cell No CIDP study 12 0 — — 1
Rozanolixizumab FcRn inhibition Phase 2 8 5 3 — 1
NVG-2089 Fc / FcγR modulation Phase 2 8 3 1 1 2
Ofatumumab B-cell depletion No CIDP study 7 0 — — 3
Batoclimab FcRn inhibition Phase 2 3 2 2 1 —
Universal CD19/BCMA CAR-T CAR-T Phase 1 2 2 5 5 —
JY231 CAR-T Phase 1 2 2 1 1 —
QH103 CAR-T Phase 1 2 2 1 1 —
RD06-05 CAR-T Phase 1 2 2 1 1 —
BCMA CAR-T (other) CAR-T Phase 1 2 2 1 1 2
Eculizumab Complement No CIDP study 2 0 — — 2
Imeroprubart Other / not stated Phase 2 0 0 1 1 —
Challengers reach a bench built around efgartigimod

The Phase 3 and 2/3 challengers are named by 20 (riliprubart), 14 (empasiprubart), 12 (nipocalimab) and 0 (claseprubart) researchers, against 172 for efgartigimod and 210 for off-label rituximab. Daratumumab and ofatumumab are discussed by 12 and 7 researchers with no CIDP study registered: expert interest that no sponsor has yet turned into a trial.

Where the experts are, and where the studies run

Country of each researcher's affiliation, against countries named on CIDP studies. Highlighted rows have at least 15 researchers and three or fewer studies.

Country Researchers Novel-therapy Industry-tied CIDP studies Active
United States 220 32 75 70 20
China 117 21 6 30 27
Japan 100 15 21 34 10
Germany 98 8 16 36 28
Italy 59 23 10 12 7
France 44 9 15 48 6
India 42 1 3 — —
Netherlands 41 3 6 32 11
South Korea 37 0 1 2 —
United Kingdom 35 4 5 12 4
Poland 32 1 2 — —
Spain 29 4 6 7 3
Australia 22 0 7 16 10
Greece 21 4 1 3 3
Turkey 20 0 0 — —
Canada 19 5 6 3 —
Brazil 18 0 0 — —
Belgium 14 8 11 5 3
Pakistan 14 2 0 — —
Bangladesh 11 0 0 — —
Expertise without trials

India, South Korea, Poland, Greece, Turkey, Canada, Brazil hold 189 CIDP researchers between them and 8 CIDP studies. China is the opposite case: 27 active studies, most of them hospital-sponsored CAR-T, and 6 of its 117 researchers tied to a company.

Nodal and paranodal antibody experts

  • Japan · 40
  • China · 31
  • Spain · 15
  • South Korea · 13
  • Germany · 9
  • Italy · 9
  • France · 8
  • India · 8
  • Netherlands · 7
  • United Kingdom · 6
An expert base few companies have reached

178 researchers work on nodal or paranodal antibodies (neurofascin, contactin-1, Caspr1), 40 in Japan, 31 in China, 15 in Spain. 22 (12%) have any industry tie, against 18% of all CIDP researchers, and no study targets the antigens.

Most connected nodal-antibody researchers

Researcher directory

Researcher Country Role Drugs named Industry ties Linked records What their record shows
Filip Eftimov Amsterdam University Medical Centres Netherlands Novel-therapy clinical development Efgartigimod, Rituximab, Rozanolixizumab UCB argenx 8 publ. · 3 stud. latest 2026 Filip Eftimov’s recent CIDP research spans targeted immunotherapies, remission-oriented treatment strategies, and optimization of established immunoglobulin treatment.
Luís Querol Hospital de la Santa Creu i Sant Pau Spain Novel-therapy clinical development Efgartigimod, Empasiprubart, Riliprubart, Rituximab Sanofi UCB argenx 15 publ. latest 2026 Luís Querol’s recent publications show involvement in FcRn-directed therapies and complement inhibition for CIDP, spanning early clinical evaluation, phase 3 trial design and long-term follow-up of an approved therapy.
Masahiro Iijima Nagoya University Japan Novel-therapy clinical development Rituximab — 3 publ. · 3 stud. · 1 proj. latest 2026 Masahiro Iijima’s recent CIDP-related research is strongest in mechanism-guided treatment of refractory disease, particularly IgG4-positive autoimmune nodopathy, rather than discovery of a broad portfolio of new drugs.
Dai-Shi Tian Tongji Hospital China Novel-therapy clinical development Universal CD19/BCMA CAR-T, JY231, QH103, RD06-05 — 1 publ. · 4 stud. latest 2026 Dai-Shi Tian’s recent CIDP research focuses on CAR-T–based approaches to refractory disease, combining early clinical development with mechanistic investigation of relapse.
Eduardo Nobile-Orazio Humanitas Research Hospital Italy Novel-therapy clinical development Efgartigimod, Nipocalimab, Rituximab, LFB Ig (I10E / Iqymune) Johnson & Johnson LFB argenx 5 publ. · 2 stud. latest 2026 Eduardo Nobile-Orazio’s recent CIDP research is most relevant to clinical evaluation of immune-directed therapies, patient selection, and treatment-response measurement, rather than discovery of new molecules.
Jeffrey A. Allen University of Minnesota Twin Cities United States Novel-therapy clinical development Efgartigimod, Empasiprubart, Riliprubart CSL Sanofi argenx 8 publ. · 1 stud. latest 2026 Jeffrey A. Allen’s recent CIDP research is concentrated on efgartigimod clinical validation and long-term outcomes, with additional involvement in riliprubart Phase 3 trial design.
Jeffrey T. Guptill Duke University School of Medicine United States Novel-therapy clinical development Efgartigimod, Riliprubart Sanofi argenx 8 publ. · 1 pat. latest 2026 Jeffrey T. Guptill’s recent CIDP research is concentrated on efgartigimod and FcRn inhibition, spanning clinical validation, long-term safety, treatment transition, and patent applications.
Satoshi Kuwabara Chiba University Japan Novel-therapy clinical development Efgartigimod, Nipocalimab, Rituximab, HyQvia (TAK-771) Takeda argenx 7 publ. · 1 proj. latest 2026 Satoshi Kuwabara’s recent CIDP research spans early target validation, emerging FcRn inhibitors, and clinical development of maintenance therapies.
Chuan Qin Tongji Hospital China Novel-therapy clinical development Universal CD19/BCMA CAR-T, JY231, QH103, RD06-05 — 1 publ. · 3 stud. latest 2026 Chuan Qin’s recent CIDP research centers on CAR-T–based immune-cell targeting for refractory disease, combining early clinical development with a small, published anti-BCMA proof-of-concept study.
Pieter A. van Doorn Erasmus University Rotterdam Netherlands Novel-therapy clinical development Efgartigimod, Riliprubart Sanofi argenx 9 publ. latest 2026 The supplied publications position Pieter A. van Doorn as a clinical contributor to novel CIDP therapies and treatment optimization, with recent work spanning riliprubart development, efgartigimod clinical evidence, and immunoglobulin maintenance strategies.
Simon Rinaldi University of Oxford United Kingdom Novel-therapy clinical development Efgartigimod, Empasiprubart, Rituximab argenx 8 publ. latest 2026 Simon Rinaldi’s recent CIDP publications show a strong focus on clinical development of targeted therapies, long-term treatment outcomes, and biomarkers.
Pietro Emiliano Doneddu Humanitas Research Hospital Italy Novel-therapy clinical development Empasiprubart, Rituximab argenx 6 publ. · 1 stud. latest 2026 Pietro Emiliano Doneddu’s recent CIDP research spans exploratory therapeutic targets, rituximab repurposing, and phase III empasiprubart study design.
Johannes Jakobsen Rigshospitalet Denmark Treatment evidence & optimisation Hizentra (IgPro20), Privigen (IgPro10), HyQvia (TAK-771), Gammagard / Kiovig — 2 publ. · 3 stud. latest 2026 Johannes Jakobsen’s supplied research profile is strongest in immunoglobulin treatment optimization, administration strategies, and clinical outcome assessment, rather than discovery of new molecular drugs.
Benjamin Van Hoorick argenx BV United States Novel-therapy clinical development Efgartigimod argenx 5 publ. · 2 pat. latest 2026 Benjamin Van Hoorick’s recent CIDP work centers on efgartigimod and its subcutaneous PH20 formulation, with contributions spanning treatment-method patents, long-term clinical outcomes, and treatment implementation.
Thomas Skripuletz Hannover Medical School Germany Novel-therapy clinical development Efgartigimod, Hizentra (IgPro20) argenx 8 publ. latest 2026 Thomas Skripuletz’s recent CIDP publications emphasize clinical validation of efgartigimod PH20 SC and optimization of immunoglobulin maintenance therapy, rather than early-stage drug discovery.
Vera Bril University of Toronto Canada Novel-therapy clinical development Efgartigimod, Nipocalimab, Rozanolixizumab, Batoclimab Takeda 6 publ. latest 2026 Vera Bril’s recent CIDP publications span emerging FcRn-targeted therapies and clinical validation of immunoglobulin treatment strategies.
Chafic Karam University of Pennsylvania United States Novel-therapy clinical development Efgartigimod, Rituximab argenx 8 publ. latest 2026 Chafic Karam’s recent CIDP publications show a strong focus on clinical development and implementation of efgartigimod, alongside treatment-response assessment, diagnostic accuracy, and real-world treatment burden.
Mamatha Pasnoor The University of Kansas United States Novel-therapy clinical development Efgartigimod, Rituximab, Acthar gel, HyQvia (TAK-771) Takeda argenx 3 publ. · 1 stud. latest 2026 Mamatha Pasnoor’s recent CIDP research is strongest in clinical evaluation of immunoglobulin therapies, relapse management, and treatment-outcome standardization.
Masahisa Katsuno Nagoya University Japan Novel-therapy clinical development Efgartigimod, Rituximab argenx 5 publ. · 1 stud. latest 2026 Masahisa Katsuno’s recent CIDP research is most relevant to biomarker-guided treatment development and repurposing, particularly rituximab for refractory disease.
Inge Van de Walle argenx BV United States Novel-therapy clinical development Empasiprubart argenx 2 publ. · 6 pat. latest 2026 Inge Van de Walle’s recent CIDP work centers on complement-directed therapeutics at argenx, spanning anti-C2 patent inventions and two 2026 phase III study-design publications for empasiprubart.
Geoffrey Istas argenx BV United States Novel-therapy clinical development Efgartigimod argenx 4 publ. · 3 pat. latest 2026 Geoffrey Istas — CIDP drug-development profile Istas’s recent documented work, with an argenx BV affiliation, is concentrated on efgartigimod, particularly subcutaneous efgartigimod PH20 : long-term clinical outcomes, transition from immunoglobulin therapy, real-world evidence, and CIDP treatment-me
Erik Hofman argenx BV United States Novel-therapy clinical development Efgartigimod argenx 6 publ. · 1 pat. latest 2026 Erik Hofman’s recent CIDP research focuses on efgartigimod and its subcutaneous PH20 formulation , spanning clinical efficacy, diagnostic adjudication, biomarkers, treatment transition and therapeutic-use patents.
Richard A. Lewis Cedars-Sinai Health System United States Novel-therapy clinical development Efgartigimod, Riliprubart Sanofi argenx 7 publ. latest 2026 Richard A. Lewis’s recent CIDP publications position him as a clinical-development contributor across two differentiated therapeutic programs: riliprubart and subcutaneous efgartigimod PH20.
Roger Collet-Vidiella Hospital de la Santa Creu i Sant Pau Spain Novel-therapy clinical development Efgartigimod, Rituximab argenx 7 publ. latest 2026 Roger Collet-Vidiella’s 2024–2026 publications indicate a focus on CIDP therapeutic evaluation, neurofilament biomarkers and immunological patient stratification, rather than discovery of named new drug candidates.
Mazen Dimachkie M.D. The University of Kansas United States Novel-therapy clinical development Efgartigimod, Riliprubart, Rituximab, Hizentra (IgPro20) — 3 publ. · 1 stud. latest 2026 Mazen Dimachkie’s recent CIDP research is most relevant to clinical development, patient stratification and treatment-outcome assessment, rather than discovery of new molecules.
Ingemar S. J. Merkies University of Curacao Dr Moises da Costa Gomez Curaçao Novel-therapy clinical development Efgartigimod, Riliprubart, Nipocalimab, Hizentra (IgPro20) CSL Johnson & Johnson Octapharma 5 publ. latest 2026 Ingemar S. J. Merkies’ recent CIDP publications show involvement in targeted immunotherapy development and clinically meaningful outcome assessment.
Motoi Kuwahara Kindai University Japan Novel-therapy clinical development Efgartigimod, Rituximab CSL argenx 1 publ. · 1 stud. · 2 proj. latest 2026 Motoi Kuwahara’s recent work is most relevant to biomarker-guided selection of patients for molecularly targeted therapies, rather than discovery of a named proprietary drug.
Yusuf A. Rajabally NIHR Surgical Reconstruction Microbiology Research Centre United Kingdom Novel-therapy clinical development Efgartigimod, Riliprubart, Nipocalimab, Batoclimab Dianthus Therapeutics Johnson & Johnson LFB 5 publ. latest 2026 Yusuf A. Rajabally’s recent publications support a profile focused on clinical evaluation of CIDP therapies, treatment optimization, and trial outcome measures, rather than discovery of new molecules.
Kalliopi Pitarokoili St. Josef-Hospital Germany Novel-therapy clinical development Efgartigimod argenx 5 publ. · 1 stud. latest 2026 Kalliopi Pitarokoili’s recent work spans immune-tolerance target discovery, propionate supplementation, and treatment-response biomarkers in CIDP. The strongest directly attributable evidence concerns translational mechanisms and treatment optimization rather than a proprietary drug pipeline.
Karissa Gable Duke University Medical Center United States Novel-therapy clinical development Efgartigimod, Empasiprubart, Riliprubart Sanofi argenx 6 publ. latest 2026 Karissa Gable’s recent CIDP publications position her as a clinical-development and translational collaborator, with contributions spanning phase III trial design, immune-mechanism research, and treatment-response assessment.
Miguel Alonso-Alonso Sanofi France Novel-therapy clinical development Riliprubart Sanofi 5 publ. · 1 pat. latest 2026 Miguel Alonso-Alonso’s recent CIDP research centers on classical complement inhibition, spanning translational models, antibody dosing intellectual property, and riliprubart clinical development.
Shahar Shelly Rambam Health Care Campus Israel Diagnosis & biomarkers Rituximab — 4 publ. · 4 pat. latest 2026 Shahar Shelly’s recent work is strongest in CIDP diagnosis, treatment-response stratification, and observational research on existing immunotherapies, rather than development of a named new CIDP drug.
Ivana Basta University of Belgrade Serbia Novel-therapy clinical development Efgartigimod, HyQvia (TAK-771) Takeda argenx 6 publ. latest 2026 Ivana Basta’s recent CIDP publications demonstrate involvement in clinical development of a targeted biologic and an improved immunoglobulin delivery formulation, rather than early-stage drug discovery.
Elba Pascual-Goñi Network of Biomedical Research Centers Spain Novel-therapy clinical development Efgartigimod, Rituximab argenx 6 publ. latest 2026 Elba Pascual-Goñi’s recent CIDP publications indicate a focus on mechanism-based treatment selection, autoantibody-defined patient subsets, and trial biomarkers, rather than discovery of proprietary drug candidates.
Krista Kuitwaard Erasmus University Rotterdam Netherlands Treatment evidence & optimisation Gammagard / Kiovig — 2 publ. · 3 stud. latest 2026 Krista Kuitwaard’s recent CIDP research emphasizes optimization of established immunoglobulin therapies and better assessment of treatment response, rather than development of novel drug assets.
Dario Cocito University of Turin Italy Novel-therapy clinical development Rituximab, HyQvia (TAK-771), Gammagard / Kiovig Takeda 5 publ. latest 2026 Dario Cocito’s recent CIDP publications emphasize clinical evaluation of repurposed therapies, adjunctive pain treatment, and immunoglobulin treatment optimization, rather than discovery of new molecular assets.
Aisling Carr University College London United Kingdom Novel-therapy clinical development Efgartigimod argenx 6 publ. latest 2026 The supplied 2024–2026 publications position Carr primarily as a clinical investigator in refractory CIDP and treatment optimisation, rather than an early-stage drug-discovery researcher.
Todd Levine HonorHealth United States Novel-therapy clinical development Efgartigimod, Rozanolixizumab, HyQvia (TAK-771), Gammagard / Kiovig Takeda UCB 4 publ. latest 2026 Todd Levine’s recent CIDP work centers on clinical evaluation of FcRn inhibitors, treatment-transition risks, and immunoglobulin rescue therapy, rather than early drug discovery.
Yuki Fukami Nagoya University Japan Novel-therapy clinical development Rituximab — 6 publ. latest 2026 Yuki Fukami’s recent CIDP research is most relevant to biomarker-guided treatment selection and rituximab repurposing, rather than discovery of new molecular drugs.
Johannes Dorst Ulm University Germany Treatment evidence & optimisation — — 2 publ. · 3 stud. latest 2026 Johannes Dorst’s recent CIDP research centers on immunoadsorption as an alternative or escalation treatment for refractory disease, rather than on discovery of new molecular drugs.
Hidenori Ogata National Hospital Organisation Kyushu Medical Center Japan Novel-therapy clinical development Efgartigimod, Rituximab, HyQvia (TAK-771) Takeda 3 publ. · 1 proj. latest 2026 Ogata’s recent work combines antibody-defined disease stratification, exploratory treatment studies, and late-stage immunoglobulin maintenance research.
Niraja Suresh Lakeland Regional Medical Center Inc United States Novel-therapy clinical development Efgartigimod argenx 6 publ. latest 2026 Niraja Suresh’s recent CIDP publications focus on clinical evaluation of subcutaneous efgartigimod PH20 and optimization of subcutaneous immunoglobulin (SCIg) maintenance therapy.
Anissa Tse argenx BV United States Novel-therapy clinical development Efgartigimod argenx 6 publ. latest 2026 Anissa Tse’s documented CIDP work centers on subcutaneous efgartigimod PH20, rather than a portfolio of distinct drug candidates.
Kelly Gwathmey Virginia Commonwealth University United States Novel-therapy clinical development Efgartigimod argenx 6 publ. latest 2026 Kelly Gwathmey’s recent CIDP drug research is concentrated on subcutaneous efgartigimod PH20, with publications addressing relapse prevention, long-term function, safety, and treatment-naïve patients.
Kevin Budding argenx BV Belgium Novel-therapy clinical development Empasiprubart argenx 2 publ. · 6 pat. latest 2026 Kevin Budding’s recent CIDP research spans complement-targeting therapeutic intellectual property and phase III empasiprubart study design.
Jean-Philippe Camdessanché University Hospital Centre Saint-Etienne France Novel-therapy clinical development Rituximab LFB 3 publ. · 1 stud. latest 2026 Jean-Philippe Camdessanché’s supplied research supports expertise in CIDP patient stratification and treatment evaluation, rather than a recent pipeline of novel drugs.
Fiore Manganelli University of Naples Federico II Italy Novel-therapy clinical development Efgartigimod, Rituximab argenx 5 publ. latest 2026 Fiore Manganelli’s recent publications support a profile in clinical evaluation of CIDP therapies, biomarker development, and patient stratification, rather than discovery of new molecular assets.
Giuseppe Lauria Foundation IRCCS Carlo Besta Neurological Institute Italy Novel-therapy clinical development Efgartigimod, Rituximab argenx 5 publ. latest 2026 Giuseppe Lauria’s recent publications support a clinical-development and treatment-evaluation profile in CIDP, principally through coauthorship of the efgartigimod ADHERE/ADHERE+ program and a randomized rituximab study.
Lorena Martín-Aguilar Hospital de la Santa Creu i Sant Pau Spain Novel-therapy clinical development Efgartigimod, Rituximab argenx 5 publ. latest 2026 Lorena Martín-Aguilar’s recent CIDP research is most relevant to mechanism-based treatment selection and translational biomarkers, rather than discovery of named new drugs.
Hans Katzberg University Health Network Canada Novel-therapy clinical development Efgartigimod, Octapharma Ig (Panzyga / NewGam / Octagam) Octapharma argenx 5 publ. latest 2026 Hans Katzberg’s recent CIDP drug research is concentrated on subcutaneous efgartigimod PH20, particularly durability of benefit, daily functioning, and treatment-naïve patients.
Mark Stettner University of Duisburg-Essen Germany Novel-therapy clinical development Efgartigimod, Empasiprubart argenx 5 publ. latest 2026 Mark Stettner’s recent publications show involvement in CIDP therapeutic development, particularly empasiprubart phase III study design and efgartigimod long-term clinical evaluation, alongside preclinical work testing FcRn inhibition.
Jun Ichi Kira Fukuoka International University Japan Novel-therapy clinical development Efgartigimod, Rituximab argenx 3 publ. · 1 proj. latest 2026 Jun Ichi Kira’s recent CIDP-related work is strongest in autoantibody-defined patient stratification and mechanism-based clinical evaluation, rather than discovery of named therapeutic molecules.
Angelo Schenone Research Hospital San Martino Italy Novel-therapy clinical development Efgartigimod, Rituximab, LFB Ig (I10E / Iqymune) LFB argenx 4 publ. latest 2026 Angelo Schenone’s recent CIDP research is strongest in biomarker development, clinical phenotyping and treatment selection, rather than discovery of new therapeutic molecules.
Luana Benedetti Research Hospital San Martino Italy Novel-therapy clinical development Rituximab — 5 publ. latest 2026 Luana Benedetti’s recent CIDP publications show participation in clinical evaluation of rituximab, treatment-response characterization, and biomarker development, rather than discovery of new molecular assets.
Yessar Hussain Austin Neuromuscular Center United States Novel-therapy clinical development Efgartigimod argenx 5 publ. latest 2026 Yessar Hussain’s recent CIDP research centers on subcutaneous efgartigimod PH20, spanning controlled efficacy testing, follow-up analyses, and transition from intravenous immunoglobulin (IVIg).
Arne De Roeck argenx BV Belgium Novel-therapy clinical development Efgartigimod argenx 7 publ. latest 2026 Arne De Roeck’s recent CIDP research is concentrated on subcutaneous efgartigimod PH20, with publications addressing long-term efficacy, treatment switching, patient-reported function, diagnostic selection and real-world use.
Murray Lowe argenx BV Belgium Novel-therapy clinical development Efgartigimod CSL argenx 3 publ. · 1 pat. latest 2026 Murray Lowe’s recent CIDP research centers on efgartigimod, combining clinical evaluation of its subcutaneous PH20 formulation with treatment-method patent applications published in 2026.
Yuwei Da Capital Medical University China Novel-therapy clinical development Efgartigimod, Rituximab argenx 4 publ. latest 2026 Yuwei Da’s recent publication record spans FcRn inhibition for CIDP, repurposed immunosuppression for maintenance treatment, and B-cell–targeted treatment for autoimmune nodopathy.
Martin Markov argenx BV Belgium Novel-therapy clinical development Efgartigimod, Empasiprubart argenx 4 publ. latest 2026 Martin Markov’s latest supplied publications place him within argenx’s CIDP clinical-development work, spanning phase III study designs for empasiprubart and diagnostic adjudication in the ADHERE trial of subcutaneous efgartigimod PH20.
Shahram Attarian Public Assistance - Hospitals of Marseille France Novel-therapy clinical development Rituximab, Hizentra (IgPro20) CSL 4 publ. latest 2026 Shahram Attarian’s recent CIDP research is primarily translational and treatment-stratification focused, rather than a documented pipeline of new drug candidates.
Sommer Claudia University of Wurzburg Germany Novel-therapy clinical development Riliprubart, Rituximab Sanofi 4 publ. latest 2026 Claudia Sommer’s most recent drug-development contribution is coauthorship of Phase 3 riliprubart trial-design and recruitment publications in CIDP. Her broader work connects experimental myelin-barrier restoration with precision diagnosis and clinical-outcome standardization.
Kazim Sheikh The University of Texas Health Science Center United States Novel-therapy clinical development NVG-2089 Nuvig Therapeutics 1 publ. · 2 proj. latest 2026 The supplied metadata identifies one recent drug-focused publication, from May 2026.
Takashi Kanda Yamaguchi University Japan Novel-therapy clinical development Efgartigimod, Rituximab, Hizentra (IgPro20) — 3 publ. latest 2026 Takashi Kanda’s recent CIDP research combines blood–nerve barrier (BNB) target discovery with antibody-defined therapeutic stratification.
Sander Bus Amsterdam University Medical Centres Netherlands Treatment evidence & optimisation — — 3 publ. · 2 stud. latest 2026 Sander Bus’s recent CIDP research focuses on optimizing established immunotherapies rather than developing novel molecular assets.
Gabriele Siciliano University of Pisa Italy Novel-therapy clinical development Efgartigimod, HyQvia (TAK-771), Gammagard / Kiovig Takeda argenx 3 publ. latest 2026 Gabriele Siciliano’s strongest directly attributable recent contributions are clinical evaluation of immunoglobulin therapy and validation of a myelin-damage biomarker, rather than discovery of new therapeutic molecules.
Nazem Atassi Sanofi France Novel-therapy clinical development Riliprubart Sanofi 4 publ. · 1 pat. latest 2026 Nazem Atassi’s recent CIDP research centers on classical complement-pathway inhibition, particularly riliprubart (SAR445088).
Giuseppe Liberatore Humanitas Research Hospital Italy Novel-therapy clinical development Rituximab — 4 publ. latest 2026 Giuseppe Liberatore’s recent publications position him as a clinical and translational CIDP research collaborator, particularly in rituximab evaluation, treatment-response heterogeneity and biomarker development.
Erdita Peci University of Turin Italy Novel-therapy clinical development Rituximab — 4 publ. latest 2026 Erdita Peci’s recent CIDP publications focus on therapeutic repurposing and clinical validation, rather than discovery of new molecular assets.
Haruki Koike Nagoya University Japan Treatment evidence & optimisation Efgartigimod, Rituximab Pfizer 5 publ. · 1 proj. latest 2026 Haruki Koike’s recent publications indicate a focus on mechanism-based treatment selection, autoantibody-defined neuropathies, and biomarkers of therapeutic response, rather than discovery of new chemical entities.
Zaeem A. Siddiqi University of Alberta Hospital Canada Novel-therapy clinical development Efgartigimod — 4 publ. latest 2026 Zaeem A. Siddiqi’s recent drug-related CIDP work centers on subcutaneous efgartigimod, supported by ADHERE trial publications and a 2026 publication on Canadian care needs and access.
Ryo Yamasaki Kyushu University Japan Novel-therapy clinical development Efgartigimod, Rituximab argenx 3 publ. latest 2026 Ryo Yamasaki’s recent profile supports expertise in clinical evaluation of IgG-directed therapies and antibody-defined patient stratification, rather than a broad pipeline of newly invented CIDP drugs.
Marinos C. Dalakas National and Kapodistrian University of Athens Greece Novel-therapy clinical development Efgartigimod, Nipocalimab, Rozanolixizumab, Rituximab Novartis Sanofi 1 publ. latest 2026 Dalakas’s recent publications position him as a mechanism-focused contributor to CIDP therapeutic strategy, particularly B-cell targeting, complement inhibition, and alternatives to immunoglobulin.
Sami Khella University of Pennsylvania United States Novel-therapy clinical development Efgartigimod, Hizentra (IgPro20) argenx 3 publ. latest 2026 Sami Khella’s recent CIDP research is primarily clinical and treatment-optimization focused, with directly documented coauthorship on subcutaneous immunoglobulin studies in 2025–2026.
Khema R. Sharma University of Miami United States Novel-therapy clinical development Efgartigimod, Hizentra (IgPro20) argenx 3 publ. latest 2026 Khema R. Sharma’s strongest recent, directly attributable contribution is optimization of subcutaneous immunoglobulin maintenance therapy, rather than discovery of new CIDP drugs.
Kenichi Kaida Saitama Medical Center Japan Novel-therapy clinical development Rituximab — 2 publ. · 1 proj. latest 2026 Kenichi Kaida’s recent CIDP research is most relevant to autoantibody-guided treatment development and refractory-disease stratification, rather than discovery of named proprietary drugs.
Thomas H. Brannagan Columbia University United States Novel-therapy clinical development Empasiprubart, HyQvia (TAK-771) Takeda argenx 3 publ. latest 2026 Thomas H. Brannagan’s recent CIDP publications show involvement in phase 3 study design for empasiprubart, alongside randomized evidence for facilitated subcutaneous immunoglobulin and guidance on established IVIg therapy.
Noriko Isobe Kyushu University Japan Novel-therapy clinical development Efgartigimod — 2 publ. · 1 proj. latest 2025 Noriko Isobe’s recent CIDP-related research is strongest in autoantibody-defined autoimmune nodopathies, therapeutic response profiling, and mechanistic validation, rather than development of a proprietary drug pipeline.
John-Philip Lawo CSL Australia Treatment evidence & optimisation Hizentra (IgPro20), Privigen (IgPro10) CSL 3 pat. latest 2026 John-Philip Lawo’s documented CIDP work centers on immunoglobulin treatment optimization—not discovery of new molecular drugs.
Tomoyuki Tanaka The University of Texas MD Anderson Cancer Center United States Novel-therapy clinical development Riliprubart Sanofi 2 stud. latest 2026 The supplied records link Tomoyuki Tanaka to two Phase 3 studies of riliprubart in CIDP, with listed start dates in July and September 2024.
Divyanshu Dubey Guru Nanak Dev University India Novel-therapy clinical development Rituximab — 5 publ. latest 2026 Divyanshu Dubey’s recent CIDP-related research is strongest in biomarker-guided treatment selection, differentiation from mimics, and response monitoring, rather than novel drug development.
Trevor Mole argenx BV Belgium Novel-therapy clinical development Efgartigimod argenx 3 publ. latest 2026 Trevor Mole’s recent CIDP publications focus on subcutaneous efgartigimod PH20, particularly long-term outcomes and communication of ADHERE trial findings.
Francesco Germano University of Genoa Italy Novel-therapy clinical development Rituximab — 3 publ. latest 2026 Francesco Germano’s recent CIDP drug research centers on clinical evaluation of rituximab, rather than discovery of new molecular assets.
Luc Truyen argenx BV United States Novel-therapy clinical development Efgartigimod argenx 1 publ. · 1 pat. latest 2026 Luc Truyen’s recent CIDP-related work centers on efgartigimod, with contributions as a co-inventor on treatment-method patent applications and a co-author on clinical safety research.
Luca Gentile University of Messina Italy Novel-therapy clinical development Rituximab — 3 publ. latest 2026 Luca Gentile’s recent CIDP drug research centers on clinical evaluation of rituximab, rather than discovery of new molecular assets.
Yuanqi Zhao Guangzhou University of Chinese Medicine China Novel-therapy clinical development Efgartigimod — 3 publ. latest 2026 Yuanqi Zhao’s recent CIDP-related publications support a profile in clinical therapeutic evaluation and diagnostic stratification, rather than discovery of new drug assets.
Erik Wallstroem Sanofi France Novel-therapy clinical development Riliprubart Novartis Sanofi 3 publ. · 1 pat. latest 2026 Erik Wallstroem’s recent CIDP research centers on riliprubart (SAR445088), an investigational C1s-targeting antibody now in Phase 3 development.
Sonoko Misawa Chiba University Japan Novel-therapy clinical development Efgartigimod, Nipocalimab, HyQvia (TAK-771) Takeda 2 publ. · 1 proj. latest 2026 Sonoko Misawa’s recent CIDP research spans early therapeutic target validation, assessment of emerging FcRn inhibitors, and clinical evaluation of immunoglobulin maintenance formulations.
Yuri Matteo Falzone San Donato Hospital Group Italy Novel-therapy clinical development Rituximab — 3 publ. latest 2026 Yuri Matteo Falzone’s recent CIDP research is most relevant to clinical evaluation of rituximab as a repurposed therapy, rather than discovery of new molecular assets.
Ting Chang Air Force Medical University China Novel-therapy clinical development Efgartigimod argenx 3 publ. latest 2026 Ting Chang’s recent CIDP work spans emerging immune-reset cell therapies and clinical validation of FcRn inhibition.
Elisa Bianchi Mario Negri Institute for Pharmacological Research Italy Novel-therapy clinical development Rituximab — 3 publ. latest 2026 Elisa Bianchi’s latest supplied CIDP research focuses on clinical evaluation of rituximab and biomarkers of axonal injury, rather than discovery of new drug assets.
Sabrina Mata' University of Florence Italy Novel-therapy clinical development Rituximab, Hizentra (IgPro20) CSL 2 publ. latest 2026 The supplied publications support expertise in CIDP diagnosis, patient stratification and treatment-response assessment—not a recent pipeline of novel drug candidates.
James F. Howard, Jr. The University of North Carolina at Chapel Hill United States Novel-therapy clinical development Efgartigimod, Riliprubart Sanofi argenx 2 publ. latest 2026 James F. Howard, Jr.’s most recent CIDP-relevant publications emphasize FcRn inhibition and efgartigimod safety, complemented by earlier translational studies of complement inhibition and inflammatory pathways.
Young Gi Min Seoul National University South Korea Treatment evidence & optimisation Rituximab — 6 publ. latest 2026 Young Gi Min’s recent publications support a profile in immune-neuropathy treatment optimization, diagnostic stratification, and repurposing, rather than development of a new CIDP drug.
P. D. Donofrio Vanderbilt University United States Novel-therapy clinical development Efgartigimod, Grifols Ig (Gamunex / Xembify) Grifols argenx 2 publ. latest 2026 P. D. Donofrio’s latest CIDP research concerns diagnostic adjudication in the ADHERE trial of subcutaneous efgartigimod PH20.
Thomas Harbo Aarhus University Hospital Denmark Novel-therapy clinical development Efgartigimod, Hizentra (IgPro20) CSL argenx 2 publ. latest 2026 Thomas Harbo’s documented CIDP work is strongest in clinical treatment evaluation, immunoglobulin maintenance therapy, and outcome standardization, rather than early-stage drug discovery.
Frauke Stascheit Humboldt University of Berlin Germany Treatment evidence & optimisation Efgartigimod, Rituximab, Daratumumab — 4 publ. · 1 stud. latest 2026 Frauke Stascheit’s recent CIDP research is strongest in human target validation, treatment-response biomarkers, and clinical characterization of refractory disease, rather than named-drug development.
Researcher Country Role Drugs named Industry ties Linked records What their record shows
Rebecca Traub The University of North Carolina at Chapel Hill United States Novel-therapy clinical development Efgartigimod, Rituximab argenx 2 publ. latest 2026 Rebecca Traub’s most recent CIDP drug-related work focuses on real-world evaluation of subcutaneous efgartigimod PH20, rather than discovery of new assets.
Jana Zschüntzsch University of Gottingen Germany Novel-therapy clinical development Efgartigimod argenx 2 publ. · 1 stud. latest 2026 The supplied 2025–2026 documents position Jana Zschüntzsch, University of Göttingen, primarily in CIDP real-world treatment evaluation and exploratory biomarker research, rather than discovery of new therapeutic assets.
Hakan Ay Takeda Japan Treatment evidence & optimisation HyQvia (TAK-771), Gammagard / Kiovig Takeda 5 publ. latest 2026 Hakan Ay’s recent CIDP publications focus on clinical validation and optimization of immunoglobulin therapy, particularly facilitated subcutaneous immunoglobulin (fSCIG), rather than discovery of new molecular targets.
Fabian Klostermann Humboldt University of Berlin Germany Treatment evidence & optimisation Hizentra (IgPro20), Privigen (IgPro10) CSL 5 publ. latest 2026 Fabian Klostermann’s latest documented CIDP research (2024–2026) focuses on non-sensorimotor disease manifestations and exploratory biomarkers—not novel drug candidates.
… and 150 more rows in the interactive table.

Sorted by a transparent ranking score: role, number of linked publications, studies, patents and projects, drugs named, strongest evidence and recency. Showing up to 250 matches at a time.

Research groups: what they work on

  • Clinical trials & treatment evidence · 48
  • Mechanism & pathobiology · 45
  • Biomarkers & diagnostics · 27
No academic group is discovering CIDP drugs

Every substantiated group works on clinical evidence, biomarkers or mechanism. Therapeutic invention in CIDP happens in companies; academia supplies the patients, the endpoints and the biology.

Research groups: where they are

  • United States · 41
  • Germany · 16
  • Canada · 12
  • Italy · 7
  • Switzerland · 7
  • United Kingdom · 7
  • France · 6
  • Japan · 5
  • Australia · 5
  • Netherlands · 3
  • Sweden · 3
  • Belgium · 2
  • India · 1
  • Denmark · 1

Research group directory

39 of the 120 groups have a name or stated focus outside neurology and immunology, which usually means one member co-authored a CIDP paper; they are hidden until you untick the filter.

Group Leads Institution Focus CIDP papers What they contribute
Immune- Mediated Neuropathies Research Group Bart K. M. Jacobs, Ruth Huizinga, Wouter van Rijs Radboud University Netherlands Clinical trials & treatment evidence 7 The group studies antibodies against the nodal/paranodal proteins NF155, CNTN1 and CASPR1, alongside B-cell biology.
Neuroimmune Disease Website ↗ Hiroo Masuda, Akiyuki Uzawa, Sonoko Misawa Chiba University Japan Clinical trials & treatment evidence 6 The Neuroimmune Disease group’s recent CIDP work combines early target discovery with clinical studies of immunomodulatory treatments. Assets discussed: Efgartigimod, Nipocalimab, Rituximab, HyQvia (TAK-771)
Neuroscience Research Group Matthew C. Kiernan University of New South Wales Australia Clinical trials & treatment evidence 5 A 2025 publication addresses quantification of immunoglobulin response, while a June 2026 study investigates clinically meaningful measures of disease activity and minimum symptom expression during maintenance therapy.
Peripheral Nerve Disease Website ↗ Kazumoto Shibuya, Sonoko Misawa Chiba University Japan Clinical trials & treatment evidence 5 The Peripheral Nerve Disease group’s recent CIDP work is strongest in clinical evaluation, disease mechanisms and patient stratification. Assets discussed: Efgartigimod, Nipocalimab, HyQvia (TAK-771)
Peripheral Neuropathies Website ↗ Francesca Castellani, Alessandro Salvalaggio, Chiara Briani University of Padua Italy Clinical trials & treatment evidence 5 The Peripheral Neuropathies group’s CIDP work is strongest in clinical characterization and treatment selection. Assets discussed: Efgartigimod, Empasiprubart, Rozanolixizumab, Rituximab
Institute for Neuropathology Kathy Keyvani University of Duisburg-Essen Germany Clinical trials & treatment evidence 3 Its documented contribution is chiefly diagnostic and prognostic: an institute-affiliated coauthor participated in a 2024 study of nerve biopsy in suspected immune neuropathies and a 2021 case report on treatment of a rare antibody-associated neuropathy. Assets discussed: Rituximab
Neuroinflammation Jan D. Lünemann University of Zurich Switzerland Mechanism & pathobiology 3 The Neuroinflammation group’s CIDP work is strongest in human target validation and treatment-mechanism research. Assets discussed: Efgartigimod
Neurosciences Antonio Uccelli, Angelo Schenone University of Genoa Italy Clinical trials & treatment evidence 3 Its 2026 multicentre study addresses variation in treatment selection and outcomes, while a 2025 study advances cerebrospinal-fluid sphingomyelin as a potential measure of myelin damage and disease activity. Assets discussed: Efgartigimod, LFB Ig (I10E / Iqymune)
Su Lab Melissa G. Lechner, Maureen A. Su University of California Los Angeles United States Mechanism & pathobiology 3 Su Lab’s CIDP work is primarily mechanism-driven target discovery.
Ag Weishaupt Jochen H. Weishaupt, Kathrin Mller, Axel Freischmidt Ulm University Germany Clinical trials & treatment evidence 2 The group’s CIDP-related work evaluates an antibody-removal procedure and explores fluid biomarkers.
Bendszus Group Martin Bendszus Heidelberg University Germany Clinical trials & treatment evidence 2 A 2016 collaborative preclinical study used an ICAM-1-deficient mouse model of chronic neuritis to examine variable responses to IVIg.
Chan Lab Website ↗ K. Ming Chan University of Alberta Canada Mechanism & pathobiology 2 Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Clinical Neurophysiology Group Maarika Liik Liik, Hans Axelson, Anna Rostedt Punga Uppsala University Sweden Biomarkers & diagnostics 2 The group’s recent CIDP work is focused on biomarkers. Assets discussed: aHSCT
Early Neuropathy Assessment Group Rayaz A. Malik, Ioannis Nikolaos Petropoulos Cornell University United States Biomarkers & diagnostics 2 In a study of 88 patients, its reported one-versus-all AUC for CIDP was 97%.
Lee Lab Seungmin Shin, Ji Won Lee, Mary Moul Dartmouth College United States Clinical trials & treatment evidence 2 A 2025 Korea–UK study of 122 patients evaluated Jamar hand-grip thresholds for detecting improvement or deterioration.
Neuroimmunology Group Renaud A. Du Pasquier University of Lausanne Switzerland Clinical trials & treatment evidence 2 The group’s recent CIDP publications are clinical reviews. Assets discussed: Efgartigimod
Neuromuscular Imaging Alexander Grimm University of Tubingen Germany Biomarkers & diagnostics 2 In a 2024 study, nerve-ultrasound scoring helped distinguish CIDP in patients with diabetes from diabetic polyneuropathy; combining the ultrasound score with a disability score yielded an AUC of 0.959.
Neuromuscular Synapse and Myasthenia Gravis Group Anna Rostedt Punga Uppsala University Sweden Clinical trials & treatment evidence 2 The group’s recent CIDP work is biomarker research.
Ag Keller Christian Wolfgang Keller University of Marburg Germany Mechanism & pathobiology 1 The most recent relevant document is a 2026 treatment overview; the group’s mechanistic CIDP studies date from 2015–2019.
Als Center for Cell Therapy and Regeneration Research Ahmet Hoke, Nicholas J. Maragakis, Jeffrey D. Rothstein Johns Hopkins University United States Mechanism & pathobiology 1 A 2018 study involving a Johns Hopkins coauthor found increased Schwann-cell-derived POSTN in CIDP nerve biopsies and an autoimmune-neuropathy mouse model.
Andy Knight Group Andrew M. Knight University of Alberta Canada Biomarkers & diagnostics 1 The group's documented contribution is a potentially useful diagnostic and patient-stratification finding in inflammatory polyradiculoneuropathy.
Ashutosh Gupta's Group Website ↗ Ashutosh Gupta Indian Institute of Technology Bombay India Clinical trials & treatment evidence 1 In this single case, seizures persisted despite IVIG and improved significantly after rituximab. Assets discussed: Rituximab
Bioinformatics and Genomics Lab John Timothy Chamberlin, Seonggyun Han, Younghee Lee The University of Utah United States Mechanism & pathobiology 1 Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Center for Integrated ​Healthcare Data Research Website ↗ Shawn N. Murphy, Joshua Lin, Sebastian Schneeweiss Harvard University United States Clinical trials & treatment evidence 1 Its relevant work is a 2025 validation study of how reliably US insurance claims identify people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Clinical Neuroimmunology Bernhard Hemmer Technical University of Munich Germany Clinical trials & treatment evidence 1 Its relevant 2024 publication is a multicenter retrospective study of treatment timing and outcomes.
Clinical Trials Unit Website ↗ Lise J Estcourt, Cara Hudson, Helen Thomas United Kingdom Department of Health and Social Care United Kingdom Clinical trials & treatment evidence 1 Its CIDP-relevant work is a 2026 systematic review comparing established treatments.
Division of Pharmacoepidemiology and Pharmacoeconomics Sebastian Schneeweiss, Brian T. Bateman, Katsiaryna Bykov Harvard University United States Clinical trials & treatment evidence 1 The Division’s recent CIDP research is pharmacoepidemiologic.
Emmy Noether Research Group Jan Krönke Ulm University Germany Mechanism & pathobiology 1 Its CIDP-related publication is a two-patient report of CIDP following cilta-cel treatment for multiple myeloma.
Excitabilite Nerveuse Et Therapeutique Jean-pascal Lefaucheur, Alain Créange University Paris-Est Creteil Val de Marne France Mechanism & pathobiology 1 In a 2016 study, MSRV-Env–related signals were elevated in CIDP samples, the protein was detected in Schwann cells in 5 of 7 CIDP nerve biopsies, and GNbAC1 inhibited MSRV-Env–induced IL-6 and CXCL10 responses in cultured human Schwann cells. Assets discussed: Rituximab, MD1003 (biotin)
Experimental Gliabiology Veit Rothhammer Technical University of Munich Germany Clinical trials & treatment evidence 1 Experimental Gliabiology has one recent CIDP drug publication. Assets discussed: Efgartigimod
Human Movement Sciences H.A.M. Daanen, Jaap H. van Dieën, Michel W. Coppieters VU Amsterdam Netherlands Biomarkers & diagnostics 1 Across a mixed group of 20 patients and 16 controls, peripheral nerve shear wave velocity was higher in patients and correlated negatively with motor nerve conduction measures.
Image at Imagine Nathalie Boddaert Gustave Eiffel University France Biomarkers & diagnostics 1 In six children with pathogenic POLG variants, the researchers observed severe polyradiculoneuropathy that mimicked CIDP, alongside intestinal dysmotility and liver disease.
Immunology Jacob Thaning Bay, Sisse R. Ostrowski University of Copenhagen Denmark Clinical trials & treatment evidence 1 Immunoglobulin therapy used by some patients with CIDP or MMN.
Ingrid Kockum S Research Group Edit Ekstrm, Rasmus Gustafsson, Ingrid Skelton Kockum Karolinska Institute Sweden Biomarkers & diagnostics 1 A newer, 2025 publication reports that pretreatment beta-trace protein levels may help diagnose CIDP and that cerebrospinal-fluid levels may predict failure of immunotherapy at three months.
Keller Lab Website ↗ Ulrich Keller Helmholtz Association of German Research Centres Germany Mechanism & pathobiology 1 Keller Lab’s recent CIDP-related publication is a two-patient report of CIDP following cilta-cel treatment for multiple myeloma.
Laeubli Lab Heinz Laubli University of Basel Switzerland Clinical trials & treatment evidence 1 An antibody–cytokine fusion comprising IL-2 and an anti-IL-2 monoclonal antibody, used to support activation of infused tumour-infiltrating lymphocytes (TILs) in vivo in place of high-dose IL-2.
Madhuranthakam Lab Ananth J. Madhuranthakam The University of Texas System United States Biomarkers & diagnostics 1 Madhuranthakam describes whole-body magnetic resonance neurography as a radiation-free way to visualize peripheral nerve anatomy and abnormalities, with potential use in diagnosing and monitoring CIDP.
N2Lab - Microneurography and Microneurostimulation Laboratory Calogero M. Oddo, Silvestro Micera Sant'Anna School of Advanced Studies Italy Biomarkers & diagnostics 1 F-wave latencies, distal latencies, and conduction velocities contributed to discrimination.
Neuro-Head Center Thomas Korn, Bernhard Hemmer, Paul Lingor Technical University of Munich Germany Clinical trials & treatment evidence 1 Oral administration of bovine peripheral-nerve myelin, including a regimen combined with cholera toxin, was tested in rats with relapsing experimental autoimmune neuritis.
Neuro-Robotic Touch Laboratory Calogero M. Oddo Sant'Anna School of Advanced Studies Italy Biomarkers & diagnostics 1 The study analyzed electrophysiological data from 67 patients, including 29 with CIDP, and found that a random-forest model achieved 80.6% test accuracy in distinguishing CIDP from two IgM-MGUS–associated neuropathy groups.
Neurobiology of Peripheral Neuropathies; Development and Regeneration of the Per Website ↗ Ahmet Hoke Johns Hopkins University United States Mechanism & pathobiology 1 Macrophage-associated inflammatory neuropathy, potentially including CIDP.
Neuroimmunology Unit Axel Petzold University College London United Kingdom Biomarkers & diagnostics 1 The Neuroimmunology Unit’s recent CIDP-related work is focused on biomarkers, not new drug development.
Neuromuscular Disorders and Dystonia Maria Lucia Valentino, Patrizia Avoni, Frank Van Der Aa University of Bologna Italy Clinical trials & treatment evidence 1 The Neuromuscular Disorders and Dystonia group’s CIDP-related work is best characterized as clinical characterization and treatment evaluation.
O'Connor Lab Website ↗ Kevin C. O’Connor, Miriam Fichtner Fichtner, Amanda Hernandez Yale University United States Mechanism & pathobiology 1 Early B-cell tolerance and B-cell receptor (BCR) signaling, with implicated changes in CD79B, CSK, BLNK, and BTK expression and altered T-cell–B-cell interactions.
Service De Nephrologie Dialyse Apherese Olivier Moranne University Hospital Centre Nimes France Clinical trials & treatment evidence 1 In a 2025 retrospective case series of three patients with CIDP, the group compared albumin and saline replacement schedules during therapeutic plasma exchange, as well as albumin-infusion schedules during double-filtration plasmapheresis (DFPP).
Song Tan's Lab Wen-Song Tan The Pennsylvania State University United States Clinical trials & treatment evidence 1 Subcutaneous neonatal Fc receptor (FcRn) inhibitor studied for CIDP. Assets discussed: Efgartigimod
Stanford Center for Undiagnosed Diseases Stanford Center for Undiagnosed Disease Website ↗ Euan A. Ashley, Jon Bernstein, Matthew T. Wheeler University of Illinois Urbana-Champaign United States Biomarkers & diagnostics 1 RNA sequencing showed excess minor-intron retention, supporting a molecular diagnosis.
The Blakemore Laboratory David Sconyers, Yun Peng, James D. Blakemore The University of Kansas United States Clinical trials & treatment evidence 1 A 2025 retrospective study of six children with anti-neurofascin-155-antibody-positive autoimmune nodopathy, a CIDP-related condition, reported symptom relief after treatment that included glucocorticoids, rituximab, and plasma exchange. Assets discussed: Rituximab
The Napier Lab Amy Seufert, James J. Hickman, Ph.D., Brooke A. Napier Portland State University United States Mechanism & pathobiology 1 Contributes CIDP publications (mechanism & pathobiology); no drug-development work described. Assets discussed: Riliprubart
Tucker Group - Motor Control and Pain Research Website ↗ Kylie Tucker, François Hug The University of Queensland Australia Biomarkers & diagnostics 1 Across 20 patients with demyelinating neuropathies and 16 controls, peripheral nerve shear wave velocity was higher in the patient group and correlated negatively with motor nerve conduction.
Virginia Willour Laboratory Marie E. Breen, Virginia L. Willour, Kelly Novak The University of Iowa United States Mechanism & pathobiology 1 Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Zippelius Lab Marina Natoli, Marcel Philipp Trefny, Alfred Zippelius University of Basel Switzerland Clinical trials & treatment evidence 1 An antibody–cytokine fusion protein comprising IL-2 fused to an anti-IL-2 monoclonal antibody.
Autism Research William M. Mcmahon, Hilary Coon, Deborah A. Bilder The University of Utah United States Mechanism & pathobiology — The publication found that a polygenic score for chronic inflammatory demyelinating polyneuropathy (CIDP) was associated with suicide death in the studied cohort.
Azrieli Centre for Autism Research Stefano Stifani, Mayada Elsabbagh, Guy A. Rouleau McGill University Canada Mechanism & pathobiology — The Azrieli Centre for Autism Research’s about-text describes a focus on autism mechanisms, diagnostics, and interventions.
Clinical Neuroimmunology Group Clemens Warnke, Finja Schweitzer, Hannah Sychla University of Cologne Germany Clinical trials & treatment evidence — A 2021 review notes that some neurological immune therapies are used in or off label for CIDP. Assets discussed: Rituximab
Cross Laboratory Anne H. Cross Washington University in St Louis United States Mechanism & pathobiology — In an IL-10-overexpressing mouse model of chronic demyelinating polyneuropathy, macrophage depletion reversed progressive nerve loss and paralysis.
Derfuss/ Kuhle Lab Website ↗ Tobias Derfuss, Jens Kuhle, David Leppert University of Basel Switzerland Mechanism & pathobiology — Enzyme inhibition aimed at limiting inflammatory tissue damage.
Functional Neuroradiology Andrea Falini, Cristina Baldoli, Nicoletta Anzalone San Donato Hospital Group Italy Biomarkers & diagnostics — In a brain MRI study of 16 people with CIDP, the group reported gray-matter atrophy and distributed white-matter abnormalities compared with healthy controls.
Hornung Lab - Innate Immunity Website ↗ Xiaoshan Hu, Joshua Kie, Veit Hornung LMU Munich Germany Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Hornung Lab - Molecular Mechanisms of Inflammation Website ↗ Veit Hornung LMU Munich Germany Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Integrated Neuroanatomy and Neuroimaging Website ↗ Tatsuya Umeda, Kenji Yoshinaga, Takashi Hanagawa Kyoto University Japan Biomarkers & diagnostics — Additional publications, project records, or other research documentation would be needed for a drug-focused evaluation.
Kapfhammer Lab Website ↗ Josef P. Kapfhammer University of Basel Switzerland Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Keightley – Myeloid Development and Disease Maria-Cristina Keightley La Trobe University Australia Mechanism & pathobiology — Keightley – Myeloid Development and Disease describes foundational research on the transcription factor Zbtb11 in blood and stem-cell development, using zebrafish models of Zbtb11 deficiency.
Kilpatrick Laboratory Trevor J. Kilpatrick The University of Melbourne Australia Mechanism & pathobiology — Its stated research interests center on CNS demyelination and MS.
Korn Laboratory Website ↗ Thomas Korn Technical University of Munich Germany Mechanism & pathobiology — The only CIDP-relevant treatment finding is a 2003 animal study coauthored by Thomas Korn.
Laboratory for Perception & Cognition and Clinical Neuroscience Website ↗ Szabolcs Kéri Budapest University of Technology and Economics Hungary Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Laboratory of Veterinary Pathology Kazuyuki Uchida, James K. Chambers The University of Tokyo Japan Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
McConnell Brain Imaging Centre Website ↗ Rick Hoge, Guy A. Rouleau McGill University Canada Biomarkers & diagnostics — Contributes CIDP publications (biomarkers & diagnostics); no drug-development work described.
Montgomery Lab Kevin Smith, Stephen B. Montgomery Stanford University United States Mechanism & pathobiology — RNU6ATAC encodes a minor-spliceosomal RNA; the study links the variants to excess minor-intron retention and proposes RNU6ATAC as a disease-associated gene.
Ms Center Laura Piccio, Robert T. Naismith, Gregory F. Wu Washington University in St Louis United States Clinical trials & treatment evidence — Contributes CIDP publications (clinical trials & treatment evidence); no drug-development work described.
Pain and Nociception Martin Koltzenburg University College London United Kingdom Biomarkers & diagnostics — Contributes CIDP publications (biomarkers & diagnostics); no drug-development work described.
Petri Kursula Petri Kursula University of Oulu Finland Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Petri Kursula Lab Petri Kursula, Anne Baumann University of Bergen Norway Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Quintana Lab Atsushi Kadowaki, Francisco J. Quintana, Liliana Maria Sanmarco Harvard University United States Biomarkers & diagnostics — Contributes CIDP publications (biomarkers & diagnostics); no drug-development work described.
RVCL Research Center Website ↗ Jonathan J. Miner, John P. Atkinson, M.D., Andria L. Ford Washington University in St Louis United States Clinical trials & treatment evidence — The available profile information describes the RVCL Research Center as focused on RVCL, a rare genetic disease associated with vision loss and stroke-like neurological problems.
Schirmer Group Website ↗ Lucas Schirmer Heidelberg University Germany Biomarkers & diagnostics — One concerns cerebrospinal-fluid diagnostics and blood-based biomarkers in CIDP; the other examines the diagnostic distinction between carpal tunnel syndrome and CIDP.
Specialised Translational Research Oxford Neuromuscular Group: Strong Website ↗ Christine Montague-johnson, Laurent Servais, Charlotte Lilien University of Oxford United Kingdom Clinical trials & treatment evidence — The group’s about-text describes work on neuromuscular clinical trials, outcome measures, personalised care, and evaluation of existing therapies.
T. Foetus Diagnostic Laboratory Website ↗ Victoria E. Watson, Stephen H. Stauffer, Jody L. Gookin NC State University United States Biomarkers & diagnostics — The T.
The Jedd Wolchok Lab Bianca D Santomasso Memorial Sloan Kettering Cancer Center United States Clinical trials & treatment evidence — The only research document is a 2019 retrospective study of 23 patients with peripheral neuropathy after immune checkpoint inhibitor (ICI) treatment.
The Theriot Lab Website ↗ Jenessa A. Winston, Casey M. Theriot, Rajani Thanissery NC State University United States Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Trent Watkins Lab Trent A. Watkins Rice University United States Mechanism & pathobiology — Contributes CIDP publications (mechanism & pathobiology); no drug-development work described.
Funding

Who pays for CIDP research, and for what

30 publicly funded projects that started between 2020 and 2026, each analysed for the asset or biomarker it develops, its stage and its role in CIDP care. 18 of them link by record ID to researchers in the expert view.

Funded projects by theme

  • Nodal / paranodal autoantibodies · 11
  • Complement · 4
  • Myelin / nerve repair · 4
  • Immunoglobulin / FcRn · 4
  • B / T cells · 4
  • Other biomarkers & diagnostics · 2
  • Macrophage (CSF1R) · 1
Public money builds the diagnostic side

20 of 30 projects are biomarker or diagnostic work and 11 study nodal or paranodal antibodies. 16 are Japanese KAKENHI grants, most of them small. Together the projects total about $8.3 million at indicative rates.

Funders

  • KAKENHI · 16 · about $0.65M indicative
  • NIH · 8 · about $6.17M indicative
  • AMED · 3 · about $0.55M indicative
  • UKRI · 2 · about $0.89M indicative
  • DFG · 1 · about $0.00M indicative

Indicative US-dollar values use fixed conversion rates stated in the method section.

Grants fund what companies have not picked up

11 of the 30 projects study nodal or paranodal antibodies, the largest single theme, and no patent family or clinical study targets those antigens. 18 projects link to researchers in the expert view; 8 of them have a researcher with any industry tie. For the 7 nodal-antibody projects with a linked researcher, the number is 2.

Projects

Start Project Funder Theme Researchers in the expert view Award
2026-09 Elucidating Novel Immunomodulatory Mechanisms of Neonatal Fc Receptor Blockade by Efgartigimod in a T Cell-Mediated Demyelinating Neuropathy Model NIH RePORTER ↗ · United States The project is exploring efgartigimod, an FcRn-blocking biologic, to clarify how it may treat CIDP through immune effects beyond IgG clearance. NIH Immunoglobulin / FcRn Other biologic · Preclinical development — $234k
2026-08 Antibiotic-Driven Campylobacter Immunogenicity and Microbiome Dysbiosis in Guillain-Barré Syndrome NIH RePORTER ↗ · United States The project mentions elevated IL-8 as a potential biomarker for distinguishing GBS from CIDP, but does not propose developing or validating it for CIDP. NIH Other biomarkers & diagnostics Biomarker · Concept or hypothesis — $231k
2026-05 Aging and T cell Senescence in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) NIH RePORTER ↗ · United States The project is exploring ruxolitinib as a senomorphic treatment to reduce senescence-associated pathology in CIDP. NIH B / T cells Small molecule · Preclinical development Maureen A. Su $236k
2026-04 Identification of novel IgG autoantigens in CIDP KAKEN ↗ Yuko Yamagisi (Kindai University) · Japan The project is exploring novel IgG autoantigens as potential CIDP biomarkers to refine disease subtypes and inform diagnosis and treatment strategies. KAKENHI Nodal / paranodal autoantibodies Biomarker · Discovery Yuko Yamagisi $30k
2026-04 Elucidation of the molecular mechanisms underlying the activation of the classical complement pathway and macrophage-associated demyelination in CIDP KAKEN ↗ Keisu Murakami (Wakayama Medical University) · Japan The project is developing an activated C1s ELISA to assess classical complement pathway activation in CIDP. KAKENHI Nodal / paranodal autoantibodies Diagnostic test · Discovery — $30k
2026-04 Development of Treatments for Autoimmune Peripheral Neuropathy: Promoting Nerve Regeneration and Elucidating Molecular Mechanisms KAKEN ↗ Xiaowen, Inside (Toho University) · Japan The project explores unspecified therapies that promote Schwann-cell-mediated remyelination to restore nerve function in CIDP. KAKENHI Myelin / nerve repair No identifiable asset · Discovery — $31k
2026-04 Identification of Peripheral Blood Lymphocyte Profiles That Determine Disease Activity in Chronic Inflammatory Demyelinating Polyneuropathy KAKEN ↗ Yongilang Amano (Tokyo Institute of Technology) · Japan The project is exploring peripheral-blood lymphocyte profiles as CIDP biomarkers to monitor disease activity and inform treatment selection. KAKENHI B / T cells Biomarker · Human observational study — $31k
2026-03 Skin biopsy as a potential biomarker for chronic inflammatory demyelinating polyneuropathy NIH RePORTER ↗ · United States The project is exploring skin-biopsy-based biomarkers to improve CIDP diagnosis and potentially assess treatment response. NIH Immunoglobulin / FcRn Biomarker · Human observational study — $246k
2025-04 Elucidation of Glycan and Complement-Related Pathophysiology and Development of Therapeutic Strategies in Immune-Mediated Neuropathy KAKEN ↗ Yuuki Fukami (Nagoya University) · Japan The project is exploring glycan- and complement-related biomarkers for CIDP and complement inhibitors as potential treatments to reduce nerve inflammation and damage. KAKENHI Complement Combination of assets (specify which ones: biomarkers and complement i · Multiple stages (specify which ones: human observational stu — $31k
2025-04 Search for novel autoantigens of autoimmune neurological diseases - challenge with improved antibody analysis method KAKEN ↗ Yukari Komuta (National Defense Medical College) | Kenichi Kaida (Saitama Medical Center | Saitama University | Saitama · Japan The project is developing an antibody-analysis method to discover CIDP-associated autoantigens, with the aim of enabling rapid diagnosis. KAKENHI Nodal / paranodal autoantibodies Diagnostic test · Discovery Kenichi Kaida
Yukari Komuta 		$31k
2024-04 Exploration of biological factors associated with severity and prognosis in immunological neuropathies KAKEN ↗ Susumu Kusunoki (Kindai University) | Motoi Kuwahara (Kindai University) | Yoshitaka Nagai (Jichi Medical University | J · Japan The project explores serum biomarkers of severity and prognosis in immunological neuropathies to support future treatment selection; CIDP is not explicitly mentioned. KAKENHI Complement Biomarker · Human observational study Motoi Kuwahara industry tie $31k
2024-04 In-depth characterization of B-cell dysfunction in chronic inflammatory demyelinating polyneuropathy NIH RePORTER ↗ · United States The project is exploring CIDP autoantigens and autoantibody biomarkers to clarify disease mechanisms and inform treatment selection. NIH Nodal / paranodal autoantibodies Biomarker · Multiple stages (Discovery and Human observational study) — $1,203k
2024-04 Elucidation of mechanisms of central and peripheral nervous system demyelination caused by newly discovered anti-nodal antibodies in autoimmune nodopathy KAKEN ↗ Jun Ichi Kira (Fukuoka International University | International University of Health and Welfare Kohokai Group | Kyushu · Japan The project is exploring anti-nodal antibodies as biomarkers and experimental probes to identify autoimmune nodopathy and clarify mechanisms relevant to CIDP. KAKENHI Nodal / paranodal autoantibodies Combination of assets (Diagnostic test and Biomarker) · Multiple stages (Discovery, Human observational study, and P Jun Ichi Kira industry tie $116k
2024-01 Inter-alpha-trypsin inhibitor heavy chain 3 as Biomarker for Neuromuscular Disorders: Validation, Specificity and Mechanistic Interactome DFG ↗ The project is exploring serum ITIH3 as a potential CIDP biomarker to assess whether its expression has diagnostic value beyond MG. DFG, German Research Foundation Complement Biomarker · Human observational study Christina B. Schroeter
Steven P. Gygi 		—
2023-12 Modulation of CSF1R Signaling to Treat Inflammatory Neuropathies NIH RePORTER ↗ · United States The project is exploring CSF1R-blocking antibodies and a small-molecule inhibitor as potential treatments to reduce macrophage-mediated nerve inflammation, with CIDP as a possible secondary indication. NIH Immunoglobulin / FcRn Combination of assets (Monoclonal antibody and Small molecule) · Multiple stages (Preclinical development and Human observati Kazim Sheikh industry tie $1,594k
2023-09 Development of peripheral nerve specific biomarker assays: from in vitro neuropathy models to clinical validation UKRI ↗ Roberto Bellanti (NIHR Surgical Reconstruction Microbiology Research Centre | University of Oxford | Oxford University H · United Kingdom The project is developing serum assays for peripherin and periaxin to detect peripheral nerve injury in CIDP and support diagnosis, disease monitoring, prognosis, and treatment adjustment. UKRI Myelin / nerve repair Biomarker · Multiple stages (Preclinical development, Human observationa Roberto Bellanti $332k
2023-09 Cellular and Genetic Mechanisms of Autoimmune Diabetes Associated Neuritis NIH RePORTER ↗ · United States The project uses a mouse model of T1D-associated autoimmune neuritis resembling CIDP to investigate disease mechanisms and discover genetic markers that could identify patients at risk. NIH B / T cells Biomarker · Discovery Jeremy J. Racine $1,997k
2023-04 Elucidation of the pathogenesis of cidp and development of new treatment methods focusing on macrophages KAKEN ↗ Haruki Koike (Saga University | Nagoya University) · Japan The project explores macrophage-directed treatment concepts for CIDP by investigating how macrophages phagocytose myelin, but identifies no specific therapeutic asset. KAKENHI Macrophage (CSF1R) No identifiable asset · Multiple stages (Human observational study, Discovery, Precl Haruki Koike industry tie $31k
2023-04 Comprehensive Glycomic Analysis of Immune-Mediated Neuropathy for Personalized Therapy KAKEN ↗ Yuuki Fukami (Nagoya University) · Japan The project is exploring serum glycan biomarkers, including sialylated IgG, to clarify CIDP pathogenesis and inform personalized therapy. KAKENHI Myelin / nerve repair Biomarker · Human observational study — $31k
2022-11 Identifying, characterising and evaluating antibodies in Guillain-Barr&eacute; syndrome UKRI ↗ Simon Rinaldi (University of Oxford) · Netherlands The project cites an already established nodal-antibody diagnostic test for identifying a CIDP subgroup that may benefit from B-cell-targeting treatment; its new assay-development work focuses on GBS. UKRI Other biomarkers & diagnostics Diagnostic test · Discovery — $554k
2022-04 Establishment of genetic biomarkers for Cidp using disease registries and biobanks KAKEN ↗ Yuya Aotsuka (Keio University | Chiba University) | Satoshi Kuwabara (Chiba University) | Yoshihiro Onouchi (Institute o · Japan The project is exploring genetic biomarkers in CIDP to understand disease susceptibility and treatment response and inform personalized medicine. KAKENHI Myelin / nerve repair Biomarker · Human observational study Satoshi Kuwabara industry tie
Sonoko Misawa industry tie
Yuya Aotsuka
Yoshihiro Onouchi 		$27k
2022-04 Mechanisms and therapy of autoimmune nodopathy type central and peripheral demyelination by newly discovered anti-nodal antibodies KAKEN ↗ Katsuhisa Masaki (Kyushu University) | Tomohiro Imamura (International University of Health and Welfare Kohokai Group) | · Japan No CIDP-specific asset is described; the project explores anti-120 kD CNS nodal antibodies as potential biomarkers and probes of CNS demyelination. KAKENHI Nodal / paranodal autoantibodies No identifiable asset · Multiple stages (specify which ones: Discovery, Preclinical Hidenori Ogata industry tie
Noriko Isobe
Guzailiayi Maimaitijiang
Yuri Nakamura 		$116k
2021-05 Generation of evidence for the development of diagnostic criteria and practice guidelines for nod antibody-positive chronic inflammatory demyelinating polyneuropathy/cent AMED ↗ Kira Jun'ichi · Japan The project is developing comprehensive testing for nodo-antibodies, including anti-NF155, to identify and characterize antibody-positive CIDP and inform diagnostic criteria. AMED Nodal / paranodal autoantibodies Diagnostic test · Multiple stages (specify which ones: Preclinical development Kira Jun'ichi $251k
2021-04 Blockade of colony stimulating factor 1 receptor to reduce inflammatory nerve injury NIH RePORTER ↗ · United States The project is exploring unnamed CSF1R-neutralizing antibodies and a small-molecule inhibitor to reduce macrophage-mediated inflammatory nerve injury, with potential relevance to CIDP. NIH Immunoglobulin / FcRn Combination of assets (specify which ones: CSF1R-neutralizing antibody · Preclinical development Kazim Sheikh industry tie $429k
2021-04 Discovery of novel anti-LGI4 antibodies in chronic demyelinating polyneuropathy and elucidation of its mechanism KAKEN ↗ Xu Zhang (International University of Health and Welfare Kohokai Group) · Japan The project is exploring anti-LGI4 antibodies as a potential CIDP biomarker and developing an ELISA to identify patients and investigate disease mechanisms. KAKENHI Nodal / paranodal autoantibodies Combination of assets (diagnostic test and biomarker) · Multiple stages (Discovery and Human observational study) Xu Zhang $31k
2021-04 A multicenter clinical trial to evaluate the efficacy and safety of rituximab in patients with IgG4 autoantibody-positive chronic inflammatory demyelinating polyneuropath AMED ↗ Iijima Masahiro · Japan Rituximab is being evaluated as a treatment for refractory, IgG4 autoantibody-positive CIDP to support an approval submission. AMED B / T cells Monoclonal antibody · Later-stage clinical testing Iijima Masahiro $268k
2020-10 Development of anti-neurofascin 155 and anti-contactin-1 antibody assay kits for the diagnosis of IgG4 autoantibody-positive CIDP AMED ↗ Ogata Hideki · Japan The project is developing anti-NF155 and anti-CNTN1 antibody ELISA kits to support definitive diagnosis of IgG4 autoantibody-positive CIDP. AMED Nodal / paranodal autoantibodies Diagnostic test · Implementation or validation — $26k
2020-04 Analysis of antibodies to glycolipid-protein complexes and elucidation of pathology in autoimmune-mediated demyelinating neuropathies KAKEN ↗ Motoi Kuwahara (Kindai University) · Japan The project is exploring autoantibodies to mixed glycolipid, phospholipid and protein antigens as potential CIDP biomarkers and clues to demyelination mechanisms. KAKENHI Complement Biomarker · Human observational study Motoi Kuwahara industry tie $29k
2020-04 Elucidation of the pathomechanisms of CIDP with anti-paranodal antibodies through the analysis of CNS and renal lesions KAKEN ↗ Hidenori Ogata (Kyushu University | National Hospital Organisation Kyushu Medical Center) · Japan The project explores anti-NF155 and anti-CNTN1 antibodies as biomarkers for defining CIDP subgroups and characterizing their extra-peripheral nerve involvement. KAKENHI Nodal / paranodal autoantibodies Biomarker · Human observational study — $25k
2020-04 Development of a novel biomarker reflecting disease activity in immune-mediated neuropathy KAKEN ↗ Masahiro Iijima (The University of Tokyo | Nagoya University | Pfizer) · Japan The project is developing serum NF-L and exploring candidate molecule X as CIDP biomarkers for disease monitoring and subtype diagnosis, while also investigating immunoglobulin fragments as potential immunomodulators. KAKENHI Nodal / paranodal autoantibodies Combination of assets (Biomarker; Immunoglobulin product) · Multiple stages (Human observational study; Discovery; Precl Masahiro Iijima $29k
News

Development events, 2023–2026

29 news items, 26 distinct stories once syndicated copies are merged. Each was analysed for the asset, the event and what would change the picture.

2026
06-10
Trial stopped Riliprubart (Sanofi) and claseprubart (Dianthus Therapeuti…

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

Sanofi is stopping its phase III Mobilize trial of riliprubart in CIDP for futility, while the implications for Dianthus’s claseprubart remain uncertain.

Sanofi reported that its phase III riliprubart trial would stop for futility; no numerical efficacy or safety results or comparator findings are provided.

Sanofi · Dianthus Therapeutics Inc · original source
04-18
Clinical results VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)…

Argenx SE Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

A post hoc ADHERE analysis found confirmed early clinical improvement in 87.5% of treatment-naïve CIDP patients receiving VYVGART Hytrulo, with a median response time of 39.5 days.

In a post hoc ADHERE analysis, 87.5% of treatment-naïve patients achieved confirmed early clinical improvement, with median response at 39.5 days. In a physician assessment, 85.7% of 91 patients attempting to switch from IVIg improved or remained stable without tolerability issues; no comparative efficacy estimate or detailed safety results are given.

argenx BV · original source
03-09
Clinical results

Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

Dianthus Therapeutics reported an early GO decision for its Phase 3 CAPTIVATE CIDP trial after 20 confirmed responders were observed before 40 participants completed open-label Part A.

Twenty confirmed responders were reported before 40 planned participants completed open-label Part A. No precise response rate, comparator results, or safety findings are provided.

Dianthus Therapeutics Inc · original source
03-09
Clinical results Claseprubart

Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Dianthus Therapeutics reached an early GO decision in its Phase 3 CAPTIVATE CIDP trial after 20 confirmed responders were observed before 40 participants completed open-label Part A.

Twenty confirmed responders were reported before 40 planned participants completed open-label Part A; no exact response rate, comparator result, or safety findings are provided.

Dianthus Therapeutics Inc · original source
2025
06-20
Regulatory VYVGART® 1000 mg (efgartigimod alfa) subcutaneous injectio…

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The European Commission approved argenx’s subcutaneous VYVGART with Halozyme’s ENHANZE as monotherapy for previously treated adults with progressive or relapsing active CIDP.

The record cites positive ADHERE trial results but reports no CIDP-specific efficacy figures, safety findings, or comparator results.

Halozyme Inc · original source
04-28
Regulatory VYVGART (efgartigimod alfa) subcutaneous injection with EN…

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CHMP recommended EU approval of subcutaneous efgartigimod alfa with ENHANZE for previously treated adults with progressive or relapsing active CIDP.

The release describes ADHERE results as positive but reports no CIDP-specific efficacy or safety figures, comparators, or detailed findings.

Halozyme Inc · original source
03-27
Regulatory HyQvia® (normal human immunoglobulin 10% plus recombinant …

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

Health Canada expanded HyQvia’s authorization to maintenance treatment of adults with CIDP after IVIG stabilization, supported by a Phase 3 trial showing fewer relapses than placebo.

In Phase 3 ADVANCE-1, relapse occurred in 15.5% of HyQvia recipients versus 31.7% of placebo recipients; the estimated difference was −16.2 percentage points (95% CI −29.92 to −1.27). Adverse events occurring at ≥5% included infusion-site reactions, headache and fatigue, but comparative safety rates were not reported.

Takeda
2024
10-07
Context Immunoglobulins; no named CIDP-specific asset is identified.

Sharing the Lifesaving Impact of Plasma Donation During International Plasma Awareness Week 2024

A patient with CIDP reports feeling like herself again after receiving plasma-derived immunoglobulins, but the record provides no clinical study data.

One patient reports feeling like herself again after immunoglobulin treatment; no CIDP-specific numerical efficacy results, comparator, or safety findings are reported.

Plasma Protein Therapeutics Association · original source
06-20
Clinical results BCMA-CD19 bispecific CAR T cells (no proprietary asset nam…

Innovative CAR T cell therapy shows promise for relapsed CIDP patients

In one patient with relapsed/refractory CIDP, BCMA-CD19 bispecific CAR T-cell therapy was associated with sustained functional improvement and more than one year without immunosuppressants or reported relapse.

In one patient, 10-meter walk time improved from 21 to 13 seconds by day 180, muscle power nearly recovered, and electrophysiology improved; he remained relapse-free off immunosuppressants for over a year. Fever (38–39°C), transient IL-6 elevation and grade 2 hypotension occurred; there was no control-group comparator.

Xuzhou Medical University · Xuzhou Medical University · Xuzhou Medical University · original source
01-16
Regulatory HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombi…

Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The FDA approved Takeda’s HYQVIA®, an immunoglobulin therapy co-formulated with Halozyme’s ENHANZE®, as maintenance treatment to prevent relapse in adults with CIDP.

The approved indication is maintenance treatment to prevent relapse of neuromuscular disability and impairment in adults with CIDP; no numerical efficacy or safety results or comparators are reported.

Halozyme Inc · original source
01-16
Context Hizentra (immune globulin subcutaneous [human] 20% liquid)

Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options

A CSL Behring-sponsored survey found that 72% of 100 people with CIDP rated at-home treatment highly important, highlighting the convenience of self-administered Hizentra maintenance therapy.

Among 100 surveyed people with CIDP, 72% rated at-home administration extremely or very important and 70% prioritized flexible dosing; no asset-specific efficacy results, comparative outcomes, or new safety findings are reported.

CSL Behring · original source
2023
Signal and noise

What a keyword search returns, and what survives reading it

Every source was searched for CIDP and every record was read by an AI analysis before anything was counted. This section shows how much of the raw return does not hold up, and why. It is the reason the figures elsewhere in this report are smaller than a database count would suggest.

Raw return against substantiated records

Clinical studies
452 registry records
313 unique studies
216 CIDP-relevant
Patents
391 filings
344 patent families
18 CIDP as primary indication
Publications
1,166 publications
698 with CIDP patient data
550 naming an actionable target
Companies
663 returned
424 not ruled out
19 with a corroborated active clinical programme
Research groups
156 returned
120 substantiated CIDP role
81 in neurology or immunology
Researchers
1,377 profiles returned
1,363 distinct people
1,115 substantiated CIDP record
204 with a documented industry tie
News
29 items
26 distinct stories

Bars are scaled within each source.

An acronym shared with two contract research organisations

74 of the 166 off-target trial records were sponsored by, or run through, the International Centre for Pharmaceutical Development and CIDP Biotech India: contract research organisations whose names abbreviate to CIDP. None of their studies concerns the disease. The other 92 do not mention CIDP in their title, conditions, summary or eligibility criteria.

CIDP in the condition list, not in the study

Pfizer's first-in-human study of PF-06755347 lists CIDP as a condition, but the analysis of the record notes that it enrolled healthy volunteers and people with immune thrombocytopenia only. Counting registry conditions would have placed it in the CIDP pipeline.

Registries disagree with the news

Sanofi discontinued the Phase 3 MOBILIZE trial of riliprubart for futility on 10 June 2026. ClinicalTrials.gov has closed the record. Its mirrors on other registries have not caught up, and neither has a completed Phase 2 study.

Study Registry Record Stated status Primary completion
Long-term extension ClinicalTrials.gov NCT06859099 Enrolling by invitation 2029-10-03
Long-term extension WHO ICTRP 2024-517032-22 Active, not recruiting —
MOBILIZE — riliprubart in refractory CIDP ClinicalTrials.gov NCT06290128 Other 2026-06-10
MOBILIZE — riliprubart in refractory CIDP WHO ICTRP JPRN-jRCT2031240109 Not yet recruiting —
MOBILIZE — riliprubart in refractory CIDP WHO ICTRP 2023-506503-26 Recruiting —
Phase 2 proof of concept ClinicalTrials.gov NCT04658472 Completed 2025-10-01
Phase 2 proof of concept EU CTR 2020-004006-54 Other —
Phase 2 proof of concept WHO ICTRP NL-OMON54382 Recruiting —
Phase 2 proof of concept WHO ICTRP 2024-512345-16 Active, not recruiting —
VITALIZE — riliprubart vs IVIG ClinicalTrials.gov NCT06290141 Recruiting 2027-07-09
VITALIZE — riliprubart vs IVIG WHO ICTRP JPRN-jRCT2031240206 Not yet recruiting —
VITALIZE — riliprubart vs IVIG WHO ICTRP 2023-508338-33 Recruiting —
Company assessments age

The company file was analysed on 20 August 2026 and describes Immunovant's CIDP work as platform-stage. The trial registry, read on 29 September, shows Immunovant sponsoring an active Phase 2 study of imeroprubart in CIDP. Developer status in this report is taken from the newest direct evidence.

Hospitals roll up to owners

Two rituximab studies from a Milan hospital network are recorded under its industrial parent group as sponsor. Sponsors are shown exactly as registered; read institutional names with that in mind.

Explorer

Every record behind the report

Search the 216 CIDP clinical studies or the 1,166 publications. Titles link to the underlying AcademicLabs record; the arrow link next to each opens the original source (registry entry or DOI).

The full list of clinical studies and publications is searchable in the interactive report.

Showing up to 250 matches at a time.

About CIDP

CIDP in plain language: the disease, the patients, the treatments and where research is heading

A short guide for readers new to chronic inflammatory demyelinating polyneuropathy: what it is, who it affects, how it is diagnosed and treated today, and what the research in this report could change. Medical facts are referenced to the sources listed at the end; figures about the pipeline come from this report's own data.

What is CIDP?

CIDP stands for chronic inflammatory demyelinating polyneuropathy (sometimes polyradiculoneuropathy). It is a rare autoimmune disease of the peripheral nerves: the nerves that run from the spinal cord to the muscles and skin.

Think of a nerve as an electrical cable. The wire inside (the axon) carries the signal, and an insulating layer around it, called myelin, makes the signal travel fast. In CIDP the immune system, which normally fights infections, attacks that insulation. Signals slow down or get lost on the way, so muscles receive weaker commands and the brain receives poorer feedback from the skin and joints.1 If the attack goes on long enough, the wire itself can be damaged, and that damage is slower to recover.

Healthy nerve: continuous myelin and a fast signal. CIDP: patches of myelin stripped away and a slowed signal.

Healthy nerve. The myelin is intact and the signal jumps quickly along the nerve. CIDP. Immune cells and antibodies strip patches of myelin, so the signal slows or fails.

Chronic is the key word. CIDP develops over at least eight weeks, and often over months.2 That separates it from its better-known acute counterpart, Guillain-Barré syndrome,3 which comes on over days and reaches its worst within about four weeks. CIDP either creeps forward steadily or comes in relapses with partial recovery in between.

The typical picture is weakness in both arms and both legs, on both sides of the body, near the trunk (hips, shoulders) as well as in the hands and feet, together with reduced or absent reflexes.2 Many people also have numbness, tingling, pain, poor balance and fatigue.1 Doctors also recognise variants that affect mainly the hands and feet, one side or one limb, or mainly movement or mainly sensation.2

Who gets CIDP, and how common is it?

CIDP is rare. The most-cited pooled estimate finds about 3 people in 100,000 living with it (2.81 per 100,000), and about 1 new case per 300,000 people each year (0.33 per 100,000).4 Individual studies range up to about 9 in 100,000, largely because they used different diagnostic criteria.45

It can start at any age, including in children, but it is most common between 40 and 60, and men are affected more often than women, roughly one and a half to two times as often.26 For scale, argenx estimates that about 24,000 people in the United States are being treated for CIDP (a company estimate).7

What CIDP means for patients

Because CIDP weakens the legs and dulls sensation in the feet, everyday tasks become hard: climbing stairs, getting up from a chair, walking without tripping, buttoning a shirt, holding a cup. Patient surveys show how much this weighs:

  • In a seven-country survey of 310 patients presented in 2025, more than half (168 of 298 who answered) needed a mobility aid, and 88 of 306 needed a caregiver's help with daily activities.8
  • In a European survey, two in three patients (67%) reported moderate to severe fatigue.9
  • Treatment itself takes time: people on intravenous immunoglobulin spend about two infusion days a month, and each infusion takes several hours.10

The long-term outlook varies widely. In a five-year follow-up of 38 patients in Japan, a quarter (26%) were in complete remission and most of the rest could walk independently, but 39% still needed immune treatment and 13% had severe disability.11 Many patients stay on maintenance treatment for years.12

Why CIDP is hard to diagnose

There is no single blood test for most patients. Diagnosis rests on the clinical picture plus nerve conduction studies: small electrical pulses that measure how fast and how well nerves carry signals.12 Supportive tests include raised protein in the spinal fluid, enlarged nerves on MRI or ultrasound, a clear response to treatment and, occasionally, a nerve biopsy.2

Getting it right is hard in both directions. At one US referral centre, 47% of patients sent in with a CIDP diagnosis did not meet the minimum diagnostic requirements.13 In an international survey of 542 patients, the median time from first symptoms to diagnosis was seven months, and 37% had been misdiagnosed at least once.14 Misdiagnosis matters commercially as well as medically: patients who do not have CIDP receive expensive treatment that cannot help them, and clinical trials that enrol them are harder to win.

The diagnostic rules were rewritten in 2021 by the European Academy of Neurology and the Peripheral Nerve Society.2 One change matters for drug development: a small group of patients with antibodies against specific proteins at the node of Ranvier (the gaps between myelin segments) is now treated as a separate disease, autoimmune nodopathy. These patients often respond poorly to standard CIDP treatment, immunoglobulin in particular.2 It is the one part of CIDP with a known target, yet this report finds no drug in clinical testing designed against those targets; two early CAR-T studies do enrol these patients (see ).

How CIDP is treated today

Current treatments calm the immune attack; none repairs nerves directly. The international guideline recommends starting with immunoglobulin or corticosteroids, and plasma exchange when those do not work:2

Immunoglobulin (IVIg, SCIg)

Concentrated antibodies purified from the donated blood plasma of thousands of donors, given into a vein (IVIg) every few weeks or under the skin (SCIg), often at home. One of the main long-term treatments.

Corticosteroids

Steroid tablets or high-dose pulses. Cheap and effective for many, but long-term use brings side effects such as weight gain, diabetes, bone loss and mood changes.

Plasma exchange

The patient's plasma, with the harmful antibodies in it, is filtered out and replaced. Recommended when immunoglobulin and steroids fail; it needs a specialised centre and its effect wears off.

These treatments work for most patients but not all. In the landmark ICE trial, 54% of patients improved on immunoglobulin against 21% on placebo.15 Across treatments, around a third of patients do not respond well enough to what is available.16

Immunoglobulin is also expensive and supply-limited. Each batch pools several thousand plasma donations,17 manufacturing takes seven to twelve months, and about 70% of the world's plasma comes from the United States, so shortages recur.18 In US claims data from 2011, total health-plan costs for patients treated with IVIg averaged about US$108,000 per patient per year;19 one UK centre that tailors doses to each patient spent about £55,000 per patient per year on immunoglobulin and infusions, and standard dosing costs more.20 CIDP is among the largest uses of immunoglobulin,19 which is why payers watch the field closely and why the standard of care is the commercial benchmark for any new drug (see ).

What changed since 2024

Until June 2024, the medicines approved specifically for CIDP in the United States were all forms of immunoglobulin, and each approval brought a new product or an easier way to take it: for example Gamunex in 2008, Hizentra in 2018 as the first under-the-skin option, Panzyga in 2021, and HyQvia and Gammagard Liquid in January 2024.21

  1. Jun 2024

    First new mechanism approved. The US FDA approved efgartigimod (Vyvgart Hytrulo, argenx), an under-the-skin injection that lowers the level of antibodies in the blood.7

  2. Nov–Dec 2024

    Approvals followed in China and Japan.21

  3. Apr 2025

    A prefilled syringe for self-injection at home, given in 20 to 30 seconds, was approved in the US.21

  4. Jun 2025

    The European Union approved efgartigimod for adults with active CIDP previously treated with steroids or immunoglobulin.21

  5. 2026

    The next class stumbled and advanced at once: Sanofi stopped one Phase 3 study of its complement inhibitor riliprubart in June, while Dianthus moved claseprubart, which also targets the complement protein C1s, into the Phase 3 part of its study in March (see ).

The approval rested on the ADHERE trial. In its first, open-label stage, two thirds of patients (66%) improved on efgartigimod; when those responders were then randomised, 27.9% relapsed on the drug against 53.6% on placebo, a 61% lower risk of relapse.16 It does not yet answer the question payers and doctors care about most: is it better than immunoglobulin? No head-to-head trial has reported.

Where research is heading

This report counts 216 CIDP clinical studies across the world's registries, with 39 active or planned studies due to report a primary result by 2030, 17 of them in 2027 alone. Beyond the clinic it finds 157 preclinical programmes from 146 developers. The approaches fall into a handful of ideas, explained here in plain terms:

Better immunoglobulin

Same medicine, easier to take: under-the-skin and home dosing, smarter dose tapering, and lab-made successors that copy the active part of immunoglobulin without needing donated plasma.

FcRn blockers

The body has a recycling receptor, FcRn, that keeps antibodies circulating for weeks. Blocking it makes the body clear antibodies faster, including the harmful ones. Efgartigimod works this way; nipocalimab and others follow.

Complement inhibitors

Complement is a chain of blood proteins that antibodies switch on to damage their target. Blocking an early link (C1s or C2) aims to stop the damage to the nerve even while antibodies are present.

B-cell therapies

B cells and plasma cells are the factories that make antibodies. Rituximab, used off-label, removes B cells and helps mainly in autoimmune nodopathy;2 newer drugs also reach plasma cells, aiming for longer-lasting control than antibody-lowering drugs.

CAR-T cell therapy

Borrowed from cancer care: immune cells are re-engineered to hunt down the B cells or plasma cells that make antibodies, with the hope of a deep "reset" of the immune system. Still in small early trials, mostly at hospitals in China.

Nerve repair and new targets

Earlier-stage work on T cells, inflammatory messengers (cytokines), immune tolerance and rebuilding myelin. This is where most preclinical programmes sit, and none of these ideas yet has an active CIDP trial.

The tab places every one of these on a single chart, and shows when each result is due.

What it means for drug developers and investors

  • The bar is immunoglobulin. It works for most patients, so a new drug has to be better, safer, easier or cheaper. Only a few registered studies compare directly against it, and they report in 2027.
  • Convenience is a battleground. Home infusions, under-the-skin dosing and a 30-second self-injection have already changed what patients and payers expect.
  • The unmet need is concentrated. Around a third of patients respond poorly, and some of those do not have CIDP at all. Better diagnosis and ways to pick the right patients could matter as much as new mechanisms.
  • Subgroups are opportunities. Autoimmune nodopathy has known targets and no targeted drug; patients who fail immunoglobulin are a defined population for trials.
  • Expertise is concentrated too. The 1,115 researchers in this report and their industry ties are mapped in ; potential partners are in .

Key terms

Peripheral nerves
The nerves outside the brain and spinal cord, connecting them to muscles, skin and organs.
Myelin, demyelination
The fatty insulation around nerve fibres; its loss is demyelination.
Autoimmune disease
A disease in which the immune system attacks the body's own tissue.
Antibody (IgG)
A protein the immune system makes to tag targets for attack. In CIDP some antibodies are thought to target the nerves.
IVIg / SCIg
Immunoglobulin (pooled donor antibodies) given intravenously, into a vein, or subcutaneously, under the skin.
Plasma exchange
Removing and replacing the liquid part of the blood to clear harmful antibodies.
FcRn
A receptor that recycles antibodies so they last longer in the blood; blocking it lowers antibody levels.
Complement
A cascade of blood proteins that antibodies switch on to destroy targets.
CAR-T
Immune cells engineered in the lab to recognise and kill a chosen cell type.
Nerve conduction study
A test that measures the speed and strength of electrical signals along nerves.
Phase 1, 2, 3
Stages of clinical testing: safety in a few people, first signs of benefit, then proof in larger controlled trials that supports approval.
Primary completion
The date a trial expects to collect the data for its main result; the readout usually follows within months.

Sources

  1. MedlinePlus (US National Library of Medicine). Chronic inflammatory demyelinating polyneuropathy.
  2. Van den Bergh PYK et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of CIDP. Eur J Neurol, 2021. doi:10.1111/ene.14959
  3. NINDS, via BrainFacts.org. Chronic inflammatory demyelinating polyneuropathy.
  4. Broers MC et al. Incidence and prevalence of CIDP: a systematic review and meta-analysis. Neuroepidemiology, 2019. doi:10.1159/000494291
  5. Practical Neurology. Taking the mis- out of CIDP diagnosis, 2020.
  6. US claims cohort, 3,409 patients (60% male, mean age 59). Front Neurol, 2025. doi:10.3389/fneur.2025.1726857
  7. argenx. FDA approval of Vyvgart Hytrulo in CIDP, 21 June 2024 (company release).
  8. Karkare et al. Burden of illness in CIDP: a multinational real-world survey. ISPOR, 2025 (authors include argenx staff). Abstract.
  9. Impact of CIDP on health-related quality of life, fatigue and daily activities: a real-world survey in France, Germany, Italy and Spain (199 patients). ISPOR Europe, 2025 (authors from argenx and Adelphi). Abstract.
  10. Hubsch et al. Experiences of immunoglobulin therapy in CIDP. Patient Prefer Adherence, 2025. Article.
  11. Kuwabara S et al. Long-term prognosis of CIDP: a five-year follow-up of 38 cases. J Neurol Neurosurg Psychiatry, 2006. doi:10.1136/jnnp.2005.065441
  12. Bunschoten C et al. Progress in diagnosis and treatment of CIDP. Lancet Neurol, 2019. doi:10.1016/S1474-4422(19)30144-9
  13. Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology, 2015. doi:10.1212/WNL.0000000000001833
  14. Arvin-Berod et al. International survey of 542 patients with CIDP (lead author from argenx). Front Neurol, 2026, as reported by NeurologyLive.
  15. Hughes RAC et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of CIDP (ICE study). Lancet Neurol, 2008. doi:10.1016/S1474-4422(07)70329-0
  16. … and 6 more.

This guide is general information for readers new to CIDP, not medical advice. People living with CIDP can find support and information from patient organisations such as the GBS|CIDP Foundation International. Sources checked 8 October 2026.

Method

How this was built

Every figure in this report traces back to individual source records. The AI never answers from memory or from the web; it reads one record at a time, and everything after that is counted in code.

  1. Search once, across eight types of intelligence. One CIDP search in AcademicLabs returned 4,264 records: publications, patents, clinical studies, companies, research groups, researchers, funded projects and news.
  2. Read each record on its own. AcademicLabs AI analysed every publication, patent, study, company, group, researcher, project and news item separately, step by step, against a fixed CIDP question set. It works only from the text of that record: no web searches, and no facts from the model's training data, which is used for reasoning only. Every answer is tied to one record you can open and check, which keeps hallucination to a minimum.
  3. Count and connect in code. Deduplication, classification, counts and cross-links between the eight types of intelligence were computed deterministically from those structured answers, so every number can be re-derived from the source files.
  4. Synthesise. A final step identified the key insights, wrote them up and built the visuals on top of the computed figures. Wherever text quotes a number from a cited record, the build checks that the number appears in that record and stops if it does not.
Source Records Search Window Analysed After cleaning
Publications 1,166 "chronic inflammatory demyelinating polyneuropathy"~4 OR CIDP 2024–2026 20 Aug 2026 698 with CIDP patient data; 550 name an actionable target
Patents 391 Same query 2024–2026 filings and publications 20 Aug 2026 344 families; 18 CIDP-primary
Companies 663 Companies with CIDP-related records, written drug-development assessment No filter 20 Aug 2026 19 with a corroborated active CIDP clinical programme; 239 with none
Clinical studies 452 "chronic inflammatory demyelinating polyradiculoneuropathy"~4 OR CIDP No filter; ClinicalTrials.gov, EU CTR, WHO ICTRP 29 Sep 2026 313 unique studies; 216 CIDP-relevant
Research groups 156 Groups with CIDP publications, written assessment Publications 2025–2026 29 Sep 2026 120 with a substantiated CIDP role
Funded projects 30 CIDP query Start 2020–2026 29 Sep 2026 11 on nodal/paranodal antibodies; ~$8.3M indicative
News 29 CIDP query 2023–2026 29 Sep 2026 26 distinct stories
Researchers 1,377 CIDP in recent publications, patents, trials, projects, function title or about-text; written drug-research assessment Recent records 30 Sep 2026 1,115 with a substantiated CIDP link; 204 with an industry tie

Coverage

The report covers what AcademicLabs held on CIDP at the export dates: clinical trials from ClinicalTrials.gov, the EU registers and WHO ICTRP (which brings in the Chinese, Japanese, Australian, Dutch, Iranian and other national registries), publications, patents, companies, research groups, researchers, funded projects and news. Two sources are not yet included: Chinese-language patent filings, and pipeline charts on company websites. Both come with AcademicLabs asset intelligence, launching soon. Until then, an early programme disclosed only there can be missing from the preclinical ring.

Registry deduplication

Records were merged when they shared any registry identifier (NCT, EudraCT, CTIS, WHO), cited each other's NCT number, or had near-identical titles (similarity ≥ 0.92). Studies registered under different titles in several registries (a brief and a scientific title, a translated title, or an EudraCT number re-registered in CTIS) were merged from an analyst-reviewed list of 27 studies. An NCT record represents its study where one exists, then the EU register, then WHO ICTRP. 52 studies appear in more than one registry.

CIDP relevance

A study is CIDP-specific when CIDP is in its title or among three or fewer listed conditions, multi-indication when CIDP appears in conditions, summary or inclusion criteria, and off-target otherwise. 160 studies are CIDP-specific and 56 multi-indication.

Asset resolution

Interventions were resolved against a dictionary of about 55 named products, codes and synonyms. Comparators, background therapy and lymphodepletion regimens are dropped when a novel agent is present. 138 of 216 relevant studies resolve to a named intervention; the rest test procedures, devices, diagnostics or unnamed drugs.

Developer evidence ladder

Marketed in CIDP requires a post-approval CIDP study of the developer's branded product or approval news. Active clinical requires being first-listed sponsor of an active interventional study of a resolved asset. Then completed studies, then patents or preclinical records, then literature or news only. Newer direct evidence overrides older written assessments.

One mechanism axis

Publication mechanisms, patent targets, trial interventions and project themes were mapped to the same twelve mechanisms so they can be read across. Cell therapies and stem-cell transplantation count under B cells and plasma cells; immunoglobulin, being polyvalent, is left off the axis.

Researcher roles and ties

Each researcher's written assessment was read in code: the role comes from what the positive sentences describe (template sentences such as 'no patents were supplied' are ignored), assets from the same dictionary as the trials, and an industry tie from a developer named in a sentence about funding, sponsorship, co-authorship or employment, or from the researcher's employer. Links to publications, patents, studies and projects use AcademicLabs record IDs. Checked against a manual reading of 30 held-out profiles, the role agreed in 26 (87%). Affiliation and country are the profile's last known affiliation, except where the researcher's own 2024–2026 CIDP publications name a different institution more often: then that institution is used (497 profiles, often name collisions in the source). Profiles of the same person (an initial against a full first name, with a shared institution or paper) are merged (14 merges).

Company assessments

Each company's written assessment was classified in code. A phase mentioned in the text is not enough for 'active CIDP clinical programme': the text often quotes phases of the company's programmes in other diseases, or of CIDP trials it only served as a site, CRO, investor or partner. A company counts as active only if its assessment names a CIDP asset or trial and it has a pharma profile, with no statement that it is not the developer or that the work is historical, or if it is first-listed sponsor of a CIDP study that is active or started since 2016. That leaves 19 company records; several belong to the same group (Sanofi, CSL, Johnson & Johnson). Sponsors of only older completed CIDP studies are shown as a past programme.

Partnering parties

A party is any organisation outside the established CIDP companies that owns or runs something partnerable: a CIDP patent family, a company programme, a study of a novel asset with no major company as sponsor, or a funded project. Records are merged on a normalised organisation name. Untied researchers and news only enrich a party. CIDP stage counts a company's clinical phase only when the company passes the corroboration rule under Company assessments, and treats a patent's clinical-stage maturity as clinical in another indication.

Trial results

Publications that name a treatment were assigned to a drug through the asset dictionary and sorted by evidence type in code; 180 were read and 120 report figures. The 44 result rows were written by an analyst from each record's AI-written key results and abstract, company news findings and registry entries, and the pipeline stops if any number in them is missing from the cited record. Confidence intervals missing from a source are computed (Wilson) and marked. The publication export covers 2024 to 2026, so older pivotal trials enter only through recent reviews.

Figures and limits

Every classification above was produced by AI reading one record at a time, then counted in code. Aggregates are more robust than any single label, and each row links to the record it came from so it can be checked. Registry dates are sponsor estimates. Award values use fixed indicative rates (JPY 150, GBP 0.79, EUR 0.93 per USD). Organisations are described only through what these records state. Every record links to its AcademicLabs entry and, where the export gives one, to the original source: the registry entry for a study, the DOI for a publication, the funder's page for a project, the website of a company or research group.

The CIDP Landscape · September 2026 · Built from AcademicLabs AI-analysed publications, patents, clinical studies, companies, research groups, researchers, funded projects and news. Every organisation is described only through what the analysed records state; statuses, scores and classifications are analytical constructs defined in the method section and are not statements about any company's plans.

academiclabs.com

Key questions

CIDP in 2026: key questions answered

Short answers drawn from this report. Each one links to the section with the full evidence.

What is CIDP, and how is it treated in 2026?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease in which the immune system damages myelin, the insulation around the peripheral nerves, causing weakness and loss of sensation. First treatment is immunoglobulin (IVIg, or subcutaneous immunoglobulin at home), corticosteroids or plasma exchange. The FcRn blocker efgartigimod (Vyvgart Hytrulo) became the first approved non-immunoglobulin option in June 2024 in the US and June 2025 in the EU; HyQvia was approved for maintenance in January 2024. About CIDP →

How common is CIDP, and who gets it?

CIDP is rare: a pooled analysis of 11 studies found about 2.8 people per 100,000 living with it and 0.33 new cases per 100,000 people each year (Broers et al., Neuroepidemiology 2019); individual studies range up to about 9 per 100,000. It can start at any age but is most common between 40 and 60, and men are affected more often than women, roughly one and a half to two times as often. Over half of patients in a seven-country survey needed a mobility aid. About CIDP →

Why is CIDP hard to diagnose?

There is no single blood test for most patients: diagnosis rests on symptoms plus nerve conduction studies, supported by spinal-fluid protein, nerve imaging and response to treatment. At one US referral centre 47% of patients referred with a CIDP diagnosis did not meet diagnostic criteria (Allen and Lewis, Neurology 2015). Since the 2021 EAN/PNS guideline, patients with antibodies against node-of-Ranvier proteins are classed separately as autoimmune nodopathy; they often respond poorly to immunoglobulin. About CIDP →

Which drugs are in clinical development for CIDP?

As of September 2026 the registries hold 216 CIDP-relevant clinical studies, 70 active and 23 planned. The late-stage novel drugs are FcRn blockers (efgartigimod, approved; nipocalimab, M281, in Phase 2/3; imeroprubart, IMVT-1402, in Phase 2), complement inhibitors (riliprubart, SAR445088; empasiprubart, ARGX-117; claseprubart, DNTH103; all in Phase 3) and B-cell depletion (rituximab and ripertamab in Phase 3). 11 CAR-T studies list CIDP, all Phase 1 or 1/2. Immunoglobulin is still the largest class, with 76 studies. Pipeline →

Which CIDP trials read out in 2027?

17 of the 39 registered primary completions between 2026 and 2030 fall in 2027, 10 of them Phase 2/3 or later. The key ones are nipocalimab's ARISE study (NCT05327114, May), riliprubart's VITALIZE (NCT06290141, July, against IVIg), empasiprubart's EMVIGORATE (NCT06920004, September, against IVIg) and EMNERGIZE (NCT07091630, October, against placebo), and an academic Phase 3 of rituximab at Amsterdam UMC (NCT06714838, October). Registry dates are sponsor estimates and often move. Readout calendar →

Which new CIDP drugs are compared head-to-head with IVIg?

Only 2 of the 32 active or planned studies of novel agents compare directly with IVIg: Sanofi's VITALIZE (riliprubart) and argenx's EMVIGORATE (empasiprubart), both with primary completion registered for 2027. The others compare with placebo, run as single-arm studies or use other designs, so there will be little direct evidence against today's standard of care. Readout calendar →

What have published trials shown for new CIDP drugs?

Of the 180 CIDP treatment publications from 2024 to 2026 read for this report, only one new mechanism has a positive randomised result: efgartigimod in ADHERE, where 27.9% of responders relapsed on the drug against 53.6% on placebo (hazard ratio 0.39). Rituximab as a way off IVIg, steroid pulses added to IVIg and rozanolixizumab in a Phase 2a did not beat their controls. IVIg itself more than doubles the chance of meaningful improvement over placebo (risk ratio 2.40). Trial results →

Why was Sanofi's MOBILIZE trial of riliprubart stopped?

Sanofi stopped the Phase 3 MOBILIZE study of riliprubart (anti-C1s) in refractory CIDP for futility on 10 June 2026, after an interim review. Its second Phase 3, VITALIZE, which compares riliprubart with IVIg, is under review by Sanofi. The other two late-stage complement antibodies, claseprubart (Dianthus Therapeutics) and empasiprubart (argenx), remain in Phase 3. Ten findings →

Which companies are developing CIDP treatments?

19 company records show a corroborated active CIDP clinical programme (several belong to the same group). Marketed in CIDP: argenx, Takeda, CSL, Octapharma and Grifols (efgartigimod, HyQvia and immunoglobulin products). Active clinical programmes: Sanofi, Johnson & Johnson, Immunovant, Dianthus Therapeutics, Kedrion, Nuvig Therapeutics, Juventas Cell Therapy, Kite (Gilead) and TG Therapeutics. Developers →

Who are the leading CIDP experts working with?

Of 1,115 researchers with a substantiated CIDP record, 204 have a documented industry tie, and 106 of them are tied to argenx, more than to CSL, Sanofi and Takeda combined (89). 41 of the 50 most-connected researchers have at least one tie. India, South Korea, Poland, Greece, Turkey, Canada and Brazil hold 189 CIDP researchers but only 8 CIDP studies between them. Experts →

Who are the most active CIDP researchers?

Ranked by the report's transparent score (role, linked publications, studies, patents and projects, drugs named, evidence and recency), the most connected academic CIDP researchers in the records are Filip Eftimov, Luís Querol, Masahiro Iijima, Dai-Shi Tian, Eduardo Nobile-Orazio, Jeffrey A. Allen, Jeffrey T. Guptill, Satoshi Kuwabara, Chuan Qin and Pieter A. van Doorn. 41 of the 50 highest-ranked researchers have at least one industry tie. The Experts section lists the top 100 of the 1,115 researchers with a substantiated CIDP record, with their country, role, drugs named and industry ties. Experts →

Which preclinical CIDP programmes are there, and how well validated are they?

Beyond the clinic, the report lists 157 preclinical programmes from 146 developers that have no CIDP clinical study, from CIDP patent families, funded projects and company records. 8 use a drug already clinical in another disease (Alpine Immune Sciences, Viela Bio, Kyverna Therapeutics, EpicentRx, Biocodex (Etifoxine)), 21 have in vivo or patient-sample data, 39 in vitro or cell data, and 89 disclose no data yet. 87 of them work on biology with no active CIDP study: T cells and Treg, tolerance, cytokines, macrophages and nerve repair. The outer ring of the pipeline bullseye and the table under it list every programme. Pipeline →

What is the nodal (paranodal) antibody subgroup of CIDP, and is anyone targeting it?

Antibodies against proteins of the node of Ranvier (neurofascin-155, contactin-1, Caspr1, neurofascin-140/186) define the one CIDP subgroup with a known antigen. It is the most human-grounded topic in the literature (48 publications, 83% with patient data) and the largest theme in public funding (11 of 30 projects), yet no clinical study targets these antibodies. Of 178 researchers working on them, 12% have an industry tie. These patients respond poorly to IVIg and well to rituximab (6 of 8, retrospective). Biology →

Where are the partnering opportunities in CIDP?

332 organisations own or run something partnerable in CIDP: 250 biotechs and SMEs, 78 universities and hospitals and 4 individual investigators. 172 of them hold no CIDP patent family, and 18 academic or investigator sponsors already test new drugs without a big company. Patents also run ahead of evidence: T-cell approaches account for 45 patent families that name CIDP and no clinical study. Partnering →

How was this landscape built, and how is AI hallucination avoided?

One search in AcademicLabs returned 4,264 CIDP records across eight types of intelligence: publications, patents, clinical studies, companies, research groups, researchers, funded projects and news. AcademicLabs AI analysed each record on its own against a fixed CIDP question set, using only that record's text: no web searches, and no facts from the model's training data, which is used for reasoning only. Counting, deduplication and cross-linking were then done in code, and a final step wrote up the insights and built the visuals. Method →

How current is this report?

The records were exported from AcademicLabs between 20 August and 30 September 2026. Readout dates are primary completion dates registered by the sponsors and often move. The report was published on 29 September 2026 and last updated on 7 October 2026, when registry duplicates were merged further and preclinical programmes were added. Method →

About this report

Prepared by Arne Smolders, Founder & CEO of AcademicLabs. Published 29 September 2026, updated 7 October 2026; data as of 30 September 2026. Built with AcademicLabs from 4,264 AI-analysed records across eight types of intelligence. Figures describe what the records state and are not medical or investment advice. Not yet covered: Chinese-language patents and pipeline charts on company websites, which come with AcademicLabs asset intelligence.

How to cite

Please cite and link this page:

Smolders A. The CIDP Landscape 2026. AcademicLabs; 2026 (updated 7 October 2026). https://academiclabs.com/research-reports/cidp-landscape-2026

The data and figures are shared under CC BY 4.0: free to reuse with credit to AcademicLabs.